0	Superiority	O
0	of	O
0	the	O
0	Triple	B-arm_description
0	Combination	B-arm_description
0	of	B-arm_description
0	Bortezomib	B-arm_description
0	-	O
0	Thalidomide	B-arm_description
0	-	O
0	Dexamethasone	B-arm_description
0	Over	O
0	the	O
0	Dual	O
0	Combination	O
0	of	O
0	Thalidomide	O
0	-	O
0	Dexamethasone	O
0	in	O
0	Patients	O
0	With	O
0	Multiple	O
0	Myeloma	O
0	Progressing	O
0	or	O
0	Relapsing	O
0	After	O
0	Autologous	O
0	Transplantation	O
0	:	O
0	The	O
0	MMVAR	O
0	/	O
0	IFM	O
0	2005	O
0	-	O
0	04	O
0	Randomized	B-study_type
0	Phase	B-study_type
0	III	B-study_type
0	Trial	B-study_type
0	From	O
0	the	O
0	Chronic	O
0	Leukemia	O
0	Working	O
0	Party	O
0	of	O
0	the	O
0	European	O
0	Group	O
0	for	O
0	Blood	O
0	and	O
0	Marrow	O
0	Transplantation	O
0	Superiority	O
0	of	O
0	the	O
0	Triple	O
0	Combination	O
0	of	O
0	Bortezomib	O
0	-	O
0	Thalidomide	O
0	-	O
0	Dexamethasone	O
0	Over	O
0	the	O
0	Dual	O
0	Combination	O
0	of	O
0	Thalidomide	O
0	-	O
0	Dexamethasone	O
0	in	O
0	Patients	O
0	With	O
0	Multiple	O
0	Myeloma	O
0	Progressing	O
0	or	O
0	Relapsing	O
0	After	O
0	Autologous	O
0	Transplantation	O
0	:	O
0	The	O
0	MMVAR	O
0	/	O
0	IFM	O
0	2005	O
0	-	O
0	04	O
0	Randomized	O
0	Phase	O
0	III	O
0	Trial	O
0	From	O
0	the	O
0	Chronic	O
0	Leukemia	O
0	Working	O
0	Party	O
0	of	O
0	the	O
0	European	O
0	Group	O
0	for	O
0	Blood	O
0	and	O
0	Marrow	O
0	Transplantation	O
0	MD	O
0	,	O
0	Hô	O
0	pital	O
0	SaintLaurentGarderet	B-authors
--------------------------------------------------------------
1	Superiority	O
1	of	O
1	the	O
1	Triple	O
1	Combination	O
1	of	O
1	Bortezomib	O
1	-	O
1	Thalidomide	O
1	-	O
1	Dexamethasone	O
1	Over	O
1	the	O
1	Dual	B-arm_description
1	Combination	B-arm_description
1	of	O
1	Thalidomide	B-arm_description
1	-	O
1	Dexamethasone	B-arm_description
1	in	O
1	Patients	O
1	With	O
1	Multiple	O
1	Myeloma	O
1	Progressing	O
1	or	O
1	Relapsing	O
1	After	O
1	Autologous	O
1	Transplantation	O
1	:	O
1	The	O
1	MMVAR	O
1	/	O
1	IFM	O
1	2005	O
1	-	O
1	04	O
1	Randomized	O
1	Phase	O
1	III	O
1	Trial	O
1	From	O
1	the	O
1	Chronic	O
1	Leukemia	O
1	Working	O
1	Party	O
1	of	O
1	the	O
1	European	O
1	Group	O
1	for	O
1	Blood	O
1	and	O
1	Marrow	O
1	Transplantation	O
1	Superiority	O
1	of	O
1	the	O
1	Triple	O
1	Combination	O
1	of	O
1	Bortezomib	O
1	-	O
1	Thalidomide	O
1	-	O
1	Dexamethasone	O
1	Over	O
1	the	O
1	Dual	O
1	Combination	O
1	of	O
1	Thalidomide	O
1	-	O
1	Dexamethasone	O
1	in	O
1	Patients	O
1	With	O
1	Multiple	O
1	Myeloma	O
1	Progressing	O
1	or	O
1	Relapsing	O
1	After	O
1	Autologous	O
1	Transplantation	O
1	:	O
1	The	O
1	MMVAR	O
1	/	O
1	IFM	O
1	2005	O
1	-	O
1	04	O
1	Randomized	O
1	Phase	O
1	III	O
1	Trial	O
1	From	O
1	the	O
1	Chronic	O
1	Leukemia	O
1	Working	O
1	Party	O
1	of	O
1	the	O
1	European	O
1	Group	O
1	for	O
1	Blood	O
1	and	O
1	Marrow	O
1	Transplantation	O
1	MD	O
1	,	O
1	Hô	O
1	pital	O
1	SaintLaurentGarderet	O
--------------------------------------------------------------
2	laurent.garderet@sat.aphp.fr	B-authors
2	.	O
2	SimonaIacobelli	B-authors
2	PhilippeMoreau	B-authors
2	MamounDib	B-authors
2	IngridLafon	B-authors
2	DietgerNiederwieser	B-authors
2	TamasMasszi	B-authors
2	JeanFontan	B-authors
2	MauricetteMichallet	B-authors
2	AloisGratwohl	B-authors
2	GiuseppeMilone	B-authors
2	ChantalDoyen	B-authors
2	BrigittePegourie	B-authors
2	RomanHajek	B-authors
2	PhilippeCasassus	B-authors
2	BrigitteKolb	B-authors
2	CarineChaleteix	B-authors
2	BerndHertenstein	B-authors
2	FrancescoOnida	B-authors
2	HeinzLudwig	B-authors
2	NicolasKetterer	B-authors
2	ChristianKoenecke	B-authors
2	MarleenVan	B-authors
2	Os	B-authors
2	MohamadMohty	B-authors
2	JeanLuc	B-authors
2	Harousseau	B-authors
2	Andrew	B-authors
2	Cakana	B-authors
2	Norbert	B-authors
2	Claude	B-authors
2	Gorin	B-authors
2	Theo	B-authors
2	de	B-authors
2	Witte	B-authors
2	Jean	B-authors
2	Luc	B-authors
2	Harousseau	B-authors
2	Curly	B-authors
2	Morris	B-authors
--------------------------------------------------------------
3	Superiority	O
3	of	O
3	the	O
3	Triple	B-arm_description
3	Combination	B-arm_description
3	of	B-arm_description
3	Bortezomib	B-arm_description
3	-	O
3	Thalidomide	B-arm_description
3	-	O
3	Dexamethasone	B-arm_description
3	Over	O
3	the	O
3	Dual	O
3	Combination	O
3	of	O
3	Thalidomide	O
3	-	O
3	Dexamethasone	O
3	in	O
3	Patients	O
3	With	O
3	Multiple	O
3	Myeloma	O
3	Progressing	O
3	or	O
3	Relapsing	O
3	After	O
3	Autologous	O
3	Transplantation	O
3	:	O
3	The	O
3	MMVAR	O
3	/	O
3	IFM	O
3	2005	O
3	-	O
3	04	O
3	Randomized	B-study_type
3	Phase	I-study_type
3	III	I-study_type
3	Trial	I-study_type
3	From	O
3	the	O
3	Chronic	O
3	Leukemia	O
3	Working	O
3	Party	O
3	of	O
3	the	O
3	European	O
3	Group	O
3	for	O
3	Blood	O
3	and	O
3	Marrow	O
3	Transplantation	O
3	10.1200	O
3	/	O
3	JCO.2011.37.4918	O
--------------------------------------------------------------
4	Superiority	O
4	of	O
4	the	O
4	Triple	O
4	Combination	O
4	of	O
4	Bortezomib	O
4	-	O
4	Thalidomide	O
4	-	O
4	Dexamethasone	O
4	Over	O
4	the	O
4	Dual	B-arm_description
4	Combination	B-arm_description
4	of	B-arm_description
4	Thalidomide	B-arm_description
4	-	O
4	Dexamethasone	B-arm_description
4	in	O
4	Patients	O
4	With	O
4	Multiple	O
4	Myeloma	O
4	Progressing	O
4	or	O
4	Relapsing	O
4	After	O
4	Autologous	O
4	Transplantation	O
4	:	O
4	The	O
4	MMVAR	O
4	/	O
4	IFM	O
4	2005	O
4	-	O
4	04	O
4	Randomized	O
4	Phase	O
4	III	O
4	Trial	O
4	From	O
4	the	O
4	Chronic	O
4	Leukemia	O
4	Working	O
4	Party	O
4	of	O
4	the	O
4	European	O
4	Group	O
4	for	O
4	Blood	O
4	and	O
4	Marrow	O
4	Transplantation	O
4	10.1200	O
4	/	O
4	JCO.2011.37.4918	O
--------------------------------------------------------------
5	Submitted	O
5	June	O
5	7	O
5	,	O
5	2011	O
5	;	O
5	accepted	O
5	March	O
5	1	O
5	,	O
5	2012	O
5	;	O
5	MD	O
5	,	O
5	Hô	O
5	pital	O
5	SaintLaurentGarderet	B-authors
5	laurent.garderet@sat.aphp.fr	I-authors
5	.	I-authors
5	SimonaIacobelli	I-authors
5	PhilippeMoreau	I-authors
5	MamounDib	I-authors
5	IngridLafon	I-authors
5	DietgerNiederwieser	I-authors
5	TamasMasszi	I-authors
5	JeanFontan	I-authors
5	MauricetteMichallet	I-authors
5	AloisGratwohl	I-authors
5	GiuseppeMilone	I-authors
5	ChantalDoyen	I-authors
5	BrigittePegourie	I-authors
5	RomanHajek	I-authors
5	PhilippeCasassus	I-authors
5	BrigitteKolb	I-authors
5	CarineChaleteix	I-authors
5	BerndHertenstein	I-authors
5	FrancescoOnida	I-authors
5	HeinzLudwig	I-authors
5	NicolasKetterer	I-authors
5	ChristianKoenecke	I-authors
5	MarleenVan	I-authors
5	Os	I-authors
5	MohamadMohty	I-authors
5	JeanLuc	I-authors
5	Harousseau	I-authors
5	Andrew	I-authors
5	Cakana	I-authors
5	Norbert	I-authors
5	Claude	I-authors
5	Gorin	I-authors
5	Theo	I-authors
5	de	I-authors
5	Witte	I-authors
5	Jean	I-authors
5	Luc	I-authors
5	Harousseau	I-authors
5	Curly	I-authors
5	Morris	B-authors
--------------------------------------------------------------
6	Superiority	O
6	of	O
6	the	O
6	Triple	B-arm_description
6	Combination	I-arm_description
6	of	I-arm_description
6	Bortezomib	I-arm_description
6	-	I-arm_description
6	Thalidomide	I-arm_description
6	-	I-arm_description
6	Dexamethasone	I-arm_description
6	Over	O
6	the	O
6	Dual	O
6	Combination	O
6	of	O
6	Thalidomide	O
6	-	O
6	Dexamethasone	O
6	in	O
6	Patients	O
6	With	O
6	Multiple	O
6	Myeloma	O
6	Progressing	O
6	or	O
6	Relapsing	O
6	After	O
6	Autologous	O
6	Transplantation	O
6	:	O
6	The	O
6	MMVAR	O
6	/	O
6	IFM	O
6	2005	O
6	-	O
6	04	O
6	Randomized	O
6	Phase	O
6	III	O
6	Trial	O
6	From	O
6	the	O
6	Chronic	O
6	Leukemia	O
6	Working	O
6	Party	O
6	of	O
6	the	O
6	European	O
6	Group	O
6	for	O
6	Blood	O
6	and	O
6	Marrow	O
6	Transplantation	O
6	MD	O
6	,	O
6	Hô	O
6	pital	O
6	SaintLaurentGarderet	B-authors
--------------------------------------------------------------
7	Superiority	O
7	of	O
7	the	O
7	Triple	O
7	Combination	O
7	of	O
7	Bortezomib	O
7	-	O
7	Thalidomide	O
7	-	O
7	Dexamethasone	O
7	Over	O
7	the	O
7	Dual	B-arm_description
7	Combination	I-arm_description
7	of	I-arm_description
7	Thalidomide	I-arm_description
7	-	I-arm_description
7	Dexamethasone	I-arm_description
7	in	O
7	Patients	O
7	With	O
7	Multiple	O
7	Myeloma	O
7	Progressing	O
7	or	O
7	Relapsing	O
7	After	O
7	Autologous	O
7	Transplantation	O
7	:	O
7	The	O
7	MMVAR	O
7	/	O
7	IFM	O
7	2005	O
7	-	O
7	04	O
7	Randomized	O
7	Phase	O
7	III	O
7	Trial	O
7	From	O
7	the	O
7	Chronic	O
7	Leukemia	O
7	Working	O
7	Party	O
7	of	O
7	the	O
7	European	O
7	Group	O
7	for	O
7	Blood	O
7	and	O
7	Marrow	O
7	Transplantation	O
7	MD	O
7	,	O
7	Hô	O
7	pital	O
7	SaintLaurentGarderet	O
--------------------------------------------------------------
8	laurent.garderet@sat.aphp.fr	B-authors
8	.	O
8	MD	B-authors
8	,	I-authors
8	Hô	I-authors
8	pital	I-authors
8	SaintLaurentGarderet	I-authors
8	MD	I-authors
8	,	I-authors
8	Hô	I-authors
8	pital	I-authors
8	Saint	I-authors
8	Laurent	I-authors
8	Garderet	I-authors
8	laurent.garderet@sat.aphp.fr	I-authors
8	.	I-authors
8	SimonaIacobelli	I-authors
8	SimonaIacobelli	I-authors
8	Simona	I-authors
8	Iacobelli	I-authors
8	PhilippeMoreau	I-authors
8	PhilippeMoreau	I-authors
8	Philippe	I-authors
8	Moreau	I-authors
8	MamounDib	I-authors
8	MamounDib	I-authors
8	Mamoun	I-authors
8	Dib	I-authors
8	IngridLafon	I-authors
8	IngridLafon	I-authors
8	Ingrid	I-authors
8	Lafon	I-authors
8	DietgerNiederwieser	I-authors
8	DietgerNiederwieser	I-authors
8	Dietger	I-authors
8	Niederwieser	I-authors
8	TamasMasszi	I-authors
8	TamasMasszi	I-authors
8	Tamas	I-authors
8	Masszi	I-authors
8	JeanFontan	I-authors
8	JeanFontan	I-authors
8	Jean	I-authors
8	Fontan	I-authors
8	MauricetteMichallet	I-authors
8	MauricetteMichallet	I-authors
8	Mauricette	I-authors
8	Michallet	I-authors
8	AloisGratwohl	I-authors
8	AloisGratwohl	I-authors
8	Alois	I-authors
8	Gratwohl	I-authors
8	GiuseppeMilone	I-authors
8	GiuseppeMilone	I-authors
8	Giuseppe	I-authors
8	Milone	I-authors
8	ChantalDoyen	I-authors
8	ChantalDoyen	I-authors
8	Chantal	I-authors
8	Doyen	I-authors
8	BrigittePegourie	I-authors
8	BrigittePegourie	I-authors
8	Brigitte	I-authors
8	Pegourie	I-authors
8	RomanHajek	I-authors
8	RomanHajek	I-authors
8	Roman	I-authors
8	Hajek	I-authors
8	PhilippeCasassus	I-authors
8	PhilippeCasassus	I-authors
8	Philippe	I-authors
8	Casassus	I-authors
8	BrigitteKolb	I-authors
8	BrigitteKolb	I-authors
8	Brigitte	I-authors
8	Kolb	I-authors
8	CarineChaleteix	I-authors
8	CarineChaleteix	I-authors
8	Carine	I-authors
8	Chaleteix	I-authors
8	BerndHertenstein	I-authors
8	BerndHertenstein	I-authors
8	Bernd	I-authors
8	Hertenstein	I-authors
8	FrancescoOnida	I-authors
8	FrancescoOnida	I-authors
8	Francesco	I-authors
8	Onida	I-authors
8	HeinzLudwig	I-authors
8	HeinzLudwig	I-authors
8	Heinz	I-authors
8	Ludwig	I-authors
8	NicolasKetterer	I-authors
8	NicolasKetterer	I-authors
8	Nicolas	I-authors
8	Ketterer	I-authors
8	ChristianKoenecke	I-authors
8	ChristianKoenecke	I-authors
8	Christian	I-authors
8	Koenecke	I-authors
8	MarleenVan	I-authors
8	Os	I-authors
8	MarleenVan	I-authors
8	Os	I-authors
8	Marleen	I-authors
8	Van	I-authors
8	Os	I-authors
8	MohamadMohty	I-authors
8	MohamadMohty	I-authors
8	Mohamad	I-authors
8	Mohty	I-authors
8	JeanLuc	I-authors
8	Harousseau	I-authors
8	JeanLuc	I-authors
8	Harousseau	I-authors
8	Jean	I-authors
8	Luc	I-authors
8	Harousseau	I-authors
8	Andrew	I-authors
8	Cakana	I-authors
8	Norbert	I-authors
8	Claude	I-authors
8	Gorin	I-authors
--------------------------------------------------------------
9	Gösta	B-authors
9	Gahrton	I-authors
9	Theo	I-authors
9	de	I-authors
9	Witte	I-authors
9	,	I-authors
9	Curly	I-authors
9	Morris	I-authors
9	Gösta	O
9	Gahrton	O
9	Superiority	O
9	of	O
9	the	O
9	Triple	B-arm_description
9	Combination	I-arm_description
9	of	I-arm_description
9	Bortezomib	I-arm_description
9	-	I-arm_description
9	Thalidomide	I-arm_description
9	-	I-arm_description
9	Dexamethasone	I-arm_description
9	Over	O
9	the	O
9	Dual	O
9	Combination	O
9	of	O
9	Thalidomide	O
9	-	O
9	Dexamethasone	O
9	in	O
9	Patients	O
9	With	O
9	Multiple	O
9	Myeloma	O
9	Progressing	O
9	or	O
9	Relapsing	O
9	After	O
9	Autologous	O
9	Transplantation	O
9	:	O
9	The	O
9	MMVAR	O
9	/	O
9	IFM	O
9	2005	O
9	-	O
9	04	O
9	Randomized	B-study_type
9	Phase	I-study_type
9	III	I-study_type
9	Trial	O
9	From	O
9	the	O
9	Chronic	O
9	Leukemia	O
9	Working	O
9	Party	O
9	of	O
9	the	O
9	European	O
9	Group	O
9	for	O
9	Blood	O
9	and	O
9	Marrow	O
9	Transplantation	O
9	10.1200	O
9	/	O
9	JCO.2011.37.4918	O
9	Submitted	O
9	June	O
9	7	O
9	,	O
9	2011	O
9	;	O
9	accepted	O
9	March	O
9	1	O
9	,	O
9	2012	O
9	;	O
--------------------------------------------------------------
10	Gösta	O
10	Gahrton	O
10	Theo	O
10	de	O
10	Witte	O
10	,	O
10	Curly	O
10	Morris	O
10	Gösta	O
10	Gahrton	O
10	Superiority	O
10	of	O
10	the	O
10	Triple	O
10	Combination	O
10	of	O
10	Bortezomib	O
10	-	O
10	Thalidomide	O
10	-	O
10	Dexamethasone	O
10	Over	O
10	the	O
10	Dual	B-arm_description
10	Combination	I-arm_description
10	of	I-arm_description
10	Thalidomide	I-arm_description
10	-	I-arm_description
10	Dexamethasone	I-arm_description
10	in	O
10	Patients	O
10	With	O
10	Multiple	O
10	Myeloma	O
10	Progressing	O
10	or	O
10	Relapsing	O
10	After	O
10	Autologous	O
10	Transplantation	O
10	:	O
10	The	O
10	MMVAR	O
10	/	O
10	IFM	O
10	2005	O
10	-	O
10	04	O
10	Randomized	O
10	Phase	O
10	III	O
10	Trial	O
10	From	O
10	the	O
10	Chronic	O
10	Leukemia	O
10	Working	O
10	Party	O
10	of	O
10	the	O
10	European	O
10	Group	O
10	for	O
10	Blood	O
10	and	O
10	Marrow	O
10	Transplantation	O
10	10.1200	O
10	/	O
10	JCO.2011.37.4918	O
10	Submitted	O
10	June	O
10	7	O
10	,	O
10	2011	O
10	;	O
10	accepted	O
10	March	O
10	1	O
10	,	O
10	2012	O
10	;	O
--------------------------------------------------------------
11	Patients	O
11	with	O
11	confirmed	O
11	MM	O
11	and	O
11	measurable	O
11	disease	O
11	were	O
11	eligible	O
11	if	O
11	they	O
11	had	O
11	progressed	O
11	or	O
11	relapsed	O
11	after	O
11	at	O
11	least	O
11	one	O
11	ASCT	O
11	and	O
11	provided	O
11	it	O
11	was	O
11	their	O
11	first	O
11	progression	O
11	or	O
11	relapse	O
11	.	O
11	Previous	O
11	allogeneic	O
11	transplantation	O
11	was	O
11	prohibited	O
11	.	O
11	A	O
11	Karnofsky	O
11	performance	O
11	status	O
11	above	O
11	50	O
11	%	O
11	,	O
11	platelets	O
11	at	O
11	or	O
11	higher	O
11	than	O
11	40,000	O
11	/	O
11	L	O
11	,	O
11	absolute	O
11	neutrophil	O
11	count	O
11	at	O
11	or	O
11	higher	O
11	than	O
11	1,000	O
11	/	O
11	L	O
11	,	O
11	and	O
11	creatinine	O
11	clearance	O
11	at	O
11	or	O
11	higher	O
11	than	O
11	30	O
11	mL	O
11	/	O
11	min	O
11	were	O
11	required	O
11	.	O
11	Exclusion	O
11	criteria	O
11	included	O
11	grade	O
11	2	O
11	or	O
11	higher	O
11	peripheral	O
11	neuropathy	O
11	.	O
11	On	O
11	retrospective	O
11	analysis	O
11	,	O
11	31	O
11	patients	O
11	did	O
11	not	O
11	meet	O
11	these	O
11	criteria	O
11	,	O
11	that	O
11	is	O
11	,	O
11	15	O
11	patients	O
11	had	O
11	neuropathy	O
11	above	O
11	grade	O
11	1	O
11	,	O
11	six	O
11	had	O
11	impaired	O
11	hematopoiesis	O
11	,	O
11	four	O
11	had	O
11	impaired	O
11	kidney	O
11	function	O
11	,	O
11	five	O
11	patients	O
11	were	O
11	in	O
11	second	O
11	relapse	O
11	,	O
11	and	O
11	one	O
11	had	O
11	nonsecretory	O
11	MM	O
11	.	O
11	These	O
11	deviations	O
11	were	O
11	evenly	O
11	distributed	O
11	in	O
11	both	O
11	arms	O
11	and	O
11	,	O
11	since	O
11	the	O
11	deviations	O
11	were	O
11	considered	O
11	minor	O
11	,	O
11	all	O
11	patients	O
11	originally	O
11	included	O
11	were	O
11	analyzed	O
11	.	O
11	Women	O
11	of	O
11	childbearing	O
11	age	O
11	had	O
11	to	O
11	use	O
11	a	O
11	method	O
11	of	O
11	birth	O
11	control	O
11	and	O
11	have	O
11	a	O
11	negative	O
11	serum	O
11	or	O
11	urine	O
11	beta	O
11	-	O
11	human	O
11	chorionic	O
11	gonadotropin	O
11	pregnancy	O
11	test	O
11	at	O
11	screening	O
11	and	O
11	throughout	O
11	the	O
11	study	O
11	.	O
11	Men	O
11	had	O
11	to	O
11	use	O
11	contraception	O
11	.	O
11	Review	O
11	boards	O
11	at	O
11	participating	O
11	institutions	O
11	and	O
11	regulatory	O
11	authorities	O
11	approved	O
11	the	O
11	study	O
11	,	O
11	which	O
11	was	O
11	conducted	O
11	according	O
11	to	O
11	the	O
11	Declaration	O
11	of	O
11	Helsinki	O
11	and	O
11	International	O
11	Conference	O
11	on	O
11	Harmonisation	O
11	Good	O
11	Clinical	O
11	Practice	O
11	Guidelines	O
11	.	O
11	All	O
11	patients	O
11	provided	O
11	written	O
11	informed	O
11	consent	O
11	.	O
--------------------------------------------------------------
12	This	O
12	international	O
12	randomized	B-study_type
12	,	I-study_type
12	controlled	I-study_type
12	,	I-study_type
12	open	I-study_type
12	-	I-study_type
12	label	I-study_type
12	study	B-study_type
12	enrolled	O
12	269	O
12	patients	O
12	from	O
12	60	O
12	centers	O
12	and	O
12	randomly	O
12	assigned	O
12	them	O
12	to	O
12	the	O
12	triple	B-arm_description
12	combination	B-arm_description
12	VTD	B-arm_description
12	or	O
12	to	O
12	the	O
12	dual	O
12	combination	O
12	TD	O
12	(	O
12	CONSORT	O
12	diagram	O
12	;	O
12	Fig	O
12	1	O
12	)	O
12	.	O
12	Patients	O
12	were	O
12	stratified	O
12	by	O
12	number	O
12	of	O
12	previous	O
12	ASCTs	O
12	and	O
12	by	O
12	center	O
12	at	O
12	screening	O
12	.	O
12	All	O
12	patients	O
12	received	O
12	thalidomide	B-arm_dosage
12	scheduled	B-arm_dosage
12	at	B-arm_dosage
12	200	B-arm_dosage
12	mg	B-arm_dosage
12	per	B-arm_dosage
12	day	B-arm_dosage
12	orally	B-arm_dosage
12	for	B-arm_dosage
12	1	B-arm_dosage
12	year	B-arm_dosage
12	and	B-arm_dosage
12	dexamethasone	B-arm_dosage
12	40	B-arm_dosage
12	mg	B-arm_dosage
12	per	B-arm_dosage
12	day	B-arm_dosage
12	orally	B-arm_dosage
12	for	B-arm_dosage
12	four	B-arm_dosage
12	days	B-arm_dosage
12	every	B-arm_dosage
12	3	B-arm_dosage
12	weeks	B-arm_dosage
12	for	B-arm_dosage
12	1	B-arm_dosage
12	year	B-arm_dosage
12	.	O
12	Patients	O
12	assigned	O
12	to	O
12	VTD	O
12	received	O
12	1.3	B-arm_dosage
12	mg	B-arm_dosage
12	/	B-arm_dosage
12	m	B-arm_dosage
12	2	B-arm_dosage
12	bortezomib	B-arm_dosage
12	as	B-arm_dosage
12	an	B-arm_dosage
12	intravenous	B-arm_dosage
12	bolus	B-arm_dosage
12	on	B-arm_dosage
12	days	B-arm_dosage
12	1	B-arm_dosage
12	,	B-arm_dosage
12	4	B-arm_dosage
12	,	B-arm_dosage
12	8	B-arm_dosage
12	,	O
12	and	B-arm_dosage
12	11	B-arm_dosage
12	followed	B-arm_dosage
12	by	B-arm_dosage
12	a	B-arm_dosage
12	10-day	I-arm_dosage
12	rest	I-arm_dosage
12	period	I-arm_dosage
12	(	I-arm_dosage
12	day	I-arm_dosage
12	12	I-arm_dosage
12	to	I-arm_dosage
12	day	I-arm_dosage
12	21	I-arm_dosage
12	)	I-arm_dosage
12	for	I-arm_dosage
12	eight	I-arm_dosage
12	cycles	I-arm_dosage
12	(	I-arm_dosage
12	6	I-arm_dosage
12	months	I-arm_dosage
12	)	I-arm_dosage
12	and	I-arm_dosage
12	then	I-arm_dosage
12	on	I-arm_dosage
12	days	I-arm_dosage
12	1	I-arm_dosage
12	,	I-arm_dosage
12	8	I-arm_dosage
12	,	I-arm_dosage
12	15	I-arm_dosage
12	,	I-arm_dosage
12	and	I-arm_dosage
12	22	I-arm_dosage
12	followed	I-arm_dosage
12	by	I-arm_dosage
12	a	I-arm_dosage
12	20-day	I-arm_dosage
12	rest	I-arm_dosage
12	period	I-arm_dosage
12	(	I-arm_dosage
12	day	I-arm_dosage
12	23	I-arm_dosage
12	to	I-arm_dosage
12	day	I-arm_dosage
12	42	I-arm_dosage
12	)	I-arm_dosage
12	for	I-arm_dosage
12	four	I-arm_dosage
12	cycles	I-arm_dosage
12	(	I-arm_dosage
12	6	I-arm_dosage
12	months	I-arm_dosage
12	)	I-arm_dosage
12	.	I-arm_dosage
12	Antithrombotic	O
12	prophylaxis	O
12	was	O
12	mandatory	O
12	in	O
12	both	O
12	arms	O
12	.	O
12	Enoxaparin	O
12	(	O
12	40	O
12	mg	O
12	per	O
12	day	O
12	subcutaneously	O
12	)	O
12	was	O
12	used	O
12	for	O
12	primary	O
12	prophylaxis	O
12	,	O
12	and	O
12	warfarin	O
12	was	O
12	used	O
12	for	O
12	secondary	O
12	prophylaxis	O
12	.	O
12	Prophylaxis	O
12	against	O
12	herpes	O
12	zoster	O
12	infection	O
12	was	O
12	highly	O
12	recommended	O
12	in	O
12	the	O
12	VTD	O
12	arm	O
12	.	O
12	Transfusion	O
12	support	O
12	as	O
12	well	O
12	as	O
12	neutrophils	O
12	and	O
12	erythropoietic	O
12	growth	O
12	factors	O
12	were	O
12	allowed	O
12	.	O
12	Bisphosphonates	O
12	were	O
12	used	O
12	according	O
12	to	O
12	established	O
12	guidelines	O
12	.	O
12	Dose	O
12	reduction	O
12	strategies	O
12	were	O
12	recommended	O
12	for	O
12	significant	O
12	toxicities	O
12	.	O
--------------------------------------------------------------
13	This	O
13	international	O
13	randomized	O
13	,	O
13	controlled	O
13	,	O
13	open	O
13	-	O
13	label	O
13	study	O
13	enrolled	O
13	269	O
13	patients	O
13	from	O
13	60	O
13	centers	O
13	and	O
13	randomly	O
13	assigned	O
13	them	O
13	to	O
13	the	O
13	triple	O
13	combination	O
13	VTD	O
13	or	O
13	to	O
13	the	O
13	dual	B-arm_description
13	combination	I-arm_description
13	TD	I-arm_description
13	(	O
13	CONSORT	O
13	diagram	O
13	;	O
13	Fig	O
13	1	O
13	)	O
13	.	O
13	Patients	O
13	were	O
13	stratified	O
13	by	O
13	number	O
13	of	O
13	previous	O
13	ASCTs	O
13	and	O
13	by	O
13	center	O
13	at	O
13	screening	O
13	.	O
13	All	O
13	patients	O
13	received	O
13	thalidomide	B-arm_dosage
13	scheduled	I-arm_dosage
13	at	I-arm_dosage
13	200	I-arm_dosage
13	mg	I-arm_dosage
13	per	I-arm_dosage
13	day	I-arm_dosage
13	orally	I-arm_dosage
13	for	I-arm_dosage
13	1	I-arm_dosage
13	year	I-arm_dosage
13	and	I-arm_dosage
13	dexamethasone	I-arm_dosage
13	40	I-arm_dosage
13	mg	I-arm_dosage
13	per	I-arm_dosage
13	day	I-arm_dosage
13	orally	I-arm_dosage
13	for	I-arm_dosage
13	four	I-arm_dosage
13	days	I-arm_dosage
13	every	I-arm_dosage
13	3	I-arm_dosage
13	weeks	I-arm_dosage
13	for	I-arm_dosage
13	1	I-arm_dosage
13	year	I-arm_dosage
13	.	O
13	Patients	O
13	assigned	O
13	to	O
13	VTD	O
13	received	O
13	1.3	O
13	mg	O
13	/	O
13	m	O
13	2	O
13	bortezomib	O
13	as	O
13	an	O
13	intravenous	O
13	bolus	O
13	on	O
13	days	O
13	1	O
13	,	O
13	4	O
13	,	O
13	8	O
13	,	O
13	and	O
13	11	O
13	followed	O
13	by	O
13	a	O
13	10-day	O
13	rest	O
13	period	O
13	(	O
13	day	O
13	12	O
13	to	O
13	day	O
13	21	O
13	)	O
13	for	O
13	eight	O
13	cycles	O
13	(	O
13	6	O
13	months	O
13	)	O
13	and	O
13	then	O
13	on	O
13	days	O
13	1	O
13	,	O
13	8	O
13	,	O
13	15	O
13	,	O
13	and	O
13	22	O
13	followed	O
13	by	O
13	a	O
13	20-day	O
13	rest	O
13	period	O
13	(	O
13	day	O
13	23	O
13	to	O
13	day	O
13	42	O
13	)	O
13	for	O
13	four	O
13	cycles	O
13	(	O
13	6	O
13	months	O
13	)	O
13	.	O
13	Antithrombotic	O
13	prophylaxis	O
13	was	O
13	mandatory	O
13	in	O
13	both	O
13	arms	O
13	.	O
13	Enoxaparin	O
13	(	O
13	40	O
13	mg	O
13	per	O
13	day	O
13	subcutaneously	O
13	)	O
13	was	O
13	used	O
13	for	O
13	primary	O
13	prophylaxis	O
13	,	O
13	and	O
13	warfarin	O
13	was	O
13	used	O
13	for	O
13	secondary	O
13	prophylaxis	O
13	.	O
13	Prophylaxis	O
13	against	O
13	herpes	O
13	zoster	O
13	infection	O
13	was	O
13	highly	O
13	recommended	O
13	in	O
13	the	O
13	VTD	O
13	arm	O
13	.	O
13	Transfusion	O
13	support	O
13	as	O
13	well	O
13	as	O
13	neutrophils	O
13	and	O
13	erythropoietic	O
13	growth	O
13	factors	O
13	were	O
13	allowed	O
13	.	O
13	Bisphosphonates	O
13	were	O
13	used	O
13	according	O
13	to	O
13	established	O
13	guidelines	O
13	.	O
13	Dose	O
13	reduction	O
13	strategies	O
13	were	O
13	recommended	O
13	for	O
13	significant	O
13	toxicities	O
13	.	O
--------------------------------------------------------------
14	Study	O
14	treatment	O
14	continued	O
14	for	O
14	1	O
14	year	O
14	.	O
14	Treatment	O
14	was	O
14	withheld	O
14	on	O
14	withdrawal	O
14	of	O
14	the	O
14	patient	O
14	's	O
14	consent	O
14	,	O
14	disease	O
14	progression	O
14	,	O
14	or	O
14	the	O
14	occurrence	O
14	of	O
14	any	O
14	grade	O
14	4	O
14	toxic	O
14	effects	O
14	.	O
14	Patients	O
14	who	O
14	were	O
14	still	O
14	responding	O
14	after	O
14	1	O
14	year	O
14	of	O
14	treatment	O
14	could	O
14	continue	O
14	,	O
14	provided	O
14	that	O
14	treatment	O
14	was	O
14	tolerated	O
14	.	O
14	A	O
14	new	O
14	transplantation	O
14	,	O
14	either	O
14	autologous	O
14	or	O
14	allogeneic	O
14	,	O
14	could	O
14	be	O
14	performed	O
14	only	O
14	in	O
14	patients	O
14	who	O
14	completed	O
14	the	O
14	planned	O
14	1-year	O
14	treatment	O
14	.	O
14	The	O
14	study	O
14	did	O
14	not	O
14	allow	O
14	crossover	O
14	from	O
14	the	O
14	TD	B-arm_description
14	arm	B-arm_description
14	to	O
14	the	O
14	VTD	O
14	arm	O
14	.	O
--------------------------------------------------------------
15	Study	O
15	treatment	O
15	continued	O
15	for	O
15	1	O
15	year	O
15	.	O
15	Treatment	O
15	was	O
15	withheld	O
15	on	O
15	withdrawal	O
15	of	O
15	the	O
15	patient	O
15	's	O
15	consent	O
15	,	O
15	disease	O
15	progression	O
15	,	O
15	or	O
15	the	O
15	occurrence	O
15	of	O
15	any	O
15	grade	O
15	4	O
15	toxic	O
15	effects	O
15	.	O
15	Patients	O
15	who	O
15	were	O
15	still	O
15	responding	O
15	after	O
15	1	O
15	year	O
15	of	O
15	treatment	O
15	could	O
15	continue	O
15	,	O
15	provided	O
15	that	O
15	treatment	O
15	was	O
15	tolerated	O
15	.	O
15	A	O
15	new	O
15	transplantation	O
15	,	O
15	either	O
15	autologous	O
15	or	O
15	allogeneic	O
15	,	O
15	could	O
15	be	O
15	performed	O
15	only	O
15	in	O
15	patients	O
15	who	O
15	completed	O
15	the	O
15	planned	O
15	1-year	O
15	treatment	O
15	.	O
15	The	O
15	study	O
15	did	O
15	not	O
15	allow	O
15	crossover	O
15	from	O
15	the	O
15	TD	O
15	arm	O
15	to	O
15	the	O
15	VTD	B-arm_description
15	arm	B-arm_description
15	.	O
--------------------------------------------------------------
16	The	O
16	primary	O
16	end	O
16	point	O
16	was	O
16	TTP	B-arm_efficacy_metric
16	,	B-arm_efficacy_metric
16	defined	O
16	as	O
16	the	O
16	interval	O
16	from	O
16	random	O
16	assignment	O
16	to	O
16	disease	O
16	progression	O
16	,	O
16	and	O
16	was	O
16	assessed	O
16	on	O
16	the	O
16	intent	O
16	-	O
16	to	O
16	-	O
16	treat	O
16	(	O
16	ITT	O
16	)	O
16	population	O
16	.	O
16	Secondary	O
16	end	O
16	points	O
16	included	O
16	progression	B-arm_efficacy_metric
16	-	I-arm_efficacy_metric
16	free	I-arm_efficacy_metric
16	survival	I-arm_efficacy_metric
16	(	B-arm_efficacy_metric
16	PFS	B-arm_efficacy_metric
16	)	B-arm_efficacy_metric
16	,	O
16	defined	O
16	as	O
16	time	O
16	from	O
16	random	O
16	assignment	O
16	to	O
16	progression	O
16	or	O
16	death	O
16	from	O
16	any	O
16	cause	O
16	,	O
16	OS	O
16	,	O
16	defined	O
16	as	O
16	the	O
16	interval	O
16	from	O
16	random	O
16	assignment	O
16	to	O
16	death	O
16	from	O
16	any	O
16	cause	O
16	,	O
16	overall	O
16	response	O
16	rate	O
16	(	O
16	CR	O
16	ϩ	O
16	PR	O
16	)	O
16	,	O
16	and	O
16	safety	O
16	.	O
--------------------------------------------------------------
17	Progression	O
17	and	O
17	response	O
17	were	O
17	determined	O
17	according	O
17	to	O
17	EBMT	O
17	criteria	O
17	15	O
17	with	O
17	reference	O
17	to	O
17	investigator	O
17	-	O
17	reported	O
17	TTP	B-arm_efficacy_metric
17	or	O
17	response	O
17	reports	O
17	.	O
17	Two	O
17	additional	O
17	PR	O
17	subcategories	O
17	were	O
17	defined	O
17	.	O
17	The	O
17	nCR	O
17	category	O
17	was	O
17	a	O
17	PR	O
17	subcategory	O
17	meeting	O
17	all	O
17	CR	O
17	criteria	O
17	except	O
17	for	O
17	a	O
17	positive	O
17	immunofixation	O
17	.	O
17	The	O
17	very	O
17	good	O
17	partial	O
17	response	O
17	(	O
17	VGPR	O
17	)	O
17	subcategory	O
17	(	O
17	International	O
17	Myeloma	O
17	Working	O
17	Group	O
17	[	O
17	IMWG	O
17	]	O
17	criteria	O
17	)	O
17	was	O
17	a	O
17	PR	O
17	subcategory	O
17	attained	O
17	by	O
17	patients	O
17	who	O
17	had	O
17	had	O
17	a	O
17	90	O
17	%	O
17	or	O
17	greater	O
17	reduction	O
17	in	O
17	their	O
17	serum	O
17	M	O
17	-	O
17	component	O
17	since	O
17	diagnosis	O
17	.	O
17	All	O
17	patients	O
17	,	O
17	including	O
17	those	O
17	who	O
17	discontinued	O
17	treatment	O
17	,	O
17	were	O
17	followed	O
17	up	O
17	for	O
17	progression	O
17	every	O
17	3	O
17	weeks	O
17	for	O
17	the	O
17	first	O
17	6	O
17	months	O
17	and	O
17	every	O
17	6	O
17	weeks	O
17	thereafter	O
17	.	O
17	Safety	O
17	,	O
17	assessed	O
17	in	O
17	all	O
17	patients	O
17	who	O
17	received	O
17	one	O
17	or	O
17	more	O
17	drug	O
17	doses	O
17	until	O
17	30	O
17	days	O
17	after	O
17	the	O
17	last	O
17	dose	O
17	,	O
17	was	O
17	graded	O
17	according	O
17	to	O
17	National	O
17	Cancer	O
17	Institute	O
17	Common	O
17	Toxicity	O
17	Criteria	O
17	(	O
17	NCI	O
17	CTC	O
17	,	O
17	version	O
17	3	O
17	)	O
17	.	O
--------------------------------------------------------------
18	The	O
18	study	O
18	was	O
18	designed	O
18	to	O
18	provide	O
18	90	O
18	%	O
18	power	O
18	to	O
18	detect	O
18	a	O
18	hazard	B-arm_efficacy_metric
18	ratio	I-arm_efficacy_metric
18	(	I-arm_efficacy_metric
18	HR	I-arm_efficacy_metric
18	)	I-arm_efficacy_metric
18	of	O
18	0.67	O
18	(	B-arm_efficacy_metric
18	VTD	I-arm_efficacy_metric
18	v	I-arm_efficacy_metric
18	TD	I-arm_efficacy_metric
18	)	I-arm_efficacy_metric
18	for	I-arm_efficacy_metric
18	TTP	I-arm_efficacy_metric
18	at	O
18	a	O
18	one	O
18	-	O
18	sided	O
18	overall	O
18	significance	O
18	level	O
18	of	O
18	0.025	O
18	.	O
18	Four	O
18	interim	O
18	analyses	O
18	were	O
18	planned	O
18	to	O
18	test	O
18	for	O
18	efficacy	O
18	and	O
18	futility	O
18	using	O
18	an	O
18	alpha	O
18	-	O
18	spending	O
18	function	O
18	as	O
18	for	O
18	O'Brien	O
18	-	O
18	Fleming	O
18	-	O
18	type	O
18	boundaries	O
18	(	O
18	for	O
18	details	O
18	,	O
18	see	O
18	Fig	O
18	1	O
18	;	O
18	implementation	O
18	in	O
18	EAST	O
18	v	O
18	3.1.0	O
18	,	O
18	Cambridge	O
18	,	O
18	MA	O
18	)	O
18	.	O
18	The	O
18	trial	O
18	was	O
18	stopped	O
18	for	O
18	superiority	O
18	of	O
18	VTD	B-arm_description
18	over	O
18	TD	O
18	after	O
18	the	O
18	second	O
18	interim	O
18	analysis	O
18	performed	O
18	after	O
18	134	O
18	events	O
18	and	O
18	a	O
18	median	O
18	follow	O
18	-	O
18	up	O
18	of	O
18	24	O
18	months	O
18	.	O
--------------------------------------------------------------
19	The	O
19	study	O
19	was	O
19	designed	O
19	to	O
19	provide	O
19	90	O
19	%	O
19	power	O
19	to	O
19	detect	O
19	a	O
19	hazard	B-arm_efficacy_metric
19	ratio	I-arm_efficacy_metric
19	(	I-arm_efficacy_metric
19	HR	I-arm_efficacy_metric
19	)	I-arm_efficacy_metric
19	of	O
19	0.67	O
19	(	B-arm_efficacy_metric
19	VTD	I-arm_efficacy_metric
19	v	I-arm_efficacy_metric
19	TD	I-arm_efficacy_metric
19	)	I-arm_efficacy_metric
19	for	I-arm_efficacy_metric
19	TTP	I-arm_efficacy_metric
19	at	O
19	a	O
19	one	O
19	-	O
19	sided	O
19	overall	O
19	significance	O
19	level	O
19	of	O
19	0.025	O
19	.	O
19	Four	O
19	interim	O
19	analyses	O
19	were	O
19	planned	O
19	to	O
19	test	O
19	for	O
19	efficacy	O
19	and	O
19	futility	O
19	using	O
19	an	O
19	alpha	O
19	-	O
19	spending	O
19	function	O
19	as	O
19	for	O
19	O'Brien	O
19	-	O
19	Fleming	O
19	-	O
19	type	O
19	boundaries	O
19	(	O
19	for	O
19	details	O
19	,	O
19	see	O
19	Fig	O
19	1	O
19	;	O
19	implementation	O
19	in	O
19	EAST	O
19	v	O
19	3.1.0	O
19	,	O
19	Cambridge	O
19	,	O
19	MA	O
19	)	O
19	.	O
19	The	O
19	trial	O
19	was	O
19	stopped	O
19	for	O
19	superiority	O
19	of	O
19	VTD	O
19	over	O
19	TD	O
19	after	O
19	the	O
19	second	O
19	interim	O
19	analysis	O
19	performed	O
19	after	O
19	134	O
19	events	O
19	and	O
19	a	O
19	median	O
19	follow	O
19	-	O
19	up	O
19	of	O
19	24	O
19	months	O
19	.	O
--------------------------------------------------------------
20	Median	B-arm_efficacy_metric
20	TTP	I-arm_efficacy_metric
20	was	O
20	estimated	O
20	from	O
20	the	O
20	cumulative	O
20	incidence	O
20	curve	O
20	for	O
20	progression	O
20	(	O
20	death	O
20	without	O
20	progression	O
20	was	O
20	a	O
20	competing	O
20	risk	O
20	)	O
20	.	O
20	The	O
20	adjusted	O
20	analysis	O
20	was	O
20	performed	O
20	on	O
20	the	O
20	stratified	O
20	Cox	O
20	regression	O
20	for	O
20	the	O
20	cause	O
20	-	O
20	specific	O
20	hazard	O
20	.	O
20	Similar	O
20	methods	O
20	for	O
20	competing	O
20	risk	O
20	end	O
20	points	O
20	were	O
20	used	O
20	to	O
20	calculate	O
20	time	O
20	to	O
20	achievement	O
20	of	O
20	response	O
20	(	O
20	with	O
20	death	O
20	and	O
20	progression	O
20	as	O
20	competing	O
20	events	O
20	)	O
20	.	O
20	The	O
20	Kaplan	O
20	-	O
20	Meier	O
20	probability	O
20	estimator	O
20	and	O
20	Cox	O
20	models	O
20	were	O
20	used	O
20	to	O
20	calculate	O
20	PFS	B-arm_efficacy_metric
20	,	O
20	OS	O
20	,	O
20	and	O
20	duration	O
20	of	O
20	response	O
20	(	O
20	DOR	O
20	)	O
20	.	O
20	All	O
20	analyses	O
20	were	O
20	performed	O
20	using	O
20	R	O
20	v	O
20	2.10.0	O
20	software	O
20	(	O
20	http://www.r-project.org	O
20	)	O
20	.	O
--------------------------------------------------------------
21	From	O
21	January	O
21	2006	O
21	to	O
21	July	O
21	2010	O
21	,	O
21	135	O
21	and	O
21	134	O
21	patients	B-study_type
21	were	B-study_type
21	randomly	B-study_type
21	assigned	B-study_type
21	to	O
21	VTD	B-arm_description
21	and	O
21	TD	O
21	,	O
21	respectively	O
21	(	O
21	Fig	O
21	1	O
21	)	O
21	.	O
21	Their	O
21	baseline	O
21	demographic	O
21	data	O
21	and	O
21	other	O
21	characteristics	O
21	,	O
21	including	O
21	number	O
21	of	O
21	prior	O
21	ASCTs	O
21	,	O
21	were	O
21	well	O
21	balanced	O
21	(	O
21	Table	O
21	1	O
21	)	O
21	.	O
21	Median	O
21	follow	O
21	-	O
21	up	O
21	at	O
21	the	O
21	last	O
21	update	O
21	(	O
21	March	O
21	2	O
21	,	O
21	2011	O
21	)	O
21	was	O
21	30	O
21	months	O
21	(	O
21	range	O
21	,	O
21	1	O
21	to	O
21	62	O
21	months	O
21	)	O
21	with	O
21	22	O
21	patients	O
21	still	O
21	being	O
21	treated	O
21	(	O
21	11	O
21	in	O
21	each	O
21	arm	O
21	)	O
21	.	O
--------------------------------------------------------------
22	From	O
22	January	O
22	2006	O
22	to	O
22	July	O
22	2010	O
22	,	O
22	135	O
22	and	O
22	134	O
22	patients	O
22	were	O
22	randomly	O
22	assigned	O
22	to	O
22	VTD	O
22	and	O
22	TD	B-arm_description
22	,	O
22	respectively	O
22	(	O
22	Fig	O
22	1	O
22	)	O
22	.	O
22	Their	O
22	baseline	O
22	demographic	O
22	data	O
22	and	O
22	other	O
22	characteristics	O
22	,	O
22	including	O
22	number	O
22	of	O
22	prior	O
22	ASCTs	O
22	,	O
22	were	O
22	well	O
22	balanced	O
22	(	O
22	Table	O
22	1	O
22	)	O
22	.	O
22	Median	O
22	follow	O
22	-	O
22	up	O
22	at	O
22	the	O
22	last	O
22	update	O
22	(	O
22	March	O
22	2	O
22	,	O
22	2011	O
22	)	O
22	was	O
22	30	O
22	months	O
22	(	O
22	range	O
22	,	O
22	1	O
22	to	O
22	62	O
22	months	O
22	)	O
22	with	O
22	22	O
22	patients	O
22	still	O
22	being	O
22	treated	O
22	(	O
22	11	O
22	in	O
22	each	O
22	arm	O
22	)	O
22	.	O
--------------------------------------------------------------
23	Median	O
23	TTP	O
23	was	O
23	longer	O
23	in	O
23	patients	O
23	receiving	O
23	VTD	B-arm_description
23	than	O
23	TD	O
23	(	O
23	19.5	O
23	v	O
23	13.8	O
23	months	O
23	)	O
23	.	O
23	VTD	O
23	reduced	O
23	the	O
23	risk	O
23	of	O
23	developing	O
23	disease	O
23	progression	O
23	by	O
23	40	O
23	%	O
23	(	O
23	HR	O
23	,	O
23	0.59	O
23	;	O
23	95	O
23	%	O
23	CI	O
23	,	O
23	0.44	O
23	to	O
23	0.80	O
23	;	O
23	P	O
23	ϭ	O
23	.001	O
23	;	O
23	Fig	O
23	2A	O
23	)	O
23	.	O
23	Median	B-arm_efficacy_metric
23	PFS	I-arm_efficacy_metric
23	was	O
23	significantly	O
23	longer	O
23	for	O
23	VTD	O
23	than	O
23	TD	O
23	(	O
23	18.3	B-arm_efficacy_results
23	months	I-arm_efficacy_results
23	[	I-arm_efficacy_results
23	95	I-arm_efficacy_results
23	%	I-arm_efficacy_results
23	CI	I-arm_efficacy_results
23	,	I-arm_efficacy_results
23	15.5	I-arm_efficacy_results
23	to	I-arm_efficacy_results
23	20.6	I-arm_efficacy_results
23	months	I-arm_efficacy_results
23	]	I-arm_efficacy_results
23	v	O
23	13.6	O
23	months	O
23	[	O
23	95	O
23	%	O
23	CI	O
23	,	O
23	9.9	O
23	to	O
23	16.1	O
23	months	O
23	]	O
23	;	B-arm_efficacy_results
23	HR	I-arm_efficacy_results
23	,	I-arm_efficacy_results
23	0.61	I-arm_efficacy_results
23	;	I-arm_efficacy_results
23	95	I-arm_efficacy_results
23	%	I-arm_efficacy_results
23	CI	I-arm_efficacy_results
23	,	I-arm_efficacy_results
23	0.45	I-arm_efficacy_results
23	to	I-arm_efficacy_results
23	0.81	I-arm_efficacy_results
23	;	I-arm_efficacy_results
23	P	I-arm_efficacy_results
23	ϭ	I-arm_efficacy_results
23	.001	I-arm_efficacy_results
23	;	O
23	Fig	O
23	2B	O
23	)	O
23	.	O
23	During	O
23	the	O
23	1-year	O
23	treatment	O
23	period	O
23	(	O
23	cutoff	O
23	,	O
23	March	O
23	2	O
23	,	O
23	2011	O
23	)	O
23	,	O
23	we	O
23	recorded	O
23	14	O
23	deaths	O
23	for	O
23	VTD	O
23	and	O
23	20	O
23	deaths	O
23	for	O
23	TD	O
23	,	O
23	11	O
23	cases	O
23	versus	O
23	17	O
23	cases	O
23	of	O
23	relapse	O
23	/	O
23	progression	O
23	,	O
23	three	O
23	cases	O
23	versus	O
23	one	O
23	case	O
23	of	O
23	infection	O
23	,	O
23	and	O
23	zero	O
23	cases	O
23	versus	O
23	two	O
23	cases	O
23	of	O
23	secondary	O
23	malignancy	O
23	.	O
23	The	O
23	24-month	O
23	OS	O
23	rates	O
23	were	O
23	not	O
23	significantly	O
23	different	O
23	(	O
23	71	O
23	%	O
23	[	O
23	95	O
23	%	O
23	CI	O
23	,	O
23	63	O
23	%	O
23	to	O
23	81	O
23	%	O
23	]	O
23	for	O
23	VTD	O
23	v	O
23	65	O
23	%	O
23	[	O
23	95	O
23	%	O
23	CI	O
23	,	O
23	57	O
23	%	O
23	to	O
23	75	O
23	%	O
23	]	O
23	for	O
23	TD	O
23	;	O
23	P	O
23	ϭ	O
23	.093	O
23	;	O
23	Fig	O
23	2C	O
23	)	O
23	.	O
23	Median	O
23	TTP	O
23	was	O
23	longer	O
23	in	O
23	patients	O
23	receiving	O
23	VTD	O
23	than	O
23	TD	O
23	regardless	O
23	of	O
23	the	O
23	number	O
23	of	O
23	previous	O
23	ASCTs	O
23	(	O
23	one	O
23	or	O
23	more	O
23	;	O
23	Fig	O
23	3	O
23	)	O
23	.	O
--------------------------------------------------------------
24	Median	O
24	TTP	O
24	was	O
24	longer	O
24	in	O
24	patients	O
24	receiving	O
24	VTD	O
24	than	O
24	TD	B-arm_description
24	(	O
24	19.5	O
24	v	O
24	13.8	O
24	months	O
24	)	O
24	.	O
24	VTD	O
24	reduced	O
24	the	O
24	risk	O
24	of	O
24	developing	O
24	disease	O
24	progression	O
24	by	O
24	40	O
24	%	O
24	(	O
24	HR	O
24	,	O
24	0.59	O
24	;	O
24	95	O
24	%	O
24	CI	O
24	,	O
24	0.44	O
24	to	O
24	0.80	O
24	;	O
24	P	O
24	ϭ	O
24	.001	O
24	;	O
24	Fig	O
24	2A	O
24	)	O
24	.	O
24	Median	B-arm_efficacy_metric
24	PFS	I-arm_efficacy_metric
24	was	O
24	significantly	O
24	longer	O
24	for	O
24	VTD	O
24	than	O
24	TD	O
24	(	O
24	18.3	O
24	months	O
24	[	O
24	95	O
24	%	O
24	CI	O
24	,	O
24	15.5	O
24	to	O
24	20.6	O
24	months	O
24	]	O
24	v	O
24	13.6	B-arm_efficacy_results
24	months	I-arm_efficacy_results
24	[	I-arm_efficacy_results
24	95	I-arm_efficacy_results
24	%	I-arm_efficacy_results
24	CI	I-arm_efficacy_results
24	,	I-arm_efficacy_results
24	9.9	I-arm_efficacy_results
24	to	I-arm_efficacy_results
24	16.1	I-arm_efficacy_results
24	months	I-arm_efficacy_results
24	]	I-arm_efficacy_results
24	;	I-arm_efficacy_results
24	HR	I-arm_efficacy_results
24	,	I-arm_efficacy_results
24	0.61	I-arm_efficacy_results
24	;	I-arm_efficacy_results
24	95	I-arm_efficacy_results
24	%	I-arm_efficacy_results
24	CI	I-arm_efficacy_results
24	,	I-arm_efficacy_results
24	0.45	I-arm_efficacy_results
24	to	I-arm_efficacy_results
24	0.81	I-arm_efficacy_results
24	;	I-arm_efficacy_results
24	P	I-arm_efficacy_results
24	ϭ	I-arm_efficacy_results
24	.001	I-arm_efficacy_results
24	;	I-arm_efficacy_results
24	Fig	B-arm_efficacy_results
24	2B	B-arm_efficacy_results
24	)	B-arm_efficacy_results
24	.	O
24	During	O
24	the	O
24	1-year	O
24	treatment	O
24	period	O
24	(	O
24	cutoff	O
24	,	O
24	March	O
24	2	O
24	,	O
24	2011	O
24	)	O
24	,	O
24	we	O
24	recorded	O
24	14	O
24	deaths	O
24	for	O
24	VTD	O
24	and	O
24	20	O
24	deaths	O
24	for	O
24	TD	O
24	,	O
24	11	O
24	cases	O
24	versus	O
24	17	O
24	cases	O
24	of	O
24	relapse	O
24	/	O
24	progression	O
24	,	O
24	three	O
24	cases	O
24	versus	O
24	one	O
24	case	O
24	of	O
24	infection	O
24	,	O
24	and	O
24	zero	O
24	cases	O
24	versus	O
24	two	O
24	cases	O
24	of	O
24	secondary	O
24	malignancy	O
24	.	O
24	The	O
24	24-month	O
24	OS	O
24	rates	O
24	were	O
24	not	O
24	significantly	O
24	different	O
24	(	O
24	71	O
24	%	O
24	[	O
24	95	O
24	%	O
24	CI	O
24	,	O
24	63	O
24	%	O
24	to	O
24	81	O
24	%	O
24	]	O
24	for	O
24	VTD	O
24	v	O
24	65	O
24	%	O
24	[	O
24	95	O
24	%	O
24	CI	O
24	,	O
24	57	O
24	%	O
24	to	O
24	75	O
24	%	O
24	]	O
24	for	O
24	TD	O
24	;	O
24	P	O
24	ϭ	O
24	.093	O
24	;	O
24	Fig	O
24	2C	O
24	)	O
24	.	O
24	Median	O
24	TTP	O
24	was	O
24	longer	O
24	in	O
24	patients	O
24	receiving	O
24	VTD	O
24	than	O
24	TD	O
24	regardless	O
24	of	O
24	the	O
24	number	O
24	of	O
24	previous	O
24	ASCTs	O
24	(	O
24	one	O
24	or	O
24	more	O
24	;	O
24	Fig	O
24	3	O
24	)	O
24	.	O
--------------------------------------------------------------
25	Complete	O
25	response	O
25	(	O
25	CR	O
25	ϩ	O
25	nCR	O
25	)	O
25	rate	O
25	was	O
25	higher	O
25	for	O
25	VTD	B-arm_description
25	than	O
25	for	O
25	TD	O
25	(	O
25	45	O
25	%	O
25	v	O
25	25	O
25	%	O
25	;	O
25	P	O
25	ϭ	O
25	.001	O
25	)	O
25	,	O
25	and	O
25	the	O
25	median	O
25	DOR	O
25	was	O
25	longer	O
25	(	O
25	17.2	O
25	v	O
25	13.4	O
25	months	O
25	;	O
25	P	O
25	ϭ	O
25	.03	O
25	)	O
25	.	O
25	If	O
25	the	O
25	VGPRs	O
25	were	O
25	included	O
25	with	O
25	the	O
25	complete	O
25	responders	O
25	(	O
25	CR	O
25	ϩ	O
25	nCR	O
25	)	O
25	,	O
25	the	O
25	response	O
25	rate	O
25	rose	O
25	to	O
25	56	O
25	%	O
25	for	O
25	VTD	O
25	and	O
25	35	O
25	%	O
25	for	O
25	TD	O
25	(	O
25	P	O
25	Ͻ	O
25	.001	O
25	;	O
25	Table	O
25	2	O
25	)	O
25	.	O
25	Median	O
25	time	O
25	to	O
25	first	O
25	response	O
25	(	O
25	PR	O
25	or	O
25	better	O
25	)	O
25	was	O
25	significantly	O
25	shorter	O
25	in	O
25	patients	O
25	treated	O
25	with	O
25	VTD	O
25	than	O
25	in	O
25	those	O
25	treated	O
25	with	O
25	TD	O
25	(	O
25	1.5	O
25	v	O
25	2.6	O
25	months	O
25	;	O
25	P	O
25	Յ	O
25	.001	O
25	)	O
25	.	O
--------------------------------------------------------------
26	Complete	O
26	response	O
26	(	O
26	CR	O
26	ϩ	O
26	nCR	O
26	)	O
26	rate	O
26	was	O
26	higher	O
26	for	O
26	VTD	O
26	than	O
26	for	O
26	TD	B-arm_description
26	(	O
26	45	O
26	%	O
26	v	O
26	25	O
26	%	O
26	;	O
26	P	O
26	ϭ	O
26	.001	O
26	)	O
26	,	O
26	and	O
26	the	O
26	median	O
26	DOR	O
26	was	O
26	longer	O
26	(	O
26	17.2	O
26	v	O
26	13.4	O
26	months	O
26	;	O
26	P	O
26	ϭ	O
26	.03	O
26	)	O
26	.	O
26	If	O
26	the	O
26	VGPRs	O
26	were	O
26	included	O
26	with	O
26	the	O
26	complete	O
26	responders	O
26	(	O
26	CR	O
26	ϩ	O
26	nCR	O
26	)	O
26	,	O
26	the	O
26	response	O
26	rate	O
26	rose	O
26	to	O
26	56	O
26	%	O
26	for	O
26	VTD	O
26	and	O
26	35	O
26	%	O
26	for	O
26	TD	O
26	(	O
26	P	O
26	Ͻ	O
26	.001	O
26	;	O
26	Table	O
26	2	O
26	)	O
26	.	O
26	Median	O
26	time	O
26	to	O
26	first	O
26	response	O
26	(	O
26	PR	O
26	or	O
26	better	O
26	)	O
26	was	O
26	significantly	O
26	shorter	O
26	in	O
26	patients	O
26	treated	O
26	with	O
26	VTD	O
26	than	O
26	in	O
26	those	O
26	treated	O
26	with	O
26	TD	O
26	(	O
26	1.5	O
26	v	O
26	2.6	O
26	months	O
26	;	O
26	P	O
26	Յ	O
26	.001	O
26	)	O
26	.	O
--------------------------------------------------------------
27	In	O
27	a	O
27	multivariate	O
27	analysis	O
27	of	O
27	the	O
27	overall	O
27	study	O
27	population	O
27	,	O
27	randomization	B-study_type
27	to	O
27	receive	O
27	VTD	B-arm_description
27	was	O
27	the	O
27	key	O
27	independent	O
27	variable	O
27	positively	O
27	related	O
27	to	O
27	a	O
27	better	O
27	TTP	O
27	(	O
27	HR	O
27	,	O
27	0.47	O
27	;	O
27	95	O
27	%	O
27	CI	O
27	,	O
27	0.31	O
27	to	O
27	0.72	O
27	;	O
27	P	O
27	Ͻ	O
27	.001	O
27	)	O
27	.	O
27	The	O
27	variables	O
27	related	O
27	to	O
27	a	O
27	worse	O
27	TTP	O
27	were	O
27	high	O
27	␤	O
27	2microglobulin	O
27	(	O
27	for	O
27	the	O
27	logarithm	O
27	:	O
27	HR	O
27	,	O
27	2.41	O
27	;	O
27	95	O
27	%	O
27	CI	O
27	,	O
27	1.63	O
27	to	O
27	3.58	O
27	;	O
27	P	O
27	Ͻ	O
27	.001	O
27	)	O
27	,	O
27	high	O
27	International	O
27	Staging	O
27	System	O
27	score	O
27	(	O
27	HR	O
27	,	O
27	1.53	O
27	;	O
27	95	O
27	%	O
27	CI	O
27	,	O
27	1.16	O
27	to	O
27	2.02	O
27	;	O
27	P	O
27	ϭ	O
27	.02	O
27	)	O
27	,	O
27	and	O
27	a	O
27	chromosome	O
27	13	O
27	deletion	O
27	(	O
27	HR	O
27	,	O
27	2.3	O
27	;	O
27	95	O
27	%	O
27	CI	O
27	,	O
27	1.49	O
27	to	O
27	3.57	O
27	;	O
27	P	O
27	Ͻ	O
27	.001	O
27	)	O
27	.	O
27	A	O
27	secondary	O
27	analysis	O
27	showed	O
27	that	O
27	early	O
27	relapse	O
27	,	O
27	within	O
27	1	O
27	year	O
27	from	O
27	last	O
27	ASCT	O
27	,	O
27	remained	O
27	a	O
27	bad	O
27	prognosis	O
27	parameter	O
27	,	O
27	but	O
27	this	O
27	risk	O
27	factor	O
27	had	O
27	a	O
27	lower	O
27	impact	O
27	in	O
27	the	O
27	VTD	O
27	group	O
27	.	O
--------------------------------------------------------------
28	In	O
28	a	O
28	multivariate	O
28	analysis	O
28	of	O
28	the	O
28	overall	O
28	study	O
28	population	O
28	,	O
28	randomization	O
28	to	O
28	receive	O
28	VTD	O
28	was	O
28	the	O
28	key	O
28	independent	O
28	variable	O
28	positively	O
28	related	O
28	to	O
28	a	O
28	better	O
28	TTP	O
28	(	O
28	HR	O
28	,	O
28	0.47	O
28	;	O
28	95	O
28	%	O
28	CI	O
28	,	O
28	0.31	O
28	to	O
28	0.72	O
28	;	O
28	P	O
28	Ͻ	O
28	.001	O
28	)	O
28	.	O
28	The	O
28	variables	O
28	related	O
28	to	O
28	a	O
28	worse	O
28	TTP	O
28	were	O
28	high	O
28	␤	O
28	2microglobulin	O
28	(	O
28	for	O
28	the	O
28	logarithm	O
28	:	O
28	HR	O
28	,	O
28	2.41	O
28	;	O
28	95	O
28	%	O
28	CI	O
28	,	O
28	1.63	O
28	to	O
28	3.58	O
28	;	O
28	P	O
28	Ͻ	O
28	.001	O
28	)	O
28	,	O
28	high	O
28	International	O
28	Staging	O
28	System	O
28	score	O
28	(	O
28	HR	O
28	,	O
28	1.53	O
28	;	O
28	95	O
28	%	O
28	CI	O
28	,	O
28	1.16	O
28	to	O
28	2.02	O
28	;	O
28	P	O
28	ϭ	O
28	.02	O
28	)	O
28	,	O
28	and	O
28	a	O
28	chromosome	O
28	13	O
28	deletion	O
28	(	O
28	HR	O
28	,	O
28	2.3	O
28	;	O
28	95	O
28	%	O
28	CI	O
28	,	O
28	1.49	O
28	to	O
28	3.57	O
28	;	O
28	P	O
28	Ͻ	O
28	.001	O
28	)	O
28	.	O
28	A	O
28	secondary	O
28	analysis	O
28	showed	O
28	that	O
28	early	O
28	relapse	O
28	,	O
28	within	O
28	1	O
28	year	O
28	from	O
28	last	O
28	ASCT	O
28	,	O
28	remained	O
28	a	O
28	bad	O
28	prognosis	O
28	parameter	O
28	,	O
28	but	O
28	this	O
28	risk	O
28	factor	O
28	had	O
28	a	O
28	lower	O
28	impact	O
28	in	O
28	the	O
28	VTD	O
28	group	O
28	.	O
--------------------------------------------------------------
29	Efficacy	O
29	and	O
29	Safety	O
29	of	O
29	Bortezomib	B-arm_description
29	plus	I-arm_description
29	Dexamethasone	I-arm_description
29	Therapy	O
29	for	O
29	Refractory	O
29	or	O
29	Relapsed	O
29	Multiple	O
29	Myeloma	O
29	:	O
29	Once	O
29	-	O
29	weekly	O
29	Administration	O
29	of	O
29	Bortezomib	O
29	may	O
29	Reduce	O
29	the	O
29	Incidence	O
29	of	O
29	Gastrointestinal	O
29	Adverse	O
29	Events	O
29	Efficacy	O
29	and	O
29	Safety	O
29	of	O
29	Bortezomib	O
29	plus	O
29	Dexamethasone	O
29	Therapy	O
29	for	O
29	Refractory	O
29	or	O
29	Relapsed	O
29	Multiple	O
29	Myeloma	O
29	:	O
29	Once	O
29	-	O
29	weekly	O
29	Administration	O
29	of	O
29	Bortezomib	O
29	may	O
29	Reduce	O
29	the	O
29	Incidence	O
29	of	O
29	Gastrointestinal	O
29	Adverse	O
29	Events	O
29	MDToshihiroFukushima	O
--------------------------------------------------------------
30	Efficacy	O
30	and	O
30	Safety	O
30	of	O
30	Bortezomib	B-arm_description
30	plus	I-arm_description
30	Dexamethasone	I-arm_description
30	Therapy	O
30	for	O
30	Refractory	O
30	or	O
30	Relapsed	O
30	Multiple	O
30	Myeloma	O
30	:	O
30	Once	O
30	-	O
30	weekly	O
30	Administration	O
30	of	O
30	Bortezomib	O
30	may	O
30	Reduce	O
30	the	O
30	Incidence	O
30	of	O
30	Gastrointestinal	O
30	Adverse	O
30	Events	O
--------------------------------------------------------------
31	Efficacy	O
31	and	O
31	Safety	O
31	of	O
31	Bortezomib	B-arm_description
31	plus	B-arm_description
31	Dexamethasone	B-arm_description
31	Therapy	O
31	for	O
31	Refractory	O
31	or	O
31	Relapsed	O
31	Multiple	O
31	Myeloma	O
31	:	O
31	Once	O
31	-	O
31	weekly	O
31	Administration	O
31	of	O
31	Bortezomib	O
31	may	O
31	Reduce	O
31	the	O
31	Incidence	O
31	of	O
31	Gastrointestinal	O
31	Adverse	O
31	Events	O
31	MDToshihiroFukushima	B-authors
--------------------------------------------------------------
32	Department	O
32	of	O
32	Hematology	O
32	and	O
32	Immunology	O
32	HisanoriUmehara	O
32	Hisanori	O
32	Umehara	O
32	Department	O
32	of	O
32	Hematology	O
32	and	O
32	Immunology	O
32	Department	O
32	of	O
32	Hematology	O
32	and	O
32	Immunology	O
32	Department	O
32	of	O
32	Hematology	O
32	and	O
32	Immunology	O
32	Kanazawa	O
32	Medical	O
32	University	O
--------------------------------------------------------------
33	Japan	O
33	1	O
33	-	O
33	1	O
33	Daigaku	O
33	920	O
33	-	O
33	0293	O
33	Uchinada	O
33	Ishikawa	O
33	Japan	O
33	Efficacy	O
33	and	O
33	Safety	O
33	of	O
33	Bortezomib	B-arm_description
33	plus	I-arm_description
33	Dexamethasone	I-arm_description
33	Therapy	O
33	for	O
33	Refractory	O
33	or	O
33	Relapsed	O
33	Multiple	O
33	Myeloma	O
33	:	O
33	Once	O
33	-	O
33	weekly	O
33	Administration	O
33	of	O
33	Bortezomib	O
33	may	O
33	Reduce	O
33	the	O
33	Incidence	O
33	of	O
33	Gastrointestinal	O
33	Adverse	O
33	Events	O
33	Received	O
33	April	O
33	6	O
33	,	O
33	2011	O
33	Revised	O
33	May	O
33	23	O
33	,	O
33	2011	O
33	Accepted	O
33	May	O
33	24	O
33	,	O
33	2011	O
--------------------------------------------------------------
34	Multiple	O
34	myeloma	O
34	(	O
34	MM	O
34	)	O
34	is	O
34	a	O
34	hematological	O
34	malignancy	O
34	characterized	O
34	by	O
34	monoclonal	O
34	proliferation	O
34	of	O
34	plasma	O
34	cells	O
34	and	O
34	the	O
34	presence	O
34	of	O
34	monoclonal	O
34	immunoglobulin	O
34	in	O
34	serum	O
34	and	O
34	urine	O
34	.	O
34	Its	O
34	common	O
34	clinical	O
34	features	O
34	are	O
34	anemia	O
34	,	O
34	renal	O
34	dysfunction	O
34	,	O
34	osteolysis	O
34	and	O
34	hypercalcemia	O
34	(	O
34	1)(2)(3	O
34	)	O
34	.	O
34	In	O
34	the	O
34	past	O
34	decade	O
34	,	O
34	there	O
34	have	O
34	been	O
34	major	O
34	advances	O
34	as	O
34	a	O
34	result	O
34	of	O
34	new	O
34	anti	O
34	-	O
34	myeloma	O
34	agents	O
34	(	O
34	2,3	O
34	)	O
34	.	O
34	A	O
34	proteasome	O
34	inhibitor	O
34	,	O
34	bortezomib	O
34	,	O
34	is	O
34	one	O
34	of	O
34	these	O
34	new	O
34	agents	O
34	(	O
34	4,5	O
34	)	O
34	and	O
34	has	O
34	been	O
34	successfully	O
34	used	O
34	for	O
34	the	O
34	treatment	O
34	of	O
34	MM	O
34	.	O
34	Bortezomib	O
34	plus	O
34	dexamethasone	O
34	(	O
34	BD	O
34	)	O
34	therapy	O
34	has	O
34	been	O
34	established	O
34	as	O
34	one	O
34	of	O
34	the	O
34	most	O
34	promising	O
34	therapies	O
34	for	O
34	refractory	O
34	or	O
34	relapsed	O
34	MM	O
34	.	O
34	On	O
34	the	O
34	other	O
34	hand	O
34	,	O
34	the	O
34	use	O
34	of	O
34	bortezomib	O
34	is	O
34	associated	O
34	with	O
34	some	O
34	severe	O
34	adverse	O
34	events	O
34	,	O
34	with	O
34	22	O
34	%	O
34	and	O
34	37	O
34	%	O
34	of	O
34	patients	O
34	being	O
34	unable	O
34	to	O
34	continue	O
34	bortezomib	O
34	therapy	O
34	due	O
34	to	O
34	adverse	O
34	events	O
34	in	O
34	the	O
34	SUMMIT	O
34	and	O
34	APEX	O
34	study	O
34	,	O
34	respectively	O
34	(	O
34	6,7	O
34	)	O
34	.	O
--------------------------------------------------------------
35	Bortezomib	O
35	-	O
35	melphalan	O
35	-	O
35	prednisolone	O
35	(	O
35	VMP	O
35	)	O
35	therapy	O
35	has	O
35	also	O
35	been	O
35	established	O
35	as	O
35	a	O
35	standard	O
35	chemotherapy	O
35	for	O
35	newly	O
35	diagnosed	O
35	MM	O
35	patients	O
35	who	O
35	were	O
35	not	O
35	eligible	O
35	for	O
35	high	O
35	-	O
35	dose	O
35	therapy	O
35	followed	O
35	by	O
35	autologous	O
35	peripheral	O
35	blood	O
35	stem	O
35	cell	O
35	transplantation	O
35	(	O
35	auto	O
35	-	O
35	PBSCT	O
35	)	O
35	;	O
35	however	O
35	,	O
35	46	O
35	%	O
35	of	O
35	patients	O
--------------------------------------------------------------
36	Patients	O
36	.	O
36	We	O
36	retrospectively	B-study_type
36	analyzed	B-study_type
36	the	B-study_type
36	medical	B-study_type
36	records	B-study_type
36	of	O
36	22	O
36	patients	O
36	with	O
36	relapsed	O
36	or	O
36	refractory	O
36	MM	O
36	who	O
36	began	O
36	BD	B-arm_description
36	therapy	O
36	in	O
36	Kanazawa	O
36	Medical	O
36	University	O
36	Hospital	O
36	between	O
36	January	O
36	2007	O
36	and	O
36	July	O
36	2010	O
36	.	O
36	The	O
36	diagnosis	O
36	of	O
36	MM	O
36	was	O
36	confirmed	O
36	using	O
36	the	O
36	International	O
36	Myeloma	O
36	Working	O
36	Group	O
36	(	O
36	IMWG	O
36	)	O
36	criteria	O
36	(	O
36	1	O
36	)	O
36	.	O
36	The	O
36	clinical	O
36	stage	O
36	was	O
36	determined	O
36	by	O
36	the	O
36	International	O
36	Staging	O
36	System	O
36	(	O
36	ISS	O
36	)	O
36	(	O
36	9	O
36	)	O
36	.	O
--------------------------------------------------------------
37	Patients	O
37	received	O
37	bortezomib	B-arm_dosage
37	(	I-arm_dosage
37	1.3	I-arm_dosage
37	mg	I-arm_dosage
37	/	I-arm_dosage
37	m	I-arm_dosage
37	2	I-arm_dosage
37	)	I-arm_dosage
37	as	I-arm_dosage
37	an	I-arm_dosage
37	intravenous	I-arm_dosage
37	bolus	I-arm_dosage
37	on	I-arm_dosage
37	days	I-arm_dosage
37	1	I-arm_dosage
37	,	I-arm_dosage
37	4	I-arm_dosage
37	,	I-arm_dosage
37	8	I-arm_dosage
37	and	I-arm_dosage
37	11	I-arm_dosage
37	in	I-arm_dosage
37	a	I-arm_dosage
37	3-week	I-arm_dosage
37	cycle	I-arm_dosage
37	(	I-arm_dosage
37	twiceweekly	I-arm_dosage
37	administration	I-arm_dosage
37	)	I-arm_dosage
37	,	I-arm_dosage
37	or	I-arm_dosage
37	on	I-arm_dosage
37	days	I-arm_dosage
37	1	I-arm_dosage
37	,	I-arm_dosage
37	8	I-arm_dosage
37	,	I-arm_dosage
37	15	I-arm_dosage
37	and	I-arm_dosage
37	22	I-arm_dosage
37	in	I-arm_dosage
37	a	I-arm_dosage
37	5-week	I-arm_dosage
37	cycle	I-arm_dosage
37	(	I-arm_dosage
37	once	I-arm_dosage
37	-	I-arm_dosage
37	weekly	I-arm_dosage
37	administration	I-arm_dosage
37	)	I-arm_dosage
37	.	O
37	Dexamethasone	B-arm_dosage
37	at	I-arm_dosage
37	20	I-arm_dosage
37	mg	I-arm_dosage
37	was	I-arm_dosage
37	given	I-arm_dosage
37	intravenously	I-arm_dosage
37	or	I-arm_dosage
37	orally	I-arm_dosage
37	on	I-arm_dosage
37	the	I-arm_dosage
37	day	I-arm_dosage
37	of	I-arm_dosage
37	and	I-arm_dosage
37	day	I-arm_dosage
37	after	I-arm_dosage
37	bortezomib	I-arm_dosage
37	treatment	I-arm_dosage
37	.	O
37	BD	O
37	therapy	O
37	was	O
37	continued	O
37	until	O
37	achieving	O
37	a	O
37	complete	O
37	response	O
37	(	O
37	CR	O
37	)	O
37	,	O
37	disease	O
37	progression	O
37	or	O
37	the	O
37	development	O
37	of	O
37	severe	O
37	adverse	O
37	events	O
37	.	O
37	If	O
37	patients	O
37	were	O
37	eligible	O
37	for	O
37	high	O
37	-	O
37	dose	O
37	therapy	O
37	,	O
37	hematopoietic	O
37	stem	O
37	cells	O
37	were	O
37	harvested	O
37	by	O
37	high	O
37	-	O
37	dose	O
37	cyclophosphamide	O
37	(	O
37	3	O
37	g	O
37	/	O
37	m	O
37	2	O
37	)	O
37	,	O
37	and	O
37	high	O
37	-	O
37	dose	O
37	melphalan	O
37	(	O
37	140	O
37	mg	O
37	/	O
37	m	O
37	2	O
37	)	O
37	was	O
37	given	O
37	followed	O
37	by	O
37	auto	O
37	-	O
37	PBSCT	O
37	.	O
--------------------------------------------------------------
38	Assessments	O
38	.	O
38	Response	O
38	to	O
38	BD	B-arm_description
38	therapy	O
38	was	O
38	assessed	O
38	using	O
38	the	O
38	IMWG	O
38	uniform	O
38	criteria	O
38	(	O
38	10	O
38	)	O
38	.	O
38	Progression	B-arm_efficacy_metric
38	-	I-arm_efficacy_metric
38	free	I-arm_efficacy_metric
38	survival	I-arm_efficacy_metric
38	(	I-arm_efficacy_metric
38	PFS	I-arm_efficacy_metric
38	)	B-arm_efficacy_metric
38	and	O
38	overall	O
38	survival	O
38	(	O
38	OS	O
38	)	O
38	were	O
38	defined	O
38	as	O
38	the	O
38	time	O
38	from	O
38	starting	O
38	BD	O
38	therapy	O
38	until	O
38	the	O
38	date	O
38	of	O
38	disease	O
38	progression	O
38	and	O
38	death	O
38	,	O
38	respectively	O
38	.	O
38	Adverse	O
38	events	O
38	were	O
38	graded	O
38	using	O
38	the	O
38	National	O
38	Cancer	O
38	Institute	O
38	's	O
38	Common	O
38	Terminology	O
38	Criteria	O
38	for	O
38	Adverse	O
38	Events	O
38	,	O
38	version	O
38	3.0	O
38	(	O
38	11	O
38	)	O
38	.	O
--------------------------------------------------------------
39	Statistical	O
39	analysis	O
39	.	O
39	Response	O
39	rates	O
39	and	O
39	the	O
39	incidence	O
39	of	O
39	any	O
39	adverse	O
39	events	O
39	were	O
39	compared	O
39	using	O
39	Fisher	O
39	's	O
39	exact	O
39	test	O
39	.	O
39	Time	O
39	-	O
39	to	O
39	-	O
39	event	O
39	analysis	O
39	was	O
39	performed	O
39	according	O
39	to	O
39	the	O
39	Kaplan	O
39	-	O
39	Meier	O
39	method	O
39	,	O
39	and	O
39	the	O
39	log	O
39	-	O
39	rank	O
39	test	O
39	was	O
39	applied	O
39	to	O
39	assess	O
39	differences	O
39	between	O
39	subgroups	O
39	.	O
39	A	O
39	value	O
39	of	O
39	p<0.05	O
39	was	O
39	considered	O
39	statistically	O
39	significant	O
39	.	O
--------------------------------------------------------------
40	Patients	O
40	'	O
40	characteristics	O
40	.	O
40	Table	O
40	I	O
40	shows	O
40	the	O
40	characteristics	O
40	of	O
40	the	O
40	22	O
40	patients	O
40	.	O
40	The	O
40	median	O
40	age	O
40	was	O
40	69	O
40	years	O
40	(	O
40	range	O
40	42	O
40	-	O
40	81	O
40	years	O
40	)	O
40	.	O
40	Performance	O
40	status	O
40	(	O
40	PS	O
40	)	O
40	of	O
40	all	O
40	patients	O
40	was	O
40	≥2	O
40	,	O
40	including	O
40	PS	O
40	3	O
40	in	O
40	seven	O
40	patients	O
40	and	O
40	PS	O
40	4	O
40	in	O
40	three	O
40	patients	O
40	.	O
40	Six	O
40	patients	O
40	had	O
40	plasmacytomas	O
40	.	O
40	Three	O
40	patients	O
40	had	O
40	renal	O
40	impairment	O
40	(	O
40	serum	O
40	creatinine	O
40	≥2	O
40	mg	O
40	/	O
40	dl	O
40	)	O
40	.	O
40	The	O
40	median	O
40	time	O
40	from	O
40	diagnosis	O
40	to	O
40	starting	O
40	BD	B-arm_description
40	therapy	O
40	was	O
40	10	O
40	months	O
40	(	O
40	range	O
40	1	O
40	-	O
40	180	O
40	months	O
40	)	O
40	.	O
40	The	O
40	median	O
40	number	O
40	of	O
40	prior	O
40	therapies	O
40	was	O
40	two	O
40	(	O
40	range	O
40	1	O
40	-	O
40	4	O
40	,	O
40	radiotherapy	O
40	was	O
40	counted	O
40	as	O
40	one	O
40	regimen	O
40	)	O
40	.	O
--------------------------------------------------------------
41	Twenty	O
41	-	O
41	one	O
41	had	O
41	received	O
41	corticosteroids	O
41	,	O
41	and	O
41	five	O
41	had	O
41	received	O
41	corticosteroids	O
41	alone	O
41	.	O
41	Fifteen	O
41	had	O
41	received	O
41	melphalan	O
41	-	O
41	containing	O
41	therapy	O
41	.	O
41	One	O
41	had	O
41	received	O
41	high	O
41	-	O
41	dose	O
41	melphalan	O
41	followed	O
41	by	O
41	auto	O
41	-	O
41	PBSCT	O
41	.	O
41	Two	O
41	had	O
41	received	O
41	thalidomide	O
41	.	O
41	Three	O
41	had	O
41	received	O
41	radiotherapy	O
41	.	O
--------------------------------------------------------------
42	Adverse	O
42	events	O
42	.	O
42	to	O
42	continue	O
42	BD	O
42	therapy	O
42	due	O
42	to	O
42	PN	O
42	.	O
42	Pulmonary	O
42	,	O
42	cardiac	O
42	and	O
42	dermatologic	O
42	≥grade	O
42	3	O
42	adverse	O
42	events	O
42	did	O
42	not	O
42	develop	O
42	.	O
42	Herpes	O
42	zoster	O
42	developed	O
42	in	O
42	four	O
42	patients	O
42	without	O
42	prophylaxis	O
42	,	O
42	two	O
42	with	O
42	twice	O
42	-	O
42	weekly	O
42	,	O
42	one	O
42	with	O
42	once	O
42	-	O
42	weekly	O
42	and	O
42	one	O
42	with	O
42	each	O
42	twice	O
42	-	O
42	weekly	O
42	and	O
42	once	O
42	-	O
42	weekly	O
42	administration	O
42	,	O
42	but	O
42	did	O
42	not	O
42	develop	O
42	in	O
42	patients	O
42	who	O
42	received	O
42	prophylactic	O
42	500	O
42	mg	O
42	valaciclovir	O
42	administration	O
42	.	O
--------------------------------------------------------------
43	UCLA	O
43	School	O
43	of	O
43	Medicine	O
43	Los	O
43	Angeles	O
43	CA	O
43	USA	O
43	NatalieCallander	O
43	Department	O
43	of	O
43	Hematology	O
43	University	O
43	of	O
43	Wisconsin	O
43	Madison	O
43	WI	O
43	USA	O
43	JohnLister	O
43	Western	O
43	Pennsylvania	O
43	Hospital	O
43	Pittsburgh	O
43	PA	O
43	MartinOken	O
--------------------------------------------------------------
44	01	O
44	Jul	O
44	2009	O
44	.	O
44	1042	O
44	-	O
44	8194	O
44	(	O
44	Print	O
44	)	O
44	1029	O
44	-	O
44	2403	O
44	01	O
44	Jul	O
44	2009	O
44	.	O
44	01	O
44	Jul	O
44	2009	O
44	.	O
44	10.1080/10428190902748971	O
44	Received	O
44	7	O
44	November	O
44	2008	O
44	;	O
44	revised	O
44	6	O
44	January	O
44	2009	O
44	;	O
44	accepted	O
44	13	O
44	January	O
44	2009	O
--------------------------------------------------------------
45	Dexamethasone	O
45	is	O
45	an	O
45	important	O
45	therapeutic	O
45	agent	O
45	for	O
45	patients	O
45	with	O
45	multiple	O
45	myeloma	O
45	.	O
45	Despite	O
45	high	O
45	initial	O
45	response	O
45	rates	O
45	,	O
45	complete	O
45	responses	O
45	are	O
45	few	O
45	and	O
45	eventually	O
45	all	O
45	patients	O
45	develop	O
45	resistance	O
45	,	O
45	resulting	O
45	in	O
45	a	O
45	compromised	O
45	median	O
45	survival	O
45	of	O
45	2	O
45	-	O
45	3	O
45	years	O
45	[	O
45	1	O
45	]	O
45	.	O
45	Bcl-2	O
45	,	O
45	an	O
45	anti	O
45	-	O
45	apoptotic	O
45	member	O
45	of	O
45	the	O
45	Bcl-2	O
45	family	O
45	of	O
45	proteins	O
45	that	O
45	regulate	O
45	mitochondria	O
45	-	O
45	mediated	O
45	apoptosis	O
45	,	O
45	has	O
45	been	O
45	shown	O
45	to	O
45	be	O
45	a	O
45	key	O
45	factor	O
45	in	O
45	chemotherapy	O
45	resistance	O
45	.	O
45	It	O
45	is	O
45	over	O
45	-	O
45	expressed	O
45	in	O
45	many	O
45	cancers	O
45	[	O
45	2,3	O
45	]	O
45	,	O
45	including	O
45	multiple	O
45	myeloma	O
45	[	O
45	4	O
45	]	O
45	.	O
--------------------------------------------------------------
46	This	O
46	over	O
46	-	O
46	expression	O
46	shifts	O
46	the	O
46	balance	O
46	of	O
46	pro	O
46	-	O
46	apoptotic	O
46	and	O
46	anti	O
46	-	O
46	apoptotic	O
46	proteins	O
46	in	O
46	favour	O
46	of	O
46	the	O
46	latter	O
46	,	O
46	thereby	O
46	preventing	O
46	apoptosis	O
46	induced	O
46	by	O
46	a	O
46	wide	O
46	variety	O
46	of	O
46	cell	O
46	death	O
46	stimuli	O
46	,	O
46	including	O
46	chemotherapeutic	O
46	agents	O
46	,	O
46	antitumor	O
46	antibodies	O
46	and	O
46	radiation	O
46	[	O
46	5,6	O
46	]	O
46	.	O
--------------------------------------------------------------
47	Evidence	O
47	for	O
47	the	O
47	role	O
47	of	O
47	Bcl-2	O
47	in	O
47	the	O
47	development	O
47	of	O
47	resistance	O
47	to	O
47	chemotherapy	O
47	in	O
47	multiple	O
47	myeloma	O
47	has	O
47	been	O
47	found	O
47	in	O
47	a	O
47	variety	O
47	of	O
47	studies	O
47	.	O
47	Several	O
47	groups	O
47	have	O
47	shown	O
47	that	O
47	over	O
47	-	O
47	expression	O
47	of	O
47	Bcl-2	O
47	in	O
47	multiple	O
47	myeloma	O
47	cells	O
47	confers	O
47	resistance	O
47	to	O
47	dexamethasone	O
47	[	O
47	7][8][9][10][11	O
47	]	O
47	and	O
47	paclitaxel	O
47	[	O
47	12	O
47	]	O
47	.	O
47	However	O
47	,	O
47	Bcl-2	O
47	over	O
47	-	O
47	expression	O
47	does	O
47	not	O
47	result	O
47	in	O
47	resistance	O
47	to	O
47	melphalan	O
47	or	O
47	gemcitabine	O
47	,	O
47	drugs	O
47	which	O
47	induce	O
47	apoptosis	O
47	through	O
47	a	O
47	separate	O
47	pathway	O
47	[	O
47	9,12	O
47	]	O
47	.	O
--------------------------------------------------------------
48	Theoretically	O
48	,	O
48	any	O
48	agent	O
48	that	O
48	interferes	O
48	with	O
48	Bcl-2	O
48	expression	O
48	can	O
48	increase	O
48	chemotherapy	O
48	sensitivity	O
48	and/or	O
48	reverse	O
48	resistance	O
48	to	O
48	therapy	O
48	,	O
48	enhancing	O
48	the	O
48	ability	O
48	of	O
48	cytotoxic	O
48	drugs	O
48	such	O
48	as	O
48	dexamethasone	O
48	to	O
48	cause	O
48	cell	O
48	death	O
48	[	O
48	5	O
48	]	O
48	.	O
48	One	O
48	means	O
48	of	O
48	inhibiting	O
48	Bcl-2	O
48	is	O
48	through	O
48	the	O
48	use	O
48	of	O
48	antisense	O
48	therapy	O
48	to	O
48	downregulate	O
48	bcl-2	O
48	mRNA	O
48	,	O
48	thereby	O
48	decreasing	O
48	levels	O
48	of	O
48	Bcl-2	O
48	protein	O
48	.	O
48	Oblimersen	O
48	sodium	O
48	is	O
48	a	O
48	bcl-2	O
48	antisense	O
48	oligonucleotide	O
48	that	O
48	is	O
48	complementary	O
48	to	O
48	the	O
48	first	O
48	six	O
48	codons	O
48	of	O
48	the	O
48	open	O
48	-	O
48	reading	O
48	frame	O
48	of	O
48	bcl-2	O
48	mRNA	O
48	.	O
48	It	O
48	forms	O
48	an	O
48	aberrant	O
48	heteroduplex	O
48	with	O
48	bcl-2	O
48	mRNA	O
48	that	O
48	is	O
48	detected	O
48	and	O
48	cleaved	O
48	by	O
48	RNAse	O
48	-	O
48	H	O
48	,	O
48	resulting	O
48	in	O
48	the	O
48	degradation	O
48	of	O
48	bcl-2	O
48	mRNA	O
48	and	O
48	decreased	O
48	translation	O
48	of	O
48	the	O
48	Bcl-2	O
48	protein	O
48	[	O
48	6,13	O
48	]	O
48	.	O
48	Preclinically	O
48	in	O
48	myeloma	O
48	cells	O
48	,	O
48	oblimersen	O
48	is	O
48	reported	O
48	to	O
48	decrease	O
48	bcl-2	O
48	mRNA	O
48	levels	O
48	and	O
48	significantly	O
48	enhance	O
48	susceptibility	O
48	to	O
48	dexamethasone	O
48	-	O
48	and	O
48	doxorubicin	O
48	-	O
48	induced	O
48	apoptosis	O
48	[	O
48	14	O
48	]	O
48	.	O
--------------------------------------------------------------
49	The	O
49	preclinical	O
49	evidence	O
49	that	O
49	Bcl-2	O
49	overexpression	O
49	in	O
49	myeloma	O
49	cells	O
49	confers	O
49	resistance	O
49	to	O
49	dexamethasone	O
49	and	O
49	that	O
49	oblimersen	O
49	can	O
49	downregulate	O
49	Bcl-2	O
49	protein	O
49	levels	O
49	and	O
49	enhance	O
49	susceptibility	O
49	to	O
49	dexamethasone	O
49	prompted	O
49	us	O
49	to	O
49	investigate	O
49	oblimersen	O
49	in	O
49	multiple	O
49	myeloma	O
49	.	O
49	The	O
49	clinical	B-study_type
49	trial	B-study_type
49	reported	O
49	here	O
49	was	O
49	undertaken	O
49	to	O
49	determine	O
49	the	O
49	role	O
49	of	O
49	oblimersen	O
49	in	O
49	combination	O
49	with	O
49	dexamethasone	O
49	for	O
49	the	O
49	treatment	O
49	of	O
49	patients	O
49	with	O
49	relapsed	O
49	or	O
49	refractory	O
49	multiple	O
49	myeloma	O
49	.	O
--------------------------------------------------------------
50	This	O
50	was	O
50	a	O
50	Phase	B-study_type
50	III	B-study_type
50	,	B-study_type
50	multicentre	I-study_type
50	,	I-study_type
50	randomised	I-study_type
50	,	I-study_type
50	openlabel	I-study_type
50	,	I-study_type
50	parallel	I-study_type
50	-	I-study_type
50	group	I-study_type
50	study	B-study_type
50	designed	O
50	to	O
50	evaluate	O
50	whether	O
50	the	O
50	addition	B-arm_description
50	of	B-arm_description
50	oblimersen	B-arm_description
50	sodium	B-arm_description
50	to	B-arm_description
50	dexamethasone	B-arm_description
50	improved	O
50	clinical	O
50	outcomes	O
50	over	O
50	that	O
50	of	O
50	dexamethasone	O
50	alone	O
50	in	O
50	patients	O
50	with	O
50	relapsed	O
50	/	O
50	refractory	O
50	multiple	O
50	myeloma	O
50	.	O
--------------------------------------------------------------
51	This	O
51	was	O
51	a	O
51	Phase	O
51	III	O
51	,	O
51	multicentre	O
51	,	O
51	randomised	O
51	,	O
51	openlabel	O
51	,	O
51	parallel	O
51	-	O
51	group	O
51	study	O
51	designed	O
51	to	O
51	evaluate	O
51	whether	O
51	the	O
51	addition	O
51	of	O
51	oblimersen	O
51	sodium	O
51	to	O
51	dexamethasone	O
51	improved	O
51	clinical	O
51	outcomes	O
51	over	O
51	that	O
51	of	O
51	dexamethasone	B-arm_description
51	alone	B-arm_description
51	in	O
51	patients	O
51	with	O
51	relapsed	O
51	/	O
51	refractory	O
51	multiple	O
51	myeloma	O
51	.	O
--------------------------------------------------------------
52	The	O
52	primary	O
52	objective	O
52	was	O
52	to	O
52	compare	O
52	time	O
52	to	O
52	tumor	O
52	progression	O
52	(	O
52	TTP	O
52	)	O
52	in	O
52	the	O
52	two	O
52	groups	O
52	.	O
52	Key	O
52	secondary	O
52	objectives	O
52	included	O
52	a	O
52	comparison	O
52	of	O
52	the	O
52	treatment	O
52	groups	O
52	with	O
52	respect	O
52	to	O
52	objective	O
52	response	O
52	rate	O
52	,	O
52	duration	O
52	of	O
52	response	O
52	among	O
52	responding	O
52	patients	O
52	and	O
52	survival	O
52	.	O
--------------------------------------------------------------
53	Patients	O
53	enrolled	O
53	with	O
53	multiple	O
53	myeloma	O
53	were	O
53	to	O
53	have	O
53	relapsed	O
53	after	O
53	achieving	O
53	at	O
53	least	O
53	a	O
53	partial	O
53	response	O
53	to	O
53	prior	O
53	therapy	O
53	or	O
53	were	O
53	to	O
53	have	O
53	refractory	O
53	disease	O
53	(	O
53	i.e.	O
53	primary	O
53	resistance	O
53	/	O
53	progressive	O
53	disease	O
53	after	O
53	achieving	O
53	less	O
53	than	O
53	a	O
53	partial	O
53	response	O
53	following	O
53	treatment	O
53	with	O
53	two	O
53	cycles	O
53	of	O
53	chemotherapy	O
53	[	O
53	including	O
53	at	O
53	least	O
53	one	O
53	myelosuppressive	O
53	drug	O
53	]	O
53	)	O
53	within	O
53	the	O
53	3	O
53	months	O
53	prior	O
53	to	O
53	randomisation	B-study_type
53	or	O
53	progressive	O
53	disease	O
53	after	O
53	high	O
53	-	O
53	dose	O
53	chemotherapy	O
53	and	O
53	autologous	O
53	stem	O
53	cell	O
53	transplantation	O
53	.	O
53	Patients	O
53	also	O
53	had	O
53	to	O
53	have	O
53	measurable	O
53	disease	O
53	as	O
53	determined	O
53	by	O
53	serum	O
53	M	O
53	protein	O
53	level	O
53	41.0	O
53	g	O
53	/	O
53	dL	O
53	(	O
53	measured	O
53	by	O
53	serum	O
53	protein	O
53	electrophoresis	O
53	)	O
53	or	O
53	urine	O
53	M	O
53	protein	O
53	excretion	O
53	4200	O
53	mg	O
53	in	O
53	24	O
53	h.	O
--------------------------------------------------------------
54	Other	O
54	requirements	O
54	included	O
54	bone	O
54	marrow	O
54	plasmacytosis	O
54	with	O
54	45	O
54	%	O
54	total	O
54	nucleated	O
54	cells	O
54	;	O
54	prothrombin	O
54	time	O
54	(	O
54	PT	O
54	)	O
54	51.5	O
54	times	O
54	the	O
54	upper	O
54	limit	O
54	of	O
54	normal	O
54	(	O
54	6ULN	O
54	)	O
54	and	O
54	partial	O
54	thromboplastin	O
54	time	O
54	51.5	O
54	6ULN	O
54	;	O
54	creatinine	O
54	1.5	O
54	mg	O
54	/	O
54	dL	O
54	;	O
54	absolute	O
54	neutrophil	O
54	count	O
54	41000	O
54	/	O
54	mL	O
54	;	O
54	platelets	O
54	50	O
54	000	O
54	/	O
54	mL	O
54	;	O
54	and	O
54	ECOG	O
54	performance	O
54	status	O
54	0	O
54	-	O
54	3	O
54	.	O
54	Patients	O
54	were	O
54	excluded	O
54	if	O
54	they	O
54	had	O
54	46	O
54	prior	O
54	treatment	O
54	regimens	O
54	,	O
54	a	O
54	previous	O
54	allogeneic	O
54	stem	O
54	cell	O
54	transplant	O
54	or	O
54	a	O
54	history	O
54	of	O
54	renal	O
54	dialysis	O
54	or	O
54	other	O
54	significant	O
54	medical	O
54	disease	O
54	.	O
--------------------------------------------------------------
55	Eligible	O
55	patients	O
55	were	O
55	stratified	O
55	according	O
55	to	O
55	three	O
55	parameters	O
55	:	O
55	relapse	O
55	after	O
55	response	O
55	vs.	O
55	primary	O
55	resistance	O
55	to	O
55	treatment	O
55	;	O
55	prior	O
55	vs.	O
55	no	O
55	prior	O
55	autologous	O
55	stem	O
55	cell	O
55	transplantation	O
55	and	O
55	one	O
55	to	O
55	two	O
55	prior	O
55	treatment	O
55	regimens	O
55	vs.	O
55	three	O
55	to	O
55	six	O
55	prior	O
55	treatment	O
55	regimens	O
55	.	O
55	Following	O
55	stratification	O
55	,	O
55	they	O
55	were	O
55	centrally	O
55	randomised	B-study_type
55	via	O
55	an	O
55	interactive	O
55	voice	O
55	response	O
55	system	O
55	in	O
55	a	O
55	1:1	B-study_type
55	ratio	B-study_type
55	to	O
55	treatment	O
55	with	O
55	oblimersen	B-arm_description
55	plus	B-arm_description
55	dexamethasone	B-arm_description
55	or	O
55	dexamethasone	O
55	alone	O
55	.	O
--------------------------------------------------------------
56	Eligible	O
56	patients	O
56	were	O
56	stratified	O
56	according	O
56	to	O
56	three	O
56	parameters	O
56	:	O
56	relapse	O
56	after	O
56	response	O
56	vs.	O
56	primary	O
56	resistance	O
56	to	O
56	treatment	O
56	;	O
56	prior	O
56	vs.	O
56	no	O
56	prior	O
56	autologous	O
56	stem	O
56	cell	O
56	transplantation	O
56	and	O
56	one	O
56	to	O
56	two	O
56	prior	O
56	treatment	O
56	regimens	O
56	vs.	O
56	three	O
56	to	O
56	six	O
56	prior	O
56	treatment	O
56	regimens	O
56	.	O
56	Following	O
56	stratification	O
56	,	O
56	they	O
56	were	O
56	centrally	O
56	randomised	O
56	via	O
56	an	O
56	interactive	O
56	voice	O
56	response	O
56	system	O
56	in	O
56	a	O
56	1:1	O
56	ratio	O
56	to	O
56	treatment	O
56	with	O
56	oblimersen	O
56	plus	O
56	dexamethasone	O
56	or	O
56	dexamethasone	B-arm_description
56	alone	B-arm_description
56	.	O
--------------------------------------------------------------
57	Treatment	O
57	was	O
57	administered	O
57	in	O
57	two	O
57	phases	O
57	:	O
57	the	O
57	induction	O
57	period	O
57	(	O
57	cycle	O
57	1	O
57	)	O
57	and	O
57	the	O
57	retreatment	O
57	period	O
57	(	O
57	cycles	O
57	subsequent	O
57	to	O
57	cycle	O
57	1	O
57	)	O
57	.	O
57	Cycle	O
57	1	O
57	:	O
57	during	B-arm_dosage
57	the	I-arm_dosage
57	28-day	I-arm_dosage
57	induction	I-arm_dosage
57	period	I-arm_dosage
57	,	I-arm_dosage
57	patients	I-arm_dosage
57	in	I-arm_dosage
57	the	I-arm_dosage
57	oblimersen/	I-arm_dosage
57	dexamethasone	I-arm_dosage
57	group	I-arm_dosage
57	received	I-arm_dosage
57	oblimersen	I-arm_dosage
57	7	I-arm_dosage
57	mg	I-arm_dosage
57	/	I-arm_dosage
57	kg/	I-arm_dosage
57	day	I-arm_dosage
57	by	I-arm_dosage
57	continuous	I-arm_dosage
57	intravenous	I-arm_dosage
57	infusion	I-arm_dosage
57	for	I-arm_dosage
57	7	I-arm_dosage
57	consecutive	I-arm_dosage
57	days	I-arm_dosage
57	(	I-arm_dosage
57	days	I-arm_dosage
57	1	I-arm_dosage
57	-	I-arm_dosage
57	7	I-arm_dosage
57	)	I-arm_dosage
57	during	I-arm_dosage
57	each	I-arm_dosage
57	of	I-arm_dosage
57	weeks	I-arm_dosage
57	1	I-arm_dosage
57	and	I-arm_dosage
57	3	I-arm_dosage
57	and	I-arm_dosage
57	dexamethasone	I-arm_dosage
57	40	I-arm_dosage
57	mg	I-arm_dosage
57	orally	I-arm_dosage
57	on	I-arm_dosage
57	days	I-arm_dosage
57	4	I-arm_dosage
57	,	I-arm_dosage
57	5	I-arm_dosage
57	,	I-arm_dosage
57	6	I-arm_dosage
57	and	I-arm_dosage
57	7	I-arm_dosage
57	during	I-arm_dosage
57	each	I-arm_dosage
57	of	I-arm_dosage
57	weeks	I-arm_dosage
57	1	I-arm_dosage
57	,	I-arm_dosage
57	2	I-arm_dosage
57	and	I-arm_dosage
57	3	I-arm_dosage
57	.	O
57	Patients	O
57	in	O
57	the	O
57	dexamethasone	O
57	only	O
57	group	O
57	received	O
57	dexamethasone	O
57	40	O
57	mg	O
57	orally	O
57	on	O
57	days	O
57	1	O
57	,	O
57	2	O
57	,	O
57	3	O
57	and	O
57	4	O
57	during	O
57	each	O
57	of	O
57	weeks	O
57	1	O
57	,	O
57	2	O
57	and	O
57	3	O
57	.	O
57	No	B-arm_dosage
57	treatment	B-arm_dosage
57	was	I-arm_dosage
57	given	I-arm_dosage
57	during	I-arm_dosage
57	week	I-arm_dosage
57	4	I-arm_dosage
57	to	I-arm_dosage
57	patients	I-arm_dosage
57	in	I-arm_dosage
57	either	I-arm_dosage
57	group	I-arm_dosage
57	.	O
57	Cycles	B-arm_dosage
57	subsequent	I-arm_dosage
57	to	I-arm_dosage
57	cycle	I-arm_dosage
57	1	I-arm_dosage
57	:	I-arm_dosage
57	patients	I-arm_dosage
57	in	I-arm_dosage
57	the	I-arm_dosage
57	combination	I-arm_dosage
57	arm	I-arm_dosage
57	received	I-arm_dosage
57	oblimersen	I-arm_dosage
57	7	I-arm_dosage
57	mg	I-arm_dosage
57	/	I-arm_dosage
57	kg	I-arm_dosage
57	/	I-arm_dosage
57	day	I-arm_dosage
57	by	I-arm_dosage
57	continuous	I-arm_dosage
57	infusion	I-arm_dosage
57	for	I-arm_dosage
57	seven	I-arm_dosage
57	consecutive	I-arm_dosage
57	days	I-arm_dosage
57	(	I-arm_dosage
57	days	I-arm_dosage
57	1	I-arm_dosage
57	-	I-arm_dosage
57	7	I-arm_dosage
57	)	I-arm_dosage
57	and	I-arm_dosage
57	dexamethasone	I-arm_dosage
57	40	I-arm_dosage
57	mg	I-arm_dosage
57	orally	I-arm_dosage
57	on	I-arm_dosage
57	days	I-arm_dosage
57	4	I-arm_dosage
57	,	I-arm_dosage
57	5	I-arm_dosage
57	,	I-arm_dosage
57	6	I-arm_dosage
57	and	I-arm_dosage
57	7	I-arm_dosage
57	during	I-arm_dosage
57	week	I-arm_dosage
57	1	I-arm_dosage
57	.	O
57	Patients	O
57	in	O
57	the	O
57	dexamethasone	O
57	only	O
57	group	O
57	received	O
57	dexamethasone	O
57	40	O
57	mg	O
57	orally	O
57	on	O
57	days	O
57	1	O
57	,	O
57	2	O
57	,	O
57	3	O
57	and	O
57	4	O
57	during	O
57	week	O
57	1	O
57	.	O
57	No	O
57	treatment	O
57	was	O
57	given	O
57	during	O
57	weeks	O
57	2	O
57	and	O
57	3	O
57	to	O
57	patients	O
57	in	O
57	either	O
57	group	O
57	.	O
57	Retreatment	O
57	cycles	O
57	were	O
57	repeated	O
57	every	O
57	3	O
57	weeks	O
57	for	O
57	a	O
57	maximum	O
57	of	O
57	1	O
57	year	O
57	in	O
57	patients	O
57	who	O
57	had	O
57	stable	O
57	or	O
57	responsive	O
57	disease	O
57	and	O
57	who	O
57	tolerated	O
57	therapy	O
57	.	O
57	Prophylaxis	O
57	:	O
57	All	O
57	patients	O
57	received	O
57	concomitant	O
57	prophylactic	O
57	treatment	O
57	with	O
57	antibiotics	O
57	,	O
57	histamine	O
57	-	O
57	receptor	O
57	antagonists	O
57	and	O
57	pamidronate	O
57	or	O
57	zoledronic	O
57	acid	O
57	.	O
--------------------------------------------------------------
58	Treatment	O
58	was	O
58	administered	O
58	in	O
58	two	O
58	phases	O
58	:	O
58	the	O
58	induction	O
58	period	O
58	(	O
58	cycle	O
58	1	O
58	)	O
58	and	O
58	the	O
58	retreatment	O
58	period	O
58	(	O
58	cycles	O
58	subsequent	O
58	to	O
58	cycle	O
58	1	O
58	)	O
58	.	O
58	Cycle	B-arm_dosage
58	1	I-arm_dosage
58	:	B-arm_dosage
58	during	O
58	the	O
58	28-day	O
58	induction	O
58	period	O
58	,	O
58	patients	O
58	in	O
58	the	O
58	oblimersen/	O
58	dexamethasone	O
58	group	O
58	received	O
58	oblimersen	O
58	7	O
58	mg	O
58	/	O
58	kg/	O
58	day	O
58	by	O
58	continuous	O
58	intravenous	O
58	infusion	O
58	for	O
58	7	O
58	consecutive	O
58	days	O
58	(	O
58	days	O
58	1	O
58	-	O
58	7	O
58	)	O
58	during	O
58	each	O
58	of	O
58	weeks	O
58	1	O
58	and	O
58	3	O
58	and	O
58	dexamethasone	O
58	40	O
58	mg	O
58	orally	O
58	on	O
58	days	O
58	4	O
58	,	O
58	5	O
58	,	O
58	6	O
58	and	O
58	7	O
58	during	O
58	each	O
58	of	O
58	weeks	O
58	1	O
58	,	O
58	2	O
58	and	O
58	3	O
58	.	O
58	Patients	B-arm_dosage
58	in	I-arm_dosage
58	the	I-arm_dosage
58	dexamethasone	I-arm_dosage
58	only	I-arm_dosage
58	group	I-arm_dosage
58	received	I-arm_dosage
58	dexamethasone	I-arm_dosage
58	40	I-arm_dosage
58	mg	I-arm_dosage
58	orally	I-arm_dosage
58	on	I-arm_dosage
58	days	I-arm_dosage
58	1	I-arm_dosage
58	,	I-arm_dosage
58	2	I-arm_dosage
58	,	I-arm_dosage
58	3	I-arm_dosage
58	and	I-arm_dosage
58	4	I-arm_dosage
58	during	I-arm_dosage
58	each	I-arm_dosage
58	of	I-arm_dosage
58	weeks	I-arm_dosage
58	1	I-arm_dosage
58	,	I-arm_dosage
58	2	I-arm_dosage
58	and	I-arm_dosage
58	3	I-arm_dosage
58	.	O
58	No	O
58	treatment	O
58	was	O
58	given	O
58	during	O
58	week	O
58	4	O
58	to	O
58	patients	O
58	in	O
58	either	O
58	group	O
58	.	O
58	Cycles	B-arm_dosage
58	subsequent	I-arm_dosage
58	to	I-arm_dosage
58	cycle	I-arm_dosage
58	1	I-arm_dosage
58	:	B-arm_dosage
58	patients	O
58	in	O
58	the	O
58	combination	O
58	arm	O
58	received	O
58	oblimersen	O
58	7	O
58	mg	O
58	/	O
58	kg	O
58	/	O
58	day	O
58	by	O
58	continuous	O
58	infusion	O
58	for	O
58	seven	O
58	consecutive	O
58	days	O
58	(	O
58	days	O
58	1	O
58	-	O
58	7	O
58	)	O
58	and	O
58	dexamethasone	O
58	40	O
58	mg	O
58	orally	O
58	on	O
58	days	O
58	4	O
58	,	O
58	5	O
58	,	O
58	6	O
58	and	O
58	7	O
58	during	O
58	week	O
58	1	O
58	.	O
58	Patients	B-arm_dosage
58	in	I-arm_dosage
58	the	I-arm_dosage
58	dexamethasone	I-arm_dosage
58	only	I-arm_dosage
58	group	I-arm_dosage
58	received	I-arm_dosage
58	dexamethasone	I-arm_dosage
58	40	I-arm_dosage
58	mg	I-arm_dosage
58	orally	I-arm_dosage
58	on	I-arm_dosage
58	days	I-arm_dosage
58	1	I-arm_dosage
58	,	I-arm_dosage
58	2	I-arm_dosage
58	,	I-arm_dosage
58	3	I-arm_dosage
58	and	I-arm_dosage
58	4	I-arm_dosage
58	during	I-arm_dosage
58	week	I-arm_dosage
58	1	I-arm_dosage
58	.	O
58	No	O
58	treatment	O
58	was	O
58	given	O
58	during	O
58	weeks	O
58	2	O
58	and	O
58	3	O
58	to	O
58	patients	O
58	in	O
58	either	O
58	group	O
58	.	O
58	Retreatment	O
58	cycles	O
58	were	O
58	repeated	O
58	every	O
58	3	O
58	weeks	O
58	for	O
58	a	O
58	maximum	O
58	of	O
58	1	O
58	year	O
58	in	O
58	patients	O
58	who	O
58	had	O
58	stable	O
58	or	O
58	responsive	O
58	disease	O
58	and	O
58	who	O
58	tolerated	O
58	therapy	O
58	.	O
58	Prophylaxis	O
58	:	O
58	All	O
58	patients	O
58	received	O
58	concomitant	O
58	prophylactic	O
58	treatment	O
58	with	O
58	antibiotics	O
58	,	O
58	histamine	O
58	-	O
58	receptor	O
58	antagonists	O
58	and	O
58	pamidronate	O
58	or	O
58	zoledronic	O
58	acid	O
58	.	O
--------------------------------------------------------------
59	Efficacy	O
59	and	O
59	safety	O
59	evaluations	O
59	were	O
59	performed	O
59	on	O
59	day	O
59	15	O
59	and	O
59	at	O
59	the	O
59	end	O
59	of	O
59	the	O
59	induction	O
59	period	O
59	(	O
59	i.e.	O
59	week	O
59	4	O
59	)	O
59	,	O
59	7	O
59	days	O
59	before	O
59	each	O
59	retreatment	O
59	cycle	O
59	,	O
59	and	O
59	within	O
59	4	O
59	weeks	O
59	after	O
59	withdrawal	O
59	from	O
59	the	O
59	study	O
59	.	O
59	Patients	O
59	were	O
59	followed	O
59	every	O
59	2	O
59	months	O
59	for	O
59	up	O
59	to	O
59	2	O
59	years	O
59	from	O
59	the	O
59	date	O
59	of	O
59	last	O
59	dose	O
59	of	O
59	study	O
59	medication	O
59	.	O
--------------------------------------------------------------
60	The	O
60	primary	O
60	endpoint	O
60	of	O
60	this	O
60	study	O
60	was	O
60	TTP	O
60	,	O
60	which	O
60	was	O
60	calculated	O
60	from	O
60	the	O
60	date	O
60	of	O
60	randomisation	O
60	to	O
60	the	O
60	date	O
60	of	O
60	progression	O
60	and	O
60	was	O
60	determined	O
60	based	O
60	on	O
60	blinded	O
60	clinical	O
60	expert	O
60	review	O
60	by	O
60	S.	O
60	Jagannath	O
60	(	O
60	St.	O
60	Vincent	O
60	's	O
60	Comprehensive	O
60	Cancer	O
60	Centre	O
60	,	O
60	New	O
60	York	O
60	,	O
60	NY	O
60	)	O
60	and	O
60	M	O
60	Oken	O
60	(	O
60	Hubert	O
60	H.	O
60	Humphrey	O
60	Cancer	O
60	Centre	O
60	,	O
60	Robbinsdale	O
60	,	O
60	MN	O
60	)	O
60	.	O
60	Progression	O
60	was	O
60	defined	O
60	as	O
60	the	O
60	first	O
60	of	O
60	the	O
60	following	O
60	events	O
60	to	O
60	occur	O
60	prior	O
60	to	O
60	initiation	O
60	of	O
60	non	O
60	-	O
60	study	O
60	myeloma	O
60	therapy	O
60	:	O
60	objective	O
60	documentation	O
60	of	O
60	progressive	O
60	disease	O
60	,	O
60	death	O
60	within	O
60	60	O
60	days	O
60	of	O
60	the	O
60	last	O
60	evaluation	O
60	of	O
60	objective	O
60	response	O
60	status	O
60	or	O
60	death	O
60	within	O
60	60	O
60	days	O
60	of	O
60	the	O
60	last	O
60	dose	O
60	if	O
60	there	O
60	was	O
60	no	O
60	evaluation	O
60	of	O
60	objective	O
60	response	O
60	status	O
60	.	O
--------------------------------------------------------------
61	Key	O
61	secondary	O
61	endpoints	O
61	included	O
61	objective	O
61	response	O
61	rate	O
61	(	O
61	i.e.	O
61	complete	O
61	response	O
61	,	O
61	response	O
61	[	O
61	75	O
61	%	O
61	improvement	O
61	]	O
61	or	O
61	partial	O
61	response	O
61	as	O
61	assessed	O
61	by	O
61	the	O
61	investigator	O
61	according	O
61	to	O
61	criteria	O
61	adapted	O
61	from	O
61	SWOG	O
61	[	O
61	15	O
61	]	O
61	)	O
61	and	O
61	overall	O
61	survival	O
61	.	O
--------------------------------------------------------------
62	A	O
62	sample	O
62	of	O
62	200	O
62	patients	O
62	(	O
62	100	O
62	per	O
62	treatment	O
62	arm	O
62	)	O
62	was	O
62	required	O
62	to	O
62	provide	O
62	an	O
62	80	O
62	%	O
62	power	O
62	to	O
62	detect	O
62	a	O
62	significant	O
62	difference	O
62	between	O
62	treatment	O
62	groups	O
62	with	O
62	respect	O
62	to	O
62	TTP	O
62	.	O
62	This	O
62	sample	O
62	size	O
62	was	O
62	based	O
62	on	O
62	the	O
62	following	O
62	assumptions	O
62	:	O
62	distributions	O
62	of	O
62	TTP	O
62	for	O
62	the	O
62	two	O
62	treatment	O
62	groups	O
62	would	O
62	be	O
62	compared	O
62	using	O
62	the	O
62	log	O
62	-	O
62	rank	O
62	test	O
62	with	O
62	a	O
62	two	O
62	-	O
62	sided	O
62	significance	O
62	level	O
62	of	O
62	0.05	O
62	;	O
62	median	O
62	TTP	O
62	would	O
62	be	O
62	4	O
62	months	O
62	for	O
62	patients	O
62	who	O
62	received	O
62	dexamethasone	O
62	alone	O
62	and	O
62	6.33	O
62	months	O
62	for	O
62	patients	O
62	who	O
62	received	O
62	oblimersen	B-arm_description
62	plus	B-arm_description
62	dexamethasone	B-arm_description
62	;	O
62	equal	O
62	numbers	O
62	of	O
62	patients	O
62	would	O
62	be	O
62	assigned	O
62	to	O
62	each	O
62	treatment	O
62	arm	O
62	and	O
62	would	O
62	be	O
62	accrued	O
62	over	O
62	12	O
62	months	O
62	(	O
62	approximately	O
62	18	O
62	per	O
62	month	O
62	)	O
62	with	O
62	a	O
62	6-month	O
62	follow	O
62	-	O
62	up	O
62	period	O
62	after	O
62	enrolment	O
62	of	O
62	the	O
62	last	O
62	patient	O
62	;	O
62	and	O
62	the	O
62	final	O
62	analysis	O
62	would	O
62	be	O
62	performed	O
62	1	O
62	year	O
62	after	O
62	the	O
62	enrolment	O
62	of	O
62	the	O
62	last	O
62	patient	O
62	.	O
62	The	O
62	sample	O
62	estimate	O
62	was	O
62	obtained	O
62	by	O
62	using	O
62	the	O
62	EaSt	O
62	Computer	O
62	Software	O
62	Package	O
62	by	O
62	Cytel	O
62	.	O
62	No	O
62	interim	O
62	analysis	O
62	was	O
62	performed	O
62	.	O
--------------------------------------------------------------
63	A	O
63	sample	O
63	of	O
63	200	O
63	patients	O
63	(	O
63	100	O
63	per	O
63	treatment	O
63	arm	O
63	)	O
63	was	O
63	required	O
63	to	O
63	provide	O
63	an	O
63	80	O
63	%	O
63	power	O
63	to	O
63	detect	O
63	a	O
63	significant	O
63	difference	O
63	between	O
63	treatment	O
63	groups	O
63	with	O
63	respect	O
63	to	O
63	TTP	O
63	.	O
63	This	O
63	sample	O
63	size	O
63	was	O
63	based	O
63	on	O
63	the	O
63	following	O
63	assumptions	O
63	:	O
63	distributions	O
63	of	O
63	TTP	O
63	for	O
63	the	O
63	two	O
63	treatment	O
63	groups	O
63	would	O
63	be	O
63	compared	O
63	using	O
63	the	O
63	log	O
63	-	O
63	rank	O
63	test	O
63	with	O
63	a	O
63	two	O
63	-	O
63	sided	O
63	significance	O
63	level	O
63	of	O
63	0.05	O
63	;	O
63	median	O
63	TTP	O
63	would	O
63	be	O
63	4	O
63	months	O
63	for	O
63	patients	O
63	who	O
63	received	O
63	dexamethasone	B-arm_description
63	alone	B-arm_description
63	and	O
63	6.33	O
63	months	O
63	for	O
63	patients	O
63	who	O
63	received	O
63	oblimersen	O
63	plus	O
63	dexamethasone	O
63	;	O
63	equal	O
63	numbers	O
63	of	O
63	patients	O
63	would	O
63	be	O
63	assigned	O
63	to	O
63	each	O
63	treatment	O
63	arm	O
63	and	O
63	would	O
63	be	O
63	accrued	O
63	over	O
63	12	O
63	months	O
63	(	O
63	approximately	O
63	18	O
63	per	O
63	month	O
63	)	O
63	with	O
63	a	O
63	6-month	O
63	follow	O
63	-	O
63	up	O
63	period	O
63	after	O
63	enrolment	O
63	of	O
63	the	O
63	last	O
63	patient	O
63	;	O
63	and	O
63	the	O
63	final	O
63	analysis	O
63	would	O
63	be	O
63	performed	O
63	1	O
63	year	O
63	after	O
63	the	O
63	enrolment	O
63	of	O
63	the	O
63	last	O
63	patient	O
63	.	O
63	The	O
63	sample	O
63	estimate	O
63	was	O
63	obtained	O
63	by	O
63	using	O
63	the	O
63	EaSt	O
63	Computer	O
63	Software	O
63	Package	O
63	by	O
63	Cytel	O
63	.	O
63	No	O
63	interim	O
63	analysis	O
63	was	O
63	performed	O
63	.	O
--------------------------------------------------------------
64	The	O
64	primary	O
64	efficacy	O
64	analysis	O
64	was	O
64	a	O
64	comparison	O
64	of	O
64	the	O
64	distributions	O
64	of	O
64	TTP	O
64	between	O
64	the	O
64	two	O
64	treatment	O
64	groups	O
64	in	O
64	the	O
64	intent	O
64	-	O
64	to	O
64	-	O
64	treat	O
64	(	O
64	ITT	O
64	)	O
64	population	O
64	using	O
64	the	O
64	log	O
64	-	O
64	rank	O
64	test	O
64	.	O
64	The	O
64	Cox	O
64	proportional	O
64	hazards	O
64	model	O
64	with	O
64	a	O
64	covariate	O
64	for	O
64	treatment	O
64	was	O
64	used	O
64	to	O
64	estimate	O
64	the	O
64	hazard	O
64	ratio	O
64	for	O
64	TTP	O
64	.	O
--------------------------------------------------------------
65	With	O
65	respect	O
65	to	O
65	key	O
65	secondary	O
65	endpoints	O
65	,	O
65	Fisher	O
65	's	O
65	exact	O
65	test	O
65	was	O
65	used	O
65	to	O
65	compare	O
65	the	O
65	proportion	O
65	of	O
65	patients	O
65	with	O
65	objective	O
65	response	O
65	in	O
65	the	O
65	two	O
65	treatment	O
65	groups	O
65	,	O
65	and	O
65	the	O
65	odds	O
65	ratio	O
65	and	O
65	exact	O
65	95	O
65	%	O
65	confidence	O
65	interval	O
65	also	O
65	were	O
65	provided	O
65	for	O
65	this	O
65	endpoint	O
65	.	O
65	Survival	O
65	time	O
65	was	O
65	calculated	O
65	from	O
65	the	O
65	date	O
65	of	O
65	randomisation	O
65	to	O
65	the	O
65	date	O
65	of	O
65	death	O
65	.	O
65	The	O
65	primary	O
65	analysis	O
65	of	O
65	survival	O
65	was	O
65	to	O
65	occur	O
65	when	O
65	all	O
65	patients	O
65	had	O
65	been	O
65	followed	O
65	for	O
65	2	O
65	years	O
65	after	O
65	the	O
65	end	O
65	of	O
65	treatment	O
65	.	O
--------------------------------------------------------------
66	A	O
66	total	O
66	of	O
66	224	O
66	patients	O
66	comprising	O
66	the	O
66	ITT	O
66	population	O
66	were	O
66	enrolled	O
66	at	O
66	78	O
66	sites	O
66	in	O
66	four	O
66	countries	O
66	(	O
66	72	O
66	sites	O
66	in	O
66	the	O
66	United	O
66	States	O
66	,	O
66	4	O
66	in	O
66	Canada	O
66	and	O
66	1	O
66	each	O
66	in	O
66	England	O
66	and	O
66	France	O
66	)	O
66	.	O
66	The	O
66	first	O
66	patient	O
66	was	O
66	enrolled	O
66	in	O
66	March	O
66	2001	O
66	and	O
66	the	O
66	last	O
66	in	O
66	April	O
66	2003	O
66	.	O
--------------------------------------------------------------
67	One	O
67	hundred	O
67	ten	O
67	patients	O
67	were	O
67	randomised	B-study_type
67	to	O
67	receive	O
67	oblimersen	B-arm_description
67	/	B-arm_description
67	dexamethasone	B-arm_description
67	and	O
67	114	O
67	to	O
67	dexamethasone	O
67	alone	O
67	.	O
67	Four	O
67	patients	O
67	in	O
67	each	O
67	group	O
67	were	O
67	randomised	O
67	but	O
67	did	O
67	not	O
67	initiate	O
67	treatment	O
67	;	O
67	thus	O
67	,	O
67	the	O
67	safety	O
67	population	O
67	was	O
67	composed	O
67	of	O
67	the	O
67	216	O
67	patients	O
67	who	O
67	received	O
67	treatment	O
67	(	O
67	106	O
67	in	O
67	the	O
67	oblimersen/	O
67	dexamethasone	O
67	group	O
67	and	O
67	110	O
67	in	O
67	the	O
67	dexamethasone	O
67	group	O
67	)	O
67	.	O
67	The	O
67	distribution	O
67	of	O
67	patients	O
67	enrolled	O
67	by	O
67	stratum	O
67	was	O
67	similar	O
67	in	O
67	both	O
67	treatment	O
67	arms	O
67	.	O
--------------------------------------------------------------
68	One	O
68	hundred	O
68	ten	O
68	patients	O
68	were	O
68	randomised	O
68	to	O
68	receive	O
68	oblimersen	O
68	/	O
68	dexamethasone	O
68	and	O
68	114	O
68	to	O
68	dexamethasone	B-arm_description
68	alone	B-arm_description
68	.	O
68	Four	O
68	patients	O
68	in	O
68	each	O
68	group	O
68	were	O
68	randomised	O
68	but	O
68	did	O
68	not	O
68	initiate	O
68	treatment	O
68	;	O
68	thus	O
68	,	O
68	the	O
68	safety	O
68	population	O
68	was	O
68	composed	O
68	of	O
68	the	O
68	216	O
68	patients	O
68	who	O
68	received	O
68	treatment	O
68	(	O
68	106	O
68	in	O
68	the	O
68	oblimersen/	O
68	dexamethasone	O
68	group	O
68	and	O
68	110	O
68	in	O
68	the	O
68	dexamethasone	O
68	group	O
68	)	O
68	.	O
68	The	O
68	distribution	O
68	of	O
68	patients	O
68	enrolled	O
68	by	O
68	stratum	O
68	was	O
68	similar	O
68	in	O
68	both	O
68	treatment	O
68	arms	O
68	.	O
--------------------------------------------------------------
69	At	O
69	baseline	O
69	,	O
69	an	O
69	imbalance	O
69	was	O
69	observed	O
69	between	O
69	the	O
69	treatment	O
69	groups	O
69	in	O
69	several	O
69	important	O
69	prognostic	O
69	factors	O
69	(	O
69	Table	O
69	I	O
69	)	O
69	.	O
69	ECOG	O
69	performance	O
69	status	O
69	at	O
69	baseline	O
69	was	O
69	significantly	O
69	worse	O
69	in	O
69	the	O
69	oblimersen/	B-arm_description
69	dexamethasone	B-arm_description
69	group	O
69	(	O
69	p	O
69	¼	O
69	0.028	O
69	)	O
69	.	O
69	In	O
69	addition	O
69	,	O
69	more	O
69	patients	O
69	in	O
69	the	O
69	oblimersen	O
69	/	O
69	dexamethasone	O
69	group	O
69	had	O
69	stage	O
69	III	O
69	disease	O
69	than	O
69	in	O
69	the	O
69	dexamethasone	O
69	group	O
69	(	O
69	70	O
69	%	O
69	vs.	O
69	61	O
69	%	O
69	,	O
69	respectively	O
69	)	O
69	.	O
69	Also	O
69	,	O
69	imbalances	O
69	in	O
69	baseline	O
69	laboratory	O
69	parameters	O
69	revealed	O
69	that	O
69	patients	O
69	in	O
69	the	O
69	oblimersen	O
69	/	O
69	dexamethasone	O
69	group	O
69	were	O
69	more	O
69	seriously	O
69	impaired	O
69	than	O
69	those	O
69	in	O
69	the	O
69	dexamethasone	O
69	group	O
69	(	O
69	serum	O
69	creatinine	O
69	42.0	O
69	mg	O
69	/	O
69	dL	O
69	:	O
69	5	O
69	%	O
69	and	O
69	0	O
69	%	O
69	,	O
69	respectively	O
69	[	O
69	p	O
69	¼	O
69	0.021	O
69	]	O
69	;	O
69	and	O
69	elevated	O
69	lactate	O
69	dehydrogenase	O
69	:	O
69	23	O
69	%	O
69	and	O
69	11	O
69	%	O
69	,	O
69	respectively	O
69	[	O
69	p	O
69	¼	O
69	0.025	O
69	]	O
69	)	O
69	.	O
--------------------------------------------------------------
70	At	O
70	baseline	O
70	,	O
70	an	O
70	imbalance	O
70	was	O
70	observed	O
70	between	O
70	the	O
70	treatment	O
70	groups	O
70	in	O
70	several	O
70	important	O
70	prognostic	O
70	factors	O
70	(	O
70	Table	O
70	I	O
70	)	O
70	.	O
70	ECOG	O
70	performance	O
70	status	O
70	at	O
70	baseline	O
70	was	O
70	significantly	O
70	worse	O
70	in	O
70	the	O
70	oblimersen/	O
70	dexamethasone	O
70	group	O
70	(	O
70	p	O
70	¼	O
70	0.028	O
70	)	O
70	.	O
70	In	O
70	addition	O
70	,	O
70	more	O
70	patients	O
70	in	O
70	the	O
70	oblimersen	O
70	/	O
70	dexamethasone	O
70	group	O
70	had	O
70	stage	O
70	III	O
70	disease	O
70	than	O
70	in	O
70	the	O
70	dexamethasone	B-arm_description
70	group	B-arm_description
70	(	O
70	70	O
70	%	O
70	vs.	O
70	61	O
70	%	O
70	,	O
70	respectively	O
70	)	O
70	.	O
70	Also	O
70	,	O
70	imbalances	O
70	in	O
70	baseline	O
70	laboratory	O
70	parameters	O
70	revealed	O
70	that	O
70	patients	O
70	in	O
70	the	O
70	oblimersen	O
70	/	O
70	dexamethasone	O
70	group	O
70	were	O
70	more	O
70	seriously	O
70	impaired	O
70	than	O
70	those	O
70	in	O
70	the	O
70	dexamethasone	O
70	group	O
70	(	O
70	serum	O
70	creatinine	O
70	42.0	O
70	mg	O
70	/	O
70	dL	O
70	:	O
70	5	O
70	%	O
70	and	O
70	0	O
70	%	O
70	,	O
70	respectively	O
70	[	O
70	p	O
70	¼	O
70	0.021	O
70	]	O
70	;	O
70	and	O
70	elevated	O
70	lactate	O
70	dehydrogenase	O
70	:	O
70	23	O
70	%	O
70	and	O
70	11	O
70	%	O
70	,	O
70	respectively	O
70	[	O
70	p	O
70	¼	O
70	0.025	O
70	]	O
70	)	O
70	.	O
--------------------------------------------------------------
71	Patients	O
71	in	O
71	both	O
71	groups	O
71	had	O
71	been	O
71	heavily	O
71	pretreated	O
71	;	O
71	the	O
71	median	O
71	number	O
71	of	O
71	prior	O
71	regimens	O
71	was	O
71	3	O
71	in	O
71	both	O
71	treatment	O
71	groups	O
71	.	O
71	A	O
71	total	O
71	of	O
71	87	O
71	(	O
71	79	O
71	%	O
71	)	O
71	patients	O
71	in	O
71	the	O
71	oblimersen	B-arm_description
71	/	B-arm_description
71	dexamethasone	B-arm_description
71	group	B-arm_description
71	and	O
71	95	O
71	(	O
71	83	O
71	%	O
71	)	O
71	patients	O
71	in	O
71	the	O
71	dexamethasone	O
71	group	O
71	had	O
71	been	O
71	previously	O
71	treated	O
71	with	O
71	dexamethasone	O
71	;	O
71	47	O
71	and	O
71	51	O
71	of	O
71	these	O
71	patients	O
71	,	O
71	respectively	O
71	,	O
71	had	O
71	been	O
71	refractory	O
71	to	O
71	that	O
71	treatment	O
71	,	O
71	achieving	O
71	a	O
71	response	O
71	not	O
71	better	O
71	than	O
71	stable	O
71	disease	O
71	.	O
--------------------------------------------------------------
72	Patients	O
72	in	O
72	both	O
72	groups	O
72	had	O
72	been	O
72	heavily	O
72	pretreated	O
72	;	O
72	the	O
72	median	O
72	number	O
72	of	O
72	prior	O
72	regimens	O
72	was	O
72	3	O
72	in	O
72	both	O
72	treatment	O
72	groups	O
72	.	O
72	A	O
72	total	O
72	of	O
72	87	O
72	(	O
72	79	O
72	%	O
72	)	O
72	patients	O
72	in	O
72	the	O
72	oblimersen	O
72	/	O
72	dexamethasone	O
72	group	O
72	and	O
72	95	O
72	(	O
72	83	O
72	%	O
72	)	O
72	patients	O
72	in	O
72	the	O
72	dexamethasone	B-arm_description
72	group	B-arm_description
72	had	O
72	been	O
72	previously	O
72	treated	O
72	with	O
72	dexamethasone	O
72	;	O
72	47	O
72	and	O
72	51	O
72	of	O
72	these	O
72	patients	O
72	,	O
72	respectively	O
72	,	O
72	had	O
72	been	O
72	refractory	O
72	to	O
72	that	O
72	treatment	O
72	,	O
72	achieving	O
72	a	O
72	response	O
72	not	O
72	better	O
72	than	O
72	stable	O
72	disease	O
72	.	O
--------------------------------------------------------------
73	In	O
73	the	O
73	ITT	O
73	population	O
73	,	O
73	103	O
73	(	O
73	94	O
73	%	O
73	)	O
73	of	O
73	the	O
73	oblimersen/	B-arm_description
73	dexamethasone	B-arm_description
73	group	B-arm_description
73	and	O
73	94	O
73	(	O
73	83	O
73	%	O
73	)	O
73	of	O
73	the	O
73	dexamethasone	O
73	group	O
73	discontinued	O
73	treatment	O
73	,	O
73	that	O
73	is	O
73	,	O
73	initiated	O
73	516	O
73	cycles	O
73	or	O
73	received	O
73	51	O
73	year	O
73	(	O
73	defined	O
73	as	O
73	335	O
73	days	O
73	)	O
73	of	O
73	protocol	O
73	-	O
73	specified	O
73	therapy	O
73	from	O
73	the	O
73	date	O
73	of	O
73	first	O
73	dose	O
73	.	O
73	Disease	O
73	progression	O
73	/	O
73	lack	O
73	of	O
73	efficacy	O
73	accounted	O
73	for	O
73	more	O
73	than	O
73	50	O
73	%	O
73	of	O
73	the	O
73	discontinuations	O
73	in	O
73	each	O
73	group	O
73	(	O
73	oblimersen	O
73	/	O
73	dexamethasone	O
73	:	O
73	63	O
73	%	O
73	;	O
73	dexamethasone	O
73	:	O
73	55	O
73	%	O
73	)	O
73	.	O
73	Adverse	O
73	event	O
73	/	O
73	toxicity	O
73	was	O
73	the	O
73	second	O
73	most	O
73	frequently	O
73	cited	O
73	reason	O
73	for	O
73	discontinuation	O
73	in	O
73	each	O
73	group	O
73	and	O
73	was	O
73	reported	O
73	for	O
73	16	O
73	%	O
73	of	O
73	patients	O
73	in	O
73	each	O
73	group	O
73	.	O
73	Seven	O
73	percent	O
73	of	O
73	the	O
73	oblimersen	O
73	/	O
73	dexamethasone	O
73	group	O
73	and	O
73	4	O
73	%	O
73	of	O
73	the	O
73	dexamethasone	O
73	group	O
73	discontinued	O
73	for	O
73	other	O
73	reasons	O
73	,	O
73	including	O
73	proceeding	O
73	to	O
73	transplant	O
73	,	O
73	noncompliance	O
73	or	O
73	removal	O
73	based	O
73	on	O
73	physician	O
73	's	O
73	request	O
73	,	O
73	and	O
73	another	O
73	7	O
73	%	O
73	and	O
73	8	O
73	%	O
73	,	O
73	respectively	O
73	,	O
73	either	O
73	withdrew	O
73	consent	O
73	or	O
73	failed	O
73	to	O
73	return	O
73	.	O
--------------------------------------------------------------
74	In	O
74	the	O
74	ITT	O
74	population	O
74	,	O
74	103	O
74	(	O
74	94	O
74	%	O
74	)	O
74	of	O
74	the	O
74	oblimersen/	O
74	dexamethasone	O
74	group	O
74	and	O
74	94	O
74	(	O
74	83	O
74	%	O
74	)	O
74	of	O
74	the	O
74	dexamethasone	B-arm_description
74	group	B-arm_description
74	discontinued	O
74	treatment	O
74	,	O
74	that	O
74	is	O
74	,	O
74	initiated	O
74	516	O
74	cycles	O
74	or	O
74	received	O
74	51	O
74	year	O
74	(	O
74	defined	O
74	as	O
74	335	O
74	days	O
74	)	O
74	of	O
74	protocol	O
74	-	O
74	specified	O
74	therapy	O
74	from	O
74	the	O
74	date	O
74	of	O
74	first	O
74	dose	O
74	.	O
74	Disease	O
74	progression	O
74	/	O
74	lack	O
74	of	O
74	efficacy	O
74	accounted	O
74	for	O
74	more	O
74	than	O
74	50	O
74	%	O
74	of	O
74	the	O
74	discontinuations	O
74	in	O
74	each	O
74	group	O
74	(	O
74	oblimersen	O
74	/	O
74	dexamethasone	O
74	:	O
74	63	O
74	%	O
74	;	O
74	dexamethasone	O
74	:	O
74	55	O
74	%	O
74	)	O
74	.	O
74	Adverse	O
74	event	O
74	/	O
74	toxicity	O
74	was	O
74	the	O
74	second	O
74	most	O
74	frequently	O
74	cited	O
74	reason	O
74	for	O
74	discontinuation	O
74	in	O
74	each	O
74	group	O
74	and	O
74	was	O
74	reported	O
74	for	O
74	16	O
74	%	O
74	of	O
74	patients	O
74	in	O
74	each	O
74	group	O
74	.	O
74	Seven	O
74	percent	O
74	of	O
74	the	O
74	oblimersen	O
74	/	O
74	dexamethasone	O
74	group	O
74	and	O
74	4	O
74	%	O
74	of	O
74	the	O
74	dexamethasone	O
74	group	O
74	discontinued	O
74	for	O
74	other	O
74	reasons	O
74	,	O
74	including	O
74	proceeding	O
74	to	O
74	transplant	O
74	,	O
74	noncompliance	O
74	or	O
74	removal	O
74	based	O
74	on	O
74	physician	O
74	's	O
74	request	O
74	,	O
74	and	O
74	another	O
74	7	O
74	%	O
74	and	O
74	8	O
74	%	O
74	,	O
74	respectively	O
74	,	O
74	either	O
74	withdrew	O
74	consent	O
74	or	O
74	failed	O
74	to	O
74	return	O
74	.	O
--------------------------------------------------------------
75	No	O
75	significant	O
75	difference	O
75	in	O
75	TTP	O
75	was	O
75	observed	O
75	between	O
75	the	O
75	oblimersen	B-arm_description
75	/	B-arm_description
75	dexamethasone	B-arm_description
75	arm	B-arm_description
75	and	O
75	the	O
75	dexamethasone	O
75	arm	O
75	(	O
75	94	O
75	vs.	O
75	108	O
75	days	O
75	,	O
75	respectively	O
75	;	O
75	p	O
75	¼	O
75	0.26	O
75	)	O
75	(	O
75	Table	O
75	II	O
75	)	O
75	.	O
75	The	O
75	objective	O
75	response	O
75	rates	O
75	in	O
75	the	O
75	two	O
75	groups	O
75	were	O
75	also	O
75	similar	O
75	(	O
75	15	O
75	%	O
75	vs.	O
75	17	O
75	%	O
75	,	O
75	respectively	O
75	)	O
75	(	O
75	Table	O
75	III	O
75	)	O
75	.	O
75	There	O
75	were	O
75	no	O
75	complete	O
75	responses	O
75	as	O
75	defined	O
75	based	O
75	on	O
75	the	O
75	Bladé	O
75	criteria	O
75	,	O
75	[	O
75	16	O
75	]	O
75	and	O
75	no	O
75	differences	O
75	were	O
75	observed	O
75	when	O
75	findings	O
75	were	O
75	analysed	O
75	by	O
75	disease	O
75	stage	O
75	(	O
75	results	O
75	not	O
75	shown	O
75	)	O
75	.	O
75	The	O
75	study	O
75	was	O
75	terminated	O
75	in	O
75	2004	O
75	,	O
75	and	O
75	the	O
75	follow	O
75	-	O
75	up	O
75	of	O
75	patients	O
75	for	O
75	up	O
75	to	O
75	2	O
75	years	O
75	after	O
75	the	O
75	end	O
75	of	O
75	treatment	O
75	was	O
75	not	O
75	completed	O
75	.	O
75	Thus	O
75	,	O
75	the	O
75	analysis	O
75	of	O
75	survival	O
75	included	O
75	data	O
75	available	O
75	through	O
75	a	O
75	cut	O
75	-	O
75	off	O
75	date	O
75	approximately	O
75	1	O
75	year	O
75	after	O
75	enrolment	O
75	of	O
75	the	O
75	last	O
75	subject	O
75	and	O
75	did	O
75	not	O
75	show	O
75	an	O
75	advantage	O
75	of	O
75	oblimersen/	O
75	dexamethasone	O
75	over	O
75	standard	O
75	therapy	O
75	(	O
75	55	O
75	%	O
75	vs.	O
75	42	O
75	%	O
75	of	O
75	treated	O
75	patients	O
75	;	O
75	p	O
75	¼	O
75	0.29	O
75	based	O
75	on	O
75	logistic	O
75	regression	O
75	analysis	O
75	after	O
75	adjustment	O
75	for	O
75	baseline	O
75	imbalances	O
75	)	O
75	.	O
--------------------------------------------------------------
76	No	O
76	significant	O
76	difference	O
76	in	O
76	TTP	O
76	was	O
76	observed	O
76	between	O
76	the	O
76	oblimersen	O
76	/	O
76	dexamethasone	O
76	arm	O
76	and	O
76	the	O
76	dexamethasone	B-arm_description
76	arm	B-arm_description
76	(	O
76	94	O
76	vs.	O
76	108	O
76	days	O
76	,	O
76	respectively	O
76	;	O
76	p	O
76	¼	O
76	0.26	O
76	)	O
76	(	O
76	Table	O
76	II	O
76	)	O
76	.	O
76	The	O
76	objective	O
76	response	O
76	rates	O
76	in	O
76	the	O
76	two	O
76	groups	O
76	were	O
76	also	O
76	similar	O
76	(	O
76	15	O
76	%	O
76	vs.	O
76	17	O
76	%	O
76	,	O
76	respectively	O
76	)	O
76	(	O
76	Table	O
76	III	O
76	)	O
76	.	O
76	There	O
76	were	O
76	no	O
76	complete	O
76	responses	O
76	as	O
76	defined	O
76	based	O
76	on	O
76	the	O
76	Bladé	O
76	criteria	O
76	,	O
76	[	O
76	16	O
76	]	O
76	and	O
76	no	O
76	differences	O
76	were	O
76	observed	O
76	when	O
76	findings	O
76	were	O
76	analysed	O
76	by	O
76	disease	O
76	stage	O
76	(	O
76	results	O
76	not	O
76	shown	O
76	)	O
76	.	O
76	The	O
76	study	O
76	was	O
76	terminated	O
76	in	O
76	2004	O
76	,	O
76	and	O
76	the	O
76	follow	O
76	-	O
76	up	O
76	of	O
76	patients	O
76	for	O
76	up	O
76	to	O
76	2	O
76	years	O
76	after	O
76	the	O
76	end	O
76	of	O
76	treatment	O
76	was	O
76	not	O
76	completed	O
76	.	O
76	Thus	O
76	,	O
76	the	O
76	analysis	O
76	of	O
76	survival	O
76	included	O
76	data	O
76	available	O
76	through	O
76	a	O
76	cut	O
76	-	O
76	off	O
76	date	O
76	approximately	O
76	1	O
76	year	O
76	after	O
76	enrolment	O
76	of	O
76	the	O
76	last	O
76	subject	O
76	and	O
76	did	O
76	not	O
76	show	O
76	an	O
76	advantage	O
76	of	O
76	oblimersen/	O
76	dexamethasone	O
76	over	O
76	standard	O
76	therapy	O
76	(	O
76	55	O
76	%	O
76	vs.	O
76	42	O
76	%	O
76	of	O
76	treated	O
76	patients	O
76	;	O
76	p	O
76	¼	O
76	0.29	O
76	based	O
76	on	O
76	logistic	O
76	regression	O
76	analysis	O
76	after	O
76	adjustment	O
76	for	O
76	baseline	O
76	imbalances	O
76	)	O
76	.	O
--------------------------------------------------------------
77	All	O
77	treated	O
77	patients	O
77	in	O
77	both	O
77	groups	O
77	had	O
77	at	O
77	least	O
77	one	O
77	adverse	O
77	event	O
77	.	O
77	The	O
77	most	O
77	common	O
77	adverse	O
77	event	O
77	in	O
77	both	O
77	treatment	O
77	groups	O
77	was	O
77	fatigue	O
77	,	O
77	occurring	O
77	in	O
77	54	O
77	%	O
77	of	O
77	the	O
77	patients	O
77	receiving	O
77	oblimersen	B-arm_description
77	/	B-arm_description
77	dexamethasone	B-arm_description
77	and	O
77	45	O
77	%	O
77	of	O
77	those	O
77	receiving	O
77	dexamethasone	O
77	.	O
77	Other	O
77	adverse	O
77	events	O
77	occurring	O
77	in	O
77	25	O
77	%	O
77	of	O
77	the	O
77	patients	O
77	in	O
77	the	O
77	oblimersen	O
77	/	O
77	dexamethasone	O
77	group	O
77	were	O
77	fever	O
77	(	O
77	48	O
77	%	O
77	)	O
77	,	O
77	nausea	O
77	(	O
77	41	O
77	%	O
77	)	O
77	,	O
77	insomnia	O
77	(	O
77	35	O
77	%	O
77	)	O
77	,	O
77	anemia	O
77	(	O
77	33	O
77	%	O
77	)	O
77	,	O
77	arthralgia	O
77	(	O
77	31	O
77	%	O
77	)	O
77	,	O
77	constipation	O
77	(	O
77	31	O
77	%	O
77	)	O
77	,	O
77	diarrhea	O
77	(	O
77	27	O
77	%	O
77	)	O
77	and	O
77	vomiting	O
77	(	O
77	25	O
77	%	O
77	)	O
77	.	O
77	In	O
77	the	O
77	dexamethasone	O
77	group	O
77	,	O
77	insomnia	O
77	(	O
77	34	O
77	%	O
77	)	O
77	and	O
77	weakness	O
77	(	O
77	25	O
77	%	O
77	)	O
77	were	O
77	the	O
77	only	O
77	adverse	O
77	events	O
77	besides	O
77	fatigue	O
77	that	O
77	occurred	O
77	in	O
77	25	O
77	%	O
77	of	O
77	patients	O
77	(	O
77	Table	O
77	IV	O
77	)	O
77	.	O
77	The	O
77	percentage	O
77	of	O
77	patients	O
77	who	O
77	discontinued	O
77	because	O
77	of	O
77	an	O
77	adverse	O
77	event	O
77	was	O
77	the	O
77	same	O
77	in	O
77	both	O
77	arms	O
77	(	O
77	16	O
77	%	O
77	)	O
77	;	O
77	events	O
77	that	O
77	resulted	O
77	in	O
77	discontinuation	O
77	and	O
77	were	O
77	considered	O
77	to	O
77	be	O
77	treatment	O
77	related	O
77	were	O
77	reported	O
77	for	O
77	12	O
77	%	O
77	of	O
77	patients	O
77	in	O
77	the	O
77	oblimersen/	O
77	dexamethasone	O
77	group	O
77	and	O
77	14	O
77	%	O
77	of	O
77	patients	O
77	in	O
77	the	O
77	dexamethasone	O
77	group	O
77	.	O
77	In	O
77	both	O
77	groups	O
77	,	O
77	half	O
77	of	O
77	the	O
77	patients	O
77	who	O
77	discontinued	O
77	due	O
77	to	O
77	an	O
77	adverse	O
77	event	O
77	did	O
77	so	O
77	in	O
77	cycle	O
77	1	O
77	.	O
77	No	O
77	single	O
77	adverse	O
77	event	O
77	or	O
77	cluster	O
77	of	O
77	adverse	O
77	events	O
77	resulted	O
77	in	O
77	cycle	O
77	1	O
77	discontinuations	O
77	.	O
--------------------------------------------------------------
78	All	O
78	treated	O
78	patients	O
78	in	O
78	both	O
78	groups	O
78	had	O
78	at	O
78	least	O
78	one	O
78	adverse	O
78	event	O
78	.	O
78	The	O
78	most	O
78	common	O
78	adverse	O
78	event	O
78	in	O
78	both	O
78	treatment	O
78	groups	O
78	was	O
78	fatigue	O
78	,	O
78	occurring	O
78	in	O
78	54	O
78	%	O
78	of	O
78	the	O
78	patients	O
78	receiving	O
78	oblimersen	O
78	/	O
78	dexamethasone	O
78	and	O
78	45	O
78	%	O
78	of	O
78	those	B-arm_description
78	receiving	B-arm_description
78	dexamethasone	B-arm_description
78	.	O
78	Other	O
78	adverse	O
78	events	O
78	occurring	O
78	in	O
78	25	O
78	%	O
78	of	O
78	the	O
78	patients	O
78	in	O
78	the	O
78	oblimersen	O
78	/	O
78	dexamethasone	O
78	group	O
78	were	O
78	fever	O
78	(	O
78	48	O
78	%	O
78	)	O
78	,	O
78	nausea	O
78	(	O
78	41	O
78	%	O
78	)	O
78	,	O
78	insomnia	O
78	(	O
78	35	O
78	%	O
78	)	O
78	,	O
78	anemia	O
78	(	O
78	33	O
78	%	O
78	)	O
78	,	O
78	arthralgia	O
78	(	O
78	31	O
78	%	O
78	)	O
78	,	O
78	constipation	O
78	(	O
78	31	O
78	%	O
78	)	O
78	,	O
78	diarrhea	O
78	(	O
78	27	O
78	%	O
78	)	O
78	and	O
78	vomiting	O
78	(	O
78	25	O
78	%	O
78	)	O
78	.	O
78	In	O
78	the	O
78	dexamethasone	O
78	group	O
78	,	O
78	insomnia	O
78	(	O
78	34	O
78	%	O
78	)	O
78	and	O
78	weakness	O
78	(	O
78	25	O
78	%	O
78	)	O
78	were	O
78	the	O
78	only	O
78	adverse	O
78	events	O
78	besides	O
78	fatigue	O
78	that	O
78	occurred	O
78	in	O
78	25	O
78	%	O
78	of	O
78	patients	O
78	(	O
78	Table	O
78	IV	O
78	)	O
78	.	O
78	The	O
78	percentage	O
78	of	O
78	patients	O
78	who	O
78	discontinued	O
78	because	O
78	of	O
78	an	O
78	adverse	O
78	event	O
78	was	O
78	the	O
78	same	O
78	in	O
78	both	O
78	arms	O
78	(	O
78	16	O
78	%	O
78	)	O
78	;	O
78	events	O
78	that	O
78	resulted	O
78	in	O
78	discontinuation	O
78	and	O
78	were	O
78	considered	O
78	to	O
78	be	O
78	treatment	O
78	related	O
78	were	O
78	reported	O
78	for	O
78	12	O
78	%	O
78	of	O
78	patients	O
78	in	O
78	the	O
78	oblimersen/	O
78	dexamethasone	O
78	group	O
78	and	O
78	14	O
78	%	O
78	of	O
78	patients	O
78	in	O
78	the	O
78	dexamethasone	O
78	group	O
78	.	O
78	In	O
78	both	O
78	groups	O
78	,	O
78	half	O
78	of	O
78	the	O
78	patients	O
78	who	O
78	discontinued	O
78	due	O
78	to	O
78	an	O
78	adverse	O
78	event	O
78	did	O
78	so	O
78	in	O
78	cycle	O
78	1	O
78	.	O
78	No	O
78	single	O
78	adverse	O
78	event	O
78	or	O
78	cluster	O
78	of	O
78	adverse	O
78	events	O
78	resulted	O
78	in	O
78	cycle	O
78	1	O
78	discontinuations	O
78	.	O
--------------------------------------------------------------
79	Renal	O
79	and	O
79	hematologic	O
79	toxicities	O
79	.	O
79	An	O
79	increase	O
79	in	O
79	blood	O
79	creatinine	O
79	was	O
79	noted	O
79	in	O
79	25	O
79	%	O
79	of	O
79	the	O
79	oblimersen/	O
79	dexamethasone	O
79	patients	O
79	and	O
79	15	O
79	%	O
79	of	O
79	the	O
79	dexamethasone	O
79	patients	O
79	,	O
79	and	O
79	was	O
79	Grade	O
79	3	O
79	or	O
79	4	O
79	in	O
79	8	O
79	%	O
79	and	O
79	4	O
79	%	O
79	,	O
79	respectively	O
79	(	O
79	Table	O
79	IV	O
79	)	O
79	.	O
79	In	O
79	both	O
79	treatment	O
79	groups	O
79	,	O
79	increase	O
79	in	O
79	blood	O
79	creatinine	O
79	was	O
79	more	O
79	likely	O
79	to	O
79	occur	O
79	in	O
79	patients	O
79	with	O
79	elevated	O
79	baseline	O
79	serum	O
79	creatinine	O
79	(	O
79	41.5	O
79	mg	O
79	/	O
79	dL	O
79	)	O
79	and	O
79	in	O
79	patients	O
79	who	O
79	were	O
79	black	O
79	and/or	O
79	had	O
79	concurrent	O
79	medical	O
79	conditions	O
79	that	O
79	affect	O
79	renal	O
79	function	O
79	,	O
79	such	O
79	as	O
79	diabetes	O
79	or	O
79	hypertension	O
79	.	O
79	Despite	O
79	the	O
79	increased	O
79	percentage	O
79	of	O
79	patients	O
79	in	O
79	the	O
79	oblimersen	B-arm_description
79	/	B-arm_description
79	dexamethasone	B-arm_description
79	group	B-arm_description
79	with	O
79	increased	O
79	blood	O
79	creatinine	O
79	,	O
79	the	O
79	incidence	O
79	of	O
79	patients	O
79	experiencing	O
79	renal	O
79	failure	O
79	was	O
79	comparable	O
79	in	O
79	the	O
79	two	O
79	groups	O
79	(	O
79	oblimersen/	O
79	dexamethasone	O
79	:	O
79	three	O
79	[	O
79	3	O
79	%	O
79	]	O
79	patients	O
79	;	O
79	dexamethasone	O
79	:	O
79	four	O
79	[	O
79	4	O
79	%	O
79	]	O
79	patients	O
79	)	O
79	.	O
79	Includes	O
79	adverse	O
79	events	O
79	(	O
79	regardless	O
79	of	O
79	relationship	O
79	to	O
79	treatment	O
79	)	O
79	that	O
79	occurred	O
79	in	O
79	20	O
79	%	O
79	of	O
79	patients	O
79	in	O
79	either	O
79	treatment	O
79	group	O
79	.	O
--------------------------------------------------------------
80	Renal	O
80	and	O
80	hematologic	O
80	toxicities	O
80	.	O
80	An	O
80	increase	O
80	in	O
80	blood	O
80	creatinine	O
80	was	O
80	noted	O
80	in	O
80	25	O
80	%	O
80	of	O
80	the	O
80	oblimersen/	O
80	dexamethasone	O
80	patients	O
80	and	O
80	15	O
80	%	O
80	of	O
80	the	O
80	dexamethasone	O
80	patients	O
80	,	O
80	and	O
80	was	O
80	Grade	O
80	3	O
80	or	O
80	4	O
80	in	O
80	8	O
80	%	O
80	and	O
80	4	O
80	%	O
80	,	O
80	respectively	O
80	(	O
80	Table	O
80	IV	O
80	)	O
80	.	O
80	In	O
80	both	O
80	treatment	O
80	groups	O
80	,	O
80	increase	O
80	in	O
80	blood	O
80	creatinine	O
80	was	O
80	more	O
80	likely	O
80	to	O
80	occur	O
80	in	O
80	patients	O
80	with	O
80	elevated	O
80	baseline	O
80	serum	O
80	creatinine	O
80	(	O
80	41.5	O
80	mg	O
80	/	O
80	dL	O
80	)	O
80	and	O
80	in	O
80	patients	O
80	who	O
80	were	O
80	black	O
80	and/or	O
80	had	O
80	concurrent	O
80	medical	O
80	conditions	O
80	that	O
80	affect	O
80	renal	O
80	function	O
80	,	O
80	such	O
80	as	O
80	diabetes	O
80	or	O
80	hypertension	O
80	.	O
80	Despite	O
80	the	O
80	increased	O
80	percentage	O
80	of	O
80	patients	O
80	in	O
80	the	O
80	oblimersen	O
80	/	O
80	dexamethasone	O
80	group	O
80	with	O
80	increased	O
80	blood	O
80	creatinine	O
80	,	O
80	the	O
80	incidence	O
80	of	O
80	patients	O
80	experiencing	O
80	renal	O
80	failure	O
80	was	O
80	comparable	O
80	in	O
80	the	O
80	two	O
80	groups	O
80	(	O
80	oblimersen/	O
80	dexamethasone	O
80	:	O
80	three	O
80	[	O
80	3	O
80	%	O
80	]	O
80	patients	O
80	;	O
80	dexamethasone	B-arm_description
80	:	O
80	four	O
80	[	O
80	4	O
80	%	O
80	]	O
80	patients	O
80	)	O
80	.	O
80	Includes	O
80	adverse	O
80	events	O
80	(	O
80	regardless	O
80	of	O
80	relationship	O
80	to	O
80	treatment	O
80	)	O
80	that	O
80	occurred	O
80	in	O
80	20	O
80	%	O
80	of	O
80	patients	O
80	in	O
80	either	O
80	treatment	O
80	group	O
80	.	O
--------------------------------------------------------------
81	Thrombocytopenia	O
81	was	O
81	observed	O
81	in	O
81	22	O
81	%	O
81	of	O
81	oblimersen	B-arm_description
81	/	B-arm_description
81	dexamethasone	B-arm_description
81	patients	O
81	and	O
81	9	O
81	%	O
81	of	O
81	dexamethasone	O
81	patients	O
81	and	O
81	was	O
81	Grade	O
81	3	O
81	or	O
81	Grade	O
81	4	O
81	in	O
81	14	O
81	%	O
81	and	O
81	5	O
81	%	O
81	,	O
81	respectively	O
81	.	O
81	The	O
81	incidence	O
81	of	O
81	Grade	O
81	3	O
81	or	O
81	4	O
81	bleeding	O
81	events	O
81	was	O
81	similar	O
81	in	O
81	the	O
81	two	O
81	treatment	O
81	groups	O
81	(	O
81	6	O
81	%	O
81	and	O
81	5	O
81	%	O
81	,	O
81	respectively	O
81	)	O
81	.	O
81	In	O
81	both	O
81	groups	O
81	,	O
81	the	O
81	incidence	O
81	of	O
81	Grade	O
81	3	O
81	or	O
81	Grade	O
81	4	O
81	anemia	O
81	was	O
81	12	O
81	%	O
81	and	O
81	the	O
81	incidence	O
81	of	O
81	Grade	O
81	3	O
81	or	O
81	Grade	O
81	4	O
81	neutropenia	O
81	was	O
81	4	O
81	%	O
81	.	O
--------------------------------------------------------------
82	Thrombocytopenia	O
82	was	O
82	observed	O
82	in	O
82	22	O
82	%	O
82	of	O
82	oblimersen	O
82	/	O
82	dexamethasone	O
82	patients	O
82	and	O
82	9	O
82	%	O
82	of	O
82	dexamethasone	B-arm_description
82	patients	B-arm_description
82	and	O
82	was	O
82	Grade	O
82	3	O
82	or	O
82	Grade	O
82	4	O
82	in	O
82	14	O
82	%	O
82	and	O
82	5	O
82	%	O
82	,	O
82	respectively	O
82	.	O
82	The	O
82	incidence	O
82	of	O
82	Grade	O
82	3	O
82	or	O
82	4	O
82	bleeding	O
82	events	O
82	was	O
82	similar	O
82	in	O
82	the	O
82	two	O
82	treatment	O
82	groups	O
82	(	O
82	6	O
82	%	O
82	and	O
82	5	O
82	%	O
82	,	O
82	respectively	O
82	)	O
82	.	O
82	In	O
82	both	O
82	groups	O
82	,	O
82	the	O
82	incidence	O
82	of	O
82	Grade	O
82	3	O
82	or	O
82	Grade	O
82	4	O
82	anemia	O
82	was	O
82	12	O
82	%	O
82	and	O
82	the	O
82	incidence	O
82	of	O
82	Grade	O
82	3	O
82	or	O
82	Grade	O
82	4	O
82	neutropenia	O
82	was	O
82	4	O
82	%	O
82	.	O
--------------------------------------------------------------
83	Deaths	O
83	.	O
83	The	O
83	incidence	O
83	of	O
83	adverse	O
83	events	O
83	with	O
83	an	O
83	outcome	O
83	of	O
83	death	O
83	during	O
83	treatment	O
83	or	O
83	within	O
83	30	O
83	days	O
83	of	O
83	the	O
83	end	O
83	of	O
83	treatment	O
83	was	O
83	similar	O
83	in	O
83	the	O
83	two	O
83	treatment	O
83	groups	O
83	(	O
83	oblimersen	B-arm_description
83	/	B-arm_description
83	dexamethasone	B-arm_description
83	:	O
83	13	O
83	(	O
83	12	O
83	%	O
83	)	O
83	;	O
83	dexamethasone	O
83	:	O
83	10	O
83	(	O
83	9	O
83	%	O
83	)	O
83	(	O
83	Table	O
83	V	O
83	)	O
83	.	O
83	Disease	O
83	progression	O
83	was	O
83	the	O
83	most	O
83	frequently	O
83	reported	O
83	cause	O
83	of	O
83	death	O
83	,	O
83	accounting	O
83	for	O
83	five	O
83	deaths	O
83	in	O
83	the	O
83	combination	O
83	arm	O
83	and	O
83	three	O
83	deaths	O
83	in	O
83	the	O
83	dexamethasone	O
83	arm	O
83	.	O
--------------------------------------------------------------
84	Deaths	O
84	.	O
84	The	O
84	incidence	O
84	of	O
84	adverse	O
84	events	O
84	with	O
84	an	O
84	outcome	O
84	of	O
84	death	O
84	during	O
84	treatment	O
84	or	O
84	within	O
84	30	O
84	days	O
84	of	O
84	the	O
84	end	O
84	of	O
84	treatment	O
84	was	O
84	similar	O
84	in	O
84	the	O
84	two	O
84	treatment	O
84	groups	O
84	(	O
84	oblimersen	O
84	/	O
84	dexamethasone	O
84	:	O
84	13	O
84	(	O
84	12	O
84	%	O
84	)	O
84	;	O
84	dexamethasone	B-arm_description
84	:	O
84	10	O
84	(	O
84	9	O
84	%	O
84	)	O
84	(	O
84	Table	O
84	V	O
84	)	O
84	.	O
84	Disease	O
84	progression	O
84	was	O
84	the	O
84	most	O
84	frequently	O
84	reported	O
84	cause	O
84	of	O
84	death	O
84	,	O
84	accounting	O
84	for	O
84	five	O
84	deaths	O
84	in	O
84	the	O
84	combination	O
84	arm	O
84	and	O
84	three	O
84	deaths	O
84	in	O
84	the	O
84	dexamethasone	O
84	arm	O
84	.	O
--------------------------------------------------------------
85	Impact	O
85	of	O
85	high	O
85	-	O
85	risk	O
85	cytogenetics	O
85	and	O
85	prior	O
85	therapy	O
85	on	O
85	outcomes	O
85	in	O
85	patients	O
85	with	O
85	advanced	O
85	relapsed	O
85	or	O
85	refractory	O
85	multiple	O
85	myeloma	O
85	treated	O
85	with	O
85	lenalidomide	B-arm_description
85	plus	B-arm_description
85	dexaméthasone	B-arm_description
85	Impact	O
85	of	O
85	high	O
85	-	O
85	risk	O
85	cytogenetics	O
85	and	O
85	prior	O
85	therapy	O
85	on	O
85	outcomes	O
85	in	O
85	patients	O
85	with	O
85	advanced	O
85	relapsed	O
85	or	O
85	refractory	O
85	multiple	O
85	myeloma	O
85	treated	O
85	with	O
85	lenalidomide	O
85	plus	O
85	dexaméthasone	O
85	14	O
85	January	O
85	2010	O
85	14	O
85	January	O
85	2010	O
85	ProfessorHAvet	B-authors
85	-	B-authors
85	Loiseau	B-authors
--------------------------------------------------------------
86	Assistance	O
86	Publique	O
86	-	O
86	Hô	O
86	pitaux	O
86	de	O
86	Paris	O
86	Paris	O
86	France	O
86	IYakoub	B-authors
86	-	B-authors
86	Agha	B-authors
86	Hematology	O
86	Department	O
86	University	O
86	Hospital	O
86	Huriez	O
86	Lille	O
86	France	O
86	MAttal	B-authors
86	Hematology	O
86	Department	O
86	Centre	O
86	Hospitalier	O
86	Purpan	O
86	Toulouse	O
86	France	O
86	CHulin	B-authors
86	Hematology	O
86	Department	O
86	University	O
86	Hospital	O
86	Brabois	O
86	Nancy	O
86	France	O
86	LGarderet	B-authors
86	Hematology	O
86	Department	O
--------------------------------------------------------------
87	Impact	O
87	of	O
87	high	O
87	-	O
87	risk	O
87	cytogenetics	O
87	and	O
87	prior	O
87	therapy	O
87	on	O
87	outcomes	O
87	in	O
87	patients	O
87	with	O
87	advanced	O
87	relapsed	O
87	or	O
87	refractory	O
87	multiple	O
87	myeloma	O
87	treated	O
87	with	O
87	lenalidomide	B-arm_description
87	plus	B-arm_description
87	dexaméthasone	B-arm_description
87	14	O
87	January	O
87	2010	O
87	10.1038	O
87	/	O
87	leu.2009.273	O
--------------------------------------------------------------
88	Impact	O
88	of	O
88	high	O
88	-	O
88	risk	O
88	cytogenetics	O
88	and	O
88	prior	O
88	therapy	O
88	on	O
88	outcomes	O
88	in	O
88	patients	O
88	with	O
88	advanced	O
88	relapsed	O
88	or	O
88	refractory	O
88	multiple	O
88	myeloma	O
88	treated	O
88	with	O
88	lenalidomide	B-arm_description
88	plus	B-arm_description
88	dexaméthasone	I-arm_description
88	ProfessorHAvet	B-authors
88	-	B-authors
88	Loiseau	B-authors
88	herve.avetloiseau@chu-nantes.fr	O
--------------------------------------------------------------
89	France	O
89	ProfessorHAvet	B-authors
89	-	B-authors
89	Loiseau	B-authors
89	Professor	O
89	H	O
89	Avet	O
89	-	O
89	Loiseau	O
89	herve.avetloiseau@chu-nantes.fr	O
89	Institut	O
89	National	O
89	de	O
89	la	O
89	Santé	O
89	et	O
89	de	O
89	la	O
89	Recherche	O
89	Médicale	O
89	(	O
89	INSERM	O
89	)	O
89	Unité	O
89	892	O
89	Nantes	O
--------------------------------------------------------------
90	France	O
90	9	O
90	quai	O
90	Moncouscu	O
90	44093	O
90	Nantes	O
90	France	O
90	Impact	O
90	of	O
90	high	O
90	-	O
90	risk	O
90	cytogenetics	O
90	and	O
90	prior	O
90	therapy	O
90	on	O
90	outcomes	O
90	in	O
90	patients	O
90	with	O
90	advanced	O
90	relapsed	O
90	or	O
90	refractory	O
90	multiple	O
90	myeloma	O
90	treated	O
90	with	O
90	lenalidomide	B-arm_description
90	plus	I-arm_description
90	dexaméthasone	I-arm_description
90	14	O
90	January	O
90	2010	O
90	14	O
90	January	O
90	2010	O
90	14	O
90	January	O
90	2010	O
90	10.1038	O
90	/	O
90	leu.2009.273	O
90	Received	O
90	6	O
90	May	O
90	2009	O
90	;	O
90	revised	O
90	29	O
90	October	O
90	2009	O
90	;	O
90	accepted	O
90	9	O
90	November	O
90	2009	O
90	;	O
--------------------------------------------------------------
91	Multiple	O
91	myeloma	O
91	(	O
91	MM	O
91	)	O
91	is	O
91	a	O
91	common	O
91	hematological	O
91	malignancy	O
91	,	O
91	which	O
91	accounts	O
91	for	O
91	B2	O
91	%	O
91	of	O
91	all	O
91	cancer	O
91	deaths	O
91	according	O
91	to	O
91	recent	O
91	US	O
91	statistics	O
91	.	O
91	1	O
91	It	O
91	is	O
91	an	O
91	incurable	O
91	disease	O
91	,	O
91	but	O
91	with	O
91	the	O
91	introduction	O
91	of	O
91	novel	O
91	therapies	O
91	,	O
91	such	O
91	as	O
91	thalidomide	O
91	,	O
91	lenalidomide	O
91	,	O
91	and	O
91	bortezomib	O
91	,	O
91	median	O
91	survival	O
91	has	O
91	doubled	O
91	to	O
91	B4	O
91	-	O
91	5	O
91	years	O
91	and	O
91	patients	O
91	now	O
91	have	O
91	a	O
91	20	O
91	%	O
91	chance	O
91	of	O
91	surviving	O
91	longer	O
91	than	O
91	10	O
91	years	O
91	.	O
91	2	O
91	Lenalidomide	O
91	(	O
91	Revlimid	O
91	;	O
91	Celgene	O
91	Corporation	O
91	,	O
91	Summit	O
91	,	O
91	NJ	O
91	,	O
91	USA	O
91	)	O
91	in	O
91	combination	O
91	with	O
91	dexamethasone	O
91	was	O
91	shown	O
91	to	O
91	be	O
91	highly	O
91	effective	O
91	in	O
91	the	O
91	treatment	O
91	of	O
91	patients	O
91	with	O
91	relapsed	O
91	or	O
91	refractory	O
91	MM	O
91	3,4	O
91	and	O
91	has	O
91	been	O
91	approved	O
91	in	O
91	the	O
91	European	O
91	Union	O
91	and	O
91	the	O
91	United	O
91	States	O
91	for	O
91	the	O
91	treatment	O
91	of	O
91	patients	O
91	with	O
91	MM	O
91	who	O
91	have	O
91	received	O
91	at	O
91	least	O
91	one	O
91	prior	O
91	therapy	O
91	.	O
--------------------------------------------------------------
92	The	O
92	chromosomal	O
92	abnormalities	O
92	of	O
92	del	O
92	(	O
92	13	O
92	)	O
92	,	O
92	t	O
92	(	O
92	4;14	O
92	)	O
92	,	O
92	and	O
92	del(17p	O
92	)	O
92	are	O
92	associated	O
92	with	O
92	poor	O
92	progression	O
92	-	O
92	free	O
92	survival	O
92	(	O
92	PFS	O
92	)	O
92	and	O
92	shorter	O
92	overall	O
92	survival	O
92	(	O
92	OS	O
92	)	O
92	in	O
92	newly	O
92	diagnosed	O
92	MM	O
92	patients	O
92	treated	O
92	with	O
92	traditional	O
92	chemotherapy	O
92	.	O
92	[	O
92	5][6][7][8	O
92	]	O
92	It	O
92	was	O
92	earlier	O
92	reported	O
92	that	O
92	newly	O
92	diagnosed	O
92	MM	O
92	patients	O
92	with	O
92	an	O
92	abnormal	O
92	karyotype	O
92	treated	O
92	with	O
92	lenalidomide	O
92	plus	O
92	dexamethasone	O
92	had	O
92	a	O
92	lower	O
92	PFS	O
92	and	O
92	OS	O
92	compared	O
92	with	O
92	patients	O
92	with	O
92	a	O
92	normal	O
92	karyotype	O
92	.	O
92	9	O
92	Preliminary	O
92	results	O
92	from	O
92	a	O
92	study	O
92	in	O
92	patients	O
92	with	O
92	relapsed	O
92	and	O
92	refractory	O
92	MM	O
92	treated	O
92	with	O
92	lenalidomide	O
92	plus	O
92	dexamethasone	O
92	showed	O
92	that	O
92	this	O
92	combination	O
92	can	O
92	overcome	O
92	the	O
92	poor	O
92	prognosis	O
92	conferred	O
92	by	O
92	the	O
92	chromosomal	O
92	abnormalities	O
92	of	O
92	del	O
92	(	O
92	13	O
92	)	O
92	and	O
92	t	O
92	(	O
92	4;14	O
92	)	O
92	,	O
92	but	O
92	not	O
92	del(17p	O
92	)	O
92	.	O
92	10	O
92	In	O
92	contrast	O
92	,	O
92	a	O
92	recent	O
92	analysis	O
92	of	O
92	100	O
92	patients	O
92	treated	O
92	with	O
92	lenalidomide	O
92	plus	O
92	dexamethasone	O
92	at	O
92	diagnosis	O
92	revealed	O
92	that	O
92	this	O
92	combination	O
92	was	O
92	not	O
92	able	O
92	to	O
92	overcome	O
92	the	O
92	poor	O
92	prognosis	O
92	of	O
92	chromosomal	O
92	abnormalities	O
92	and	O
92	high	O
92	labeling	O
92	index	O
92	.	O
92	11	O
92	The	O
92	prognostic	O
92	value	O
92	of	O
92	these	O
92	cytogenetic	O
92	abnormalities	O
92	and	O
92	the	O
92	impact	O
92	of	O
92	prior	O
92	therapy	O
92	in	O
92	the	O
92	relapsed	O
92	and	O
92	refractory	O
92	setting	O
92	remain	O
92	to	O
92	be	O
92	fully	O
92	defined	O
92	.	O
--------------------------------------------------------------
93	We	O
93	performed	O
93	a	O
93	retrospective	B-study_type
93	analysis	B-study_type
93	to	O
93	investigate	O
93	the	O
93	prognostic	O
93	values	O
93	of	O
93	del	O
93	(	O
93	13	O
93	)	O
93	,	O
93	t	O
93	(	O
93	4;14	O
93	)	O
93	,	O
93	and	O
93	del(17p	O
93	)	O
93	and	O
93	the	O
93	impact	O
93	of	O
93	prior	O
93	treatment	O
93	on	O
93	outcomes	O
93	in	O
93	relapsed	O
93	or	O
93	refractory	O
93	MM	O
93	patients	O
93	treated	O
93	with	O
93	lenalidomide	B-arm_description
93	plus	B-arm_description
93	dexamethasone	B-arm_description
93	.	O
--------------------------------------------------------------
94	Temporary	O
94	Authorization	O
94	for	O
94	Use	O
94	,	O
94	is	O
94	the	O
94	regulatory	O
94	mechanism	O
94	used	O
94	by	O
94	the	O
94	French	O
94	Health	O
94	Products	O
94	and	O
94	Safety	O
94	Agency	O
94	,	O
94	which	O
94	allows	O
94	access	O
94	of	O
94	non	O
94	-	O
94	approved	O
94	drugs	O
94	to	O
94	patients	O
94	in	O
94	France	O
94	,	O
94	on	O
94	a	O
94	named	O
94	-	O
94	patient	O
94	basis	O
94	.	O
94	Medical	B-study_type
94	records	B-study_type
94	were	I-study_type
94	obtained	I-study_type
94	from	O
94	49	O
94	clinical	O
94	centers	O
94	participating	O
94	in	O
94	the	O
94	French	O
94	Autorisation	O
94	Temporaire	O
94	d'Utilisation	O
94	program	O
94	.	O
--------------------------------------------------------------
95	Patients	O
95	with	O
95	relapsed	O
95	or	O
95	refractory	O
95	MM	O
95	who	O
95	had	O
95	earlier	O
95	received	O
95	alkylating	O
95	agents	O
95	as	O
95	well	O
95	as	O
95	prior	O
95	thalidomide	O
95	and/or	O
95	bortezomib	O
95	and	O
95	patients	O
95	with	O
95	available	O
95	fluorescence	O
95	in	O
95	situ	O
95	hybridization	O
95	(	O
95	FISH	O
95	)	O
95	data	O
95	were	O
95	included	O
95	in	O
95	the	O
95	analysis	O
95	.	O
95	Patients	O
95	received	O
95	oral	B-arm_dosage
95	treatment	B-arm_dosage
95	with	B-arm_dosage
95	lenalidomide	B-arm_dosage
95	(	B-arm_dosage
95	25	I-arm_dosage
95	mg	I-arm_dosage
95	per	I-arm_dosage
95	day	I-arm_dosage
95	on	I-arm_dosage
95	days	I-arm_dosage
95	1	I-arm_dosage
95	-	I-arm_dosage
95	21	I-arm_dosage
95	of	I-arm_dosage
95	every	I-arm_dosage
95	28-day	I-arm_dosage
95	cycle	I-arm_dosage
95	)	I-arm_dosage
95	plus	I-arm_dosage
95	dexamethasone	I-arm_dosage
95	(	I-arm_dosage
95	40	I-arm_dosage
95	mg	I-arm_dosage
95	per	I-arm_dosage
95	day	I-arm_dosage
95	on	I-arm_dosage
95	days	I-arm_dosage
95	1	I-arm_dosage
95	-	I-arm_dosage
95	4	I-arm_dosage
95	,	I-arm_dosage
95	9	I-arm_dosage
95	-	I-arm_dosage
95	12	I-arm_dosage
95	,	I-arm_dosage
95	and	I-arm_dosage
95	17	I-arm_dosage
95	-	I-arm_dosage
95	20	I-arm_dosage
95	for	I-arm_dosage
95	four	I-arm_dosage
95	cycles	I-arm_dosage
95	,	I-arm_dosage
95	then	I-arm_dosage
95	days	I-arm_dosage
95	1	I-arm_dosage
95	-	I-arm_dosage
95	4	I-arm_dosage
95	beginning	I-arm_dosage
95	with	I-arm_dosage
95	cycle	I-arm_dosage
95	5	I-arm_dosage
95	)	I-arm_dosage
95	.	O
--------------------------------------------------------------
96	At	O
96	enrolment	O
96	,	O
96	FISH	O
96	cytogenetic	O
96	analysis	O
96	was	O
96	performed	O
96	by	O
96	two	O
96	laboratories	O
96	(	O
96	in	O
96	Nantes	O
96	and	O
96	Paris	O
96	)	O
96	.	O
96	CD138-purified	O
96	plasma	O
96	cells	O
96	were	O
96	analyzed	O
96	for	O
96	del	O
96	(	O
96	13	O
96	)	O
96	,	O
96	t	O
96	(	O
96	4;14	O
96	)	O
96	,	O
96	and	O
96	del(17p	O
96	)	O
96	as	O
96	described	O
96	earlier	O
96	.	O
96	6	O
96	Response	O
96	and	O
96	disease	O
96	progression	O
96	endpoints	O
96	were	O
96	evaluated	O
96	using	O
96	the	O
96	European	O
96	Group	O
96	for	O
96	Blood	O
96	and	O
96	Marrow	O
96	Transplantation	O
96	criteria	O
96	.	O
96	12,13	O
96	OS	O
96	data	O
96	were	O
96	collected	O
96	at	O
96	the	O
96	time	O
96	of	O
96	the	O
96	patients	O
96	'	O
96	last	O
96	visit	O
96	.	O
--------------------------------------------------------------
97	The	O
97	independent	O
97	prognostic	O
97	impact	O
97	of	O
97	the	O
97	chromosomal	O
97	abnormalities	O
97	del(13	O
97	)	O
97	and	O
97	t	O
97	(	O
97	4;14	O
97	)	O
97	was	O
97	analyzed	O
97	by	O
97	comparing	O
97	the	O
97	outcomes	O
97	(	O
97	overall	O
97	response	O
97	rate	O
97	[	O
97	ORR	O
97	]	O
97	,	O
97	PFS	B-arm_efficacy_metric
97	,	O
97	and	O
97	OS	O
97	)	O
97	of	O
97	patients	O
97	with	O
97	or	O
97	without	O
97	the	O
97	respective	O
97	abnormality	O
97	.	O
97	Patient	O
97	response	O
97	and	O
97	survival	O
97	according	O
97	to	O
97	the	O
97	presence	O
97	or	O
97	absence	O
97	of	O
97	del(17p	O
97	)	O
97	were	O
97	not	O
97	evaluable	O
97	because	O
97	of	O
97	the	O
97	small	O
97	number	O
97	of	O
97	patients	O
97	with	O
97	del(17p	O
97	)	O
97	(	O
97	n	O
97	¼	O
97	8)	O
97	.	O
97	The	O
97	w	O
97	2	O
97	tests	O
97	,	O
97	Fisher	O
97	's	O
97	exact	O
97	test	O
97	,	O
97	and	O
97	logistic	O
97	regression	O
97	were	O
97	used	O
97	to	O
97	compare	O
97	ORR	O
97	between	O
97	groups	O
97	.	O
97	Time	O
97	-	O
97	to	O
97	-	O
97	event	O
97	variables	O
97	were	O
97	estimated	O
97	by	O
97	Kaplan	O
97	-	O
97	Meier	O
97	methods	O
97	.	O
97	Two	O
97	-	O
97	sided	O
97	log	O
97	-	O
97	rank	O
97	tests	O
97	were	O
97	used	O
97	to	O
97	compare	O
97	survivorship	O
97	functions	O
97	between	O
97	groups	O
97	.	O
--------------------------------------------------------------
98	Multivariate	O
98	analyses	O
98	using	O
98	Cox	O
98	proportional	O
98	-	O
98	hazard	O
98	regression	O
98	model	O
98	were	O
98	performed	O
98	to	O
98	assess	O
98	the	O
98	impact	O
98	of	O
98	the	O
98	following	O
98	variables	O
98	on	O
98	ORR	O
98	,	O
98	PFS	B-arm_efficacy_metric
98	,	O
98	and	O
98	OS	O
98	:	O
98	age	O
98	,	O
98	sex	O
98	,	O
98	hemoglobin	O
98	level	O
98	,	O
98	presence	O
98	of	O
98	del	O
98	(	O
98	13	O
98	)	O
98	,	O
98	presence	O
98	of	O
98	t	O
98	(	O
98	4;14	O
98	)	O
98	,	O
98	prior	O
98	bortezomib	O
98	treatment	O
98	,	O
98	prior	O
98	thalidomide	O
98	treatment	O
98	,	O
98	progression	O
98	on	O
98	thalidomide	O
98	,	O
98	prior	O
98	stem	O
98	cell	O
98	transplant	O
98	,	O
98	and	O
98	number	O
98	of	O
98	lines	O
98	of	O
98	earlier	O
98	therapy	O
98	.	O
98	Age	O
98	,	O
98	hemoglobin	O
98	,	O
98	and	O
98	number	O
98	of	O
98	lines	O
98	of	O
98	earlier	O
98	therapy	O
98	were	O
98	continuous	O
98	variables	O
98	;	O
98	all	O
98	other	O
98	variables	O
98	were	O
98	dichotomous	O
98	.	O
98	The	O
98	thresholds	O
98	for	O
98	entry	O
98	and	O
98	stay	O
98	were	O
98	0.25	O
98	and	O
98	0.15	O
98	,	O
98	respectively	O
98	.	O
--------------------------------------------------------------
99	Of	O
99	228	O
99	eligible	O
99	patients	O
99	,	O
99	207	O
99	patients	O
99	enrolled	O
99	in	O
99	the	O
99	Autorisation	O
99	Temporaire	O
99	d'Utilisation	O
99	program	O
99	between	O
99	April	O
99	2006	O
99	and	O
99	March	O
99	2007	O
99	were	O
99	included	O
99	in	O
99	this	O
99	analysis	O
99	.	O
99	The	O
99	remaining	O
99	21	O
99	patients	O
99	were	O
99	excluded	O
99	either	O
99	because	O
99	of	O
99	early	O
99	death	O
99	before	O
99	the	O
99	end	O
99	of	O
99	the	O
99	first	O
99	cycle	O
99	(	O
99	n	O
99	¼	O
99	14	O
99	)	O
99	or	O
99	because	O
99	of	O
99	patient	O
99	or	O
99	physician	O
99	refusal	O
99	for	O
99	continued	O
99	participation	O
99	(	O
99	n	O
99	¼	O
99	7	O
99	)	O
99	.	O
--------------------------------------------------------------
100	FISH	O
100	data	O
100	for	O
100	del	O
100	(	O
100	13	O
100	)	O
100	were	O
100	available	O
100	in	O
100	92	O
100	%	O
100	(	O
100	191	O
100	of	O
100	207	O
100	)	O
100	of	O
100	patients	O
100	,	O
100	for	O
100	t	O
100	(	O
100	4;14	O
100	)	O
100	in	O
100	89	O
100	%	O
100	(	O
100	184	O
100	of	O
100	207	O
100	)	O
100	of	O
100	patients	O
100	,	O
100	and	O
100	for	O
100	del(17p	O
100	)	O
100	in	O
100	58	O
100	%	O
100	(	O
100	120	O
100	of	O
100	207	O
100	)	O
100	of	O
100	patients	O
100	.	O
100	Del	O
100	(	O
100	13	O
100	)	O
100	was	O
100	observed	O
100	in	O
100	41	O
100	%	O
100	of	O
100	analyzed	O
100	patients	O
100	,	O
100	t	O
100	(	O
100	4;14	O
100	)	O
100	in	O
100	14	O
100	%	O
100	of	O
100	patients	O
100	,	O
100	and	O
100	del(17p	O
100	)	O
100	in	O
100	7	O
100	%	O
100	of	O
100	patients	O
100	(	O
100	Table	O
100	1	O
100	)	O
100	,	O
100	in	O
100	agreement	O
100	with	O
100	earlier	O
100	reports	O
100	.	O
100	Patients	O
100	had	O
100	received	O
100	a	O
100	median	O
100	of	O
100	three	O
100	prior	O
100	therapies	O
100	(	O
100	range	O
100	,	O
100	1	O
100	-	O
100	10	O
100	)	O
100	;	O
100	86	O
100	%	O
100	of	O
100	patients	O
100	had	O
100	received	O
100	prior	O
100	thalidomide	O
100	therapy	O
100	and	O
100	81	O
100	%	O
100	had	O
100	received	O
100	prior	O
100	bortezomib	O
100	therapy	O
100	.	O
100	At	O
100	the	O
100	time	O
100	of	O
100	analysis	O
100	(	O
100	November	O
100	2007	O
100	)	O
100	,	O
100	all	O
100	patients	O
100	had	O
100	received	O
100	lenalidomide	O
100	plus	O
100	dexamethasone	O
100	for	O
100	a	O
100	median	O
100	of	O
100	five	O
100	cycles	O
100	(	O
100	range	O
100	,	O
100	1	O
100	-	O
100	22	O
100	)	O
100	(	O
100	Table	O
100	1	O
100	)	O
100	.	O
--------------------------------------------------------------
101	Among	O
101	the	O
101	207	O
101	patients	O
101	,	O
101	the	O
101	ORR	O
101	was	O
101	achieved	O
101	in	O
101	59	O
101	%	O
101	of	O
101	patients	O
101	,	O
101	including	O
101	complete	O
101	response	O
101	in	O
101	7	O
101	%	O
101	and	O
101	very	O
101	good	O
101	partial	O
101	response	O
101	in	O
101	14	O
101	%	O
101	.	O
101	The	O
101	median	B-arm_efficacy_metric
101	PFS	B-arm_efficacy_metric
101	was	O
101	9.6	B-arm_efficacy_results
101	months	B-arm_efficacy_results
101	and	O
101	the	O
101	median	O
101	OS	O
101	was	O
101	15.1	O
101	months	O
101	(	O
101	Table	O
101	2	O
101	)	O
101	.	O
--------------------------------------------------------------
102	Impact	O
102	of	O
102	chromosomal	O
102	abnormalities	O
102	.	O
102	Among	B-arm_description
102	patients	B-arm_description
102	with	B-arm_description
102	del(13	B-arm_description
102	)	B-arm_description
102	compared	O
102	with	O
102	patients	O
102	without	O
102	del(13	O
102	)	O
102	,	O
102	the	O
102	ORR	O
102	was	O
102	significantly	O
102	lower	O
102	,	O
102	and	O
102	median	O
102	PFS	O
102	and	O
102	OS	O
102	were	O
102	significantly	O
102	shorter	O
102	,	O
102	(	O
102	ORR	O
102	43	O
102	%	O
102	vs	O
102	71	O
102	%	O
102	,	O
102	respectively	O
102	,	O
102	Po0.001	O
102	;	O
102	median	B-arm_efficacy_metric
102	PFS	B-arm_efficacy_metric
102	5.0	B-arm_efficacy_results
102	months	B-arm_efficacy_results
102	vs	O
102	12.5	O
102	months	O
102	,	O
102	Po0.0001	O
102	;	O
102	median	O
102	OS	O
102	10.4	O
102	months	O
102	vs	O
102	17.4	O
102	months	O
102	,	O
102	P	O
102	¼	O
102	0.001	O
102	)	O
102	(	O
102	Table	O
102	2	O
102	;	O
102	Figures	O
102	1a	O
102	and	O
102	b	O
102	)	O
102	.	O
102	A	O
102	similar	O
102	pattern	O
102	was	O
102	observed	O
102	among	O
102	patients	O
102	with	O
102	t(4;14	O
102	)	O
102	compared	O
102	with	O
102	patients	O
102	without	O
102	t(4;14	O
102	)	O
102	(	O
102	ORR	O
102	39	O
102	%	O
102	vs	O
102	62	O
102	%	O
102	,	O
102	respectively	O
102	,	O
102	P	O
102	¼	O
102	0.04	O
102	;	O
102	median	O
102	PFS	O
102	5.5	O
102	months	O
102	vs	O
102	10.6	O
102	months	O
102	,	O
102	Po0.01	O
102	;	O
102	median	O
102	OS	O
102	9.4	O
102	months	O
102	vs	O
102	15.4	O
102	months	O
102	,	O
102	P	O
102	¼	O
102	0.005	O
102	)	O
102	(	O
102	Table	O
102	2	O
102	)	O
102	.	O
--------------------------------------------------------------
103	Impact	O
103	of	O
103	chromosomal	O
103	abnormalities	O
103	.	O
103	Among	O
103	patients	O
103	with	O
103	del(13	O
103	)	O
103	compared	O
103	with	O
103	patients	B-arm_description
103	without	B-arm_description
103	del(13	B-arm_description
103	)	B-arm_description
103	,	O
103	the	O
103	ORR	O
103	was	O
103	significantly	O
103	lower	O
103	,	O
103	and	O
103	median	O
103	PFS	O
103	and	O
103	OS	O
103	were	O
103	significantly	O
103	shorter	O
103	,	O
103	(	O
103	ORR	O
103	43	O
103	%	O
103	vs	O
103	71	O
103	%	O
103	,	O
103	respectively	O
103	,	O
103	Po0.001	O
103	;	O
103	median	B-arm_efficacy_metric
103	PFS	B-arm_efficacy_metric
103	5.0	O
103	months	O
103	vs	O
103	12.5	B-arm_efficacy_results
103	months	B-arm_efficacy_results
103	,	B-arm_efficacy_results
103	Po0.0001	B-arm_efficacy_results
103	;	O
103	median	O
103	OS	O
103	10.4	O
103	months	O
103	vs	O
103	17.4	O
103	months	O
103	,	O
103	P	O
103	¼	O
103	0.001	O
103	)	O
103	(	O
103	Table	O
103	2	O
103	;	O
103	Figures	O
103	1a	O
103	and	O
103	b	O
103	)	O
103	.	O
103	A	O
103	similar	O
103	pattern	O
103	was	O
103	observed	O
103	among	O
103	patients	O
103	with	O
103	t(4;14	O
103	)	O
103	compared	O
103	with	O
103	patients	O
103	without	O
103	t(4;14	O
103	)	O
103	(	O
103	ORR	O
103	39	O
103	%	O
103	vs	O
103	62	O
103	%	O
103	,	O
103	respectively	O
103	,	O
103	P	O
103	¼	O
103	0.04	O
103	;	O
103	median	O
103	PFS	O
103	5.5	O
103	months	O
103	vs	O
103	10.6	O
103	months	O
103	,	O
103	Po0.01	O
103	;	O
103	median	O
103	OS	O
103	9.4	O
103	months	O
103	vs	O
103	15.4	O
103	months	O
103	,	O
103	P	O
103	¼	O
103	0.005	O
103	)	O
103	(	O
103	Table	O
103	2	O
103	)	O
103	.	O
--------------------------------------------------------------
104	Impact	O
104	of	O
104	chromosomal	O
104	abnormalities	O
104	.	O
104	Among	O
104	patients	O
104	with	O
104	del(13	O
104	)	O
104	compared	O
104	with	O
104	patients	O
104	without	O
104	del(13	O
104	)	O
104	,	O
104	the	O
104	ORR	O
104	was	O
104	significantly	O
104	lower	O
104	,	O
104	and	O
104	median	O
104	PFS	O
104	and	O
104	OS	O
104	were	O
104	significantly	O
104	shorter	O
104	,	O
104	(	O
104	ORR	O
104	43	O
104	%	O
104	vs	O
104	71	O
104	%	O
104	,	O
104	respectively	O
104	,	O
104	Po0.001	O
104	;	O
104	median	O
104	PFS	O
104	5.0	O
104	months	O
104	vs	O
104	12.5	O
104	months	O
104	,	O
104	Po0.0001	O
104	;	O
104	median	O
104	OS	O
104	10.4	O
104	months	O
104	vs	O
104	17.4	O
104	months	O
104	,	O
104	P	O
104	¼	O
104	0.001	O
104	)	O
104	(	O
104	Table	O
104	2	O
104	;	O
104	Figures	O
104	1a	O
104	and	O
104	b	O
104	)	O
104	.	O
104	A	O
104	similar	O
104	pattern	O
104	was	O
104	observed	O
104	among	O
104	patients	B-arm_description
104	with	B-arm_description
104	t(4;14	B-arm_description
104	)	B-arm_description
104	compared	O
104	with	O
104	patients	O
104	without	O
104	t(4;14	O
104	)	O
104	(	O
104	ORR	O
104	39	O
104	%	O
104	vs	O
104	62	O
104	%	O
104	,	O
104	respectively	O
104	,	O
104	P	O
104	¼	O
104	0.04	O
104	;	O
104	median	B-arm_efficacy_metric
104	PFS	B-arm_efficacy_metric
104	5.5	B-arm_efficacy_results
104	months	B-arm_efficacy_results
104	vs	O
104	10.6	O
104	months	O
104	,	O
104	Po0.01	B-arm_efficacy_results
104	;	O
104	median	O
104	OS	O
104	9.4	O
104	months	O
104	vs	O
104	15.4	O
104	months	O
104	,	O
104	P	O
104	¼	O
104	0.005	O
104	)	O
104	(	O
104	Table	O
104	2	O
104	)	O
104	.	O
--------------------------------------------------------------
105	Impact	O
105	of	O
105	chromosomal	O
105	abnormalities	O
105	.	O
105	Among	O
105	patients	O
105	with	O
105	del(13	O
105	)	O
105	compared	O
105	with	O
105	patients	O
105	without	O
105	del(13	O
105	)	O
105	,	O
105	the	O
105	ORR	O
105	was	O
105	significantly	O
105	lower	O
105	,	O
105	and	O
105	median	O
105	PFS	O
105	and	O
105	OS	O
105	were	O
105	significantly	O
105	shorter	O
105	,	O
105	(	O
105	ORR	O
105	43	O
105	%	O
105	vs	O
105	71	O
105	%	O
105	,	O
105	respectively	O
105	,	O
105	Po0.001	O
105	;	O
105	median	O
105	PFS	O
105	5.0	O
105	months	O
105	vs	O
105	12.5	O
105	months	O
105	,	O
105	Po0.0001	O
105	;	O
105	median	O
105	OS	O
105	10.4	O
105	months	O
105	vs	O
105	17.4	O
105	months	O
105	,	O
105	P	O
105	¼	O
105	0.001	O
105	)	O
105	(	O
105	Table	O
105	2	O
105	;	O
105	Figures	O
105	1a	O
105	and	O
105	b	O
105	)	O
105	.	O
105	A	O
105	similar	O
105	pattern	O
105	was	O
105	observed	O
105	among	O
105	patients	O
105	with	O
105	t(4;14	O
105	)	O
105	compared	O
105	with	O
105	patients	B-arm_description
105	without	B-arm_description
105	t(4;14	B-arm_description
105	)	B-arm_description
105	(	O
105	ORR	O
105	39	O
105	%	O
105	vs	O
105	62	O
105	%	O
105	,	O
105	respectively	O
105	,	O
105	P	O
105	¼	O
105	0.04	O
105	;	O
105	median	B-arm_efficacy_metric
105	PFS	B-arm_efficacy_metric
105	5.5	O
105	months	O
105	vs	O
105	10.6	B-arm_efficacy_results
105	months	B-arm_efficacy_results
105	,	O
105	Po0.01	B-arm_efficacy_results
105	;	O
105	median	O
105	OS	O
105	9.4	O
105	months	O
105	vs	O
105	15.4	O
105	months	O
105	,	O
105	P	O
105	¼	O
105	0.005	O
105	)	O
105	(	O
105	Table	O
105	2	O
105	)	O
105	.	O
--------------------------------------------------------------
106	Patients	O
106	with	O
106	isolated	O
106	del(13	O
106	)	O
106	,	O
106	defined	O
106	as	O
106	the	O
106	presence	O
106	of	O
106	del(13	O
106	)	O
106	without	O
106	t	O
106	(	O
106	4;14	O
106	)	O
106	or	O
106	del(17p	O
106	)	O
106	,	O
106	had	O
106	significantly	O
106	lower	O
106	ORR	O
106	compared	O
106	with	O
106	patients	O
106	without	O
106	isolated	O
106	del(13	O
106	)	O
106	(	O
106	43	O
106	%	O
106	vs	O
106	71	O
106	%	O
106	,	O
106	respectively	O
106	;	O
106	P	O
106	¼	O
106	0.01	O
106	)	O
106	(	O
106	Table	O
106	2	O
106	)	O
106	.	O
106	In	O
106	contrast	O
106	,	O
106	the	O
106	median	B-arm_efficacy_metric
106	PFS	B-arm_efficacy_metric
106	and	O
106	OS	O
106	were	O
106	not	O
106	(	O
106	or	O
106	marginally	O
106	)	O
106	shorter	O
106	in	O
106	patients	B-arm_description
106	with	B-arm_description
106	isolated	B-arm_description
106	del(13	B-arm_description
106	)	B-arm_description
106	(	O
106	PFS	O
106	was	O
106	8	B-arm_efficacy_results
106	months	B-arm_efficacy_results
106	vs	O
106	10.4	O
106	months	O
106	,	B-arm_efficacy_results
106	P	B-arm_efficacy_results
106	¼	B-arm_efficacy_results
106	0.05	B-arm_efficacy_results
106	;	O
106	OS	O
106	was	O
106	10.8	O
106	months	O
106	vs	O
106	15.1	O
106	months	O
106	,	O
106	P	O
106	¼	O
106	0.56	O
106	)	O
106	.	O
106	The	O
106	number	O
106	of	O
106	patients	O
106	with	O
106	del(17p	O
106	)	O
106	was	O
106	too	O
106	low	O
106	for	O
106	meaningful	O
106	interpretation	O
106	.	O
--------------------------------------------------------------
107	Patients	O
107	with	O
107	isolated	O
107	del(13	O
107	)	O
107	,	O
107	defined	O
107	as	O
107	the	O
107	presence	O
107	of	O
107	del(13	O
107	)	O
107	without	O
107	t	O
107	(	O
107	4;14	O
107	)	O
107	or	O
107	del(17p	O
107	)	O
107	,	O
107	had	O
107	significantly	O
107	lower	O
107	ORR	O
107	compared	O
107	with	O
107	patients	B-arm_description
107	without	B-arm_description
107	isolated	B-arm_description
107	del(13	B-arm_description
107	)	B-arm_description
107	(	O
107	43	O
107	%	O
107	vs	O
107	71	O
107	%	O
107	,	O
107	respectively	O
107	;	O
107	P	O
107	¼	O
107	0.01	O
107	)	O
107	(	O
107	Table	O
107	2	O
107	)	O
107	.	O
107	In	O
107	contrast	O
107	,	O
107	the	O
107	median	B-arm_efficacy_metric
107	PFS	B-arm_efficacy_metric
107	and	O
107	OS	O
107	were	O
107	not	O
107	(	O
107	or	O
107	marginally	O
107	)	O
107	shorter	O
107	in	O
107	patients	O
107	with	O
107	isolated	O
107	del(13	O
107	)	O
107	(	O
107	PFS	O
107	was	O
107	8	O
107	months	O
107	vs	O
107	10.4	B-arm_efficacy_results
107	months	B-arm_efficacy_results
107	,	B-arm_efficacy_results
107	P	B-arm_efficacy_results
107	¼	B-arm_efficacy_results
107	0.05	B-arm_efficacy_results
107	;	O
107	OS	O
107	was	O
107	10.8	O
107	months	O
107	vs	O
107	15.1	O
107	months	O
107	,	O
107	P	O
107	¼	O
107	0.56	O
107	)	O
107	.	O
107	The	O
107	number	O
107	of	O
107	patients	O
107	with	O
107	del(17p	O
107	)	O
107	was	O
107	too	O
107	low	O
107	for	O
107	meaningful	O
107	interpretation	O
107	.	O
--------------------------------------------------------------
108	Impact	O
108	of	O
108	prior	O
108	treatment	O
108	.	O
108	Patients	B-arm_description
108	who	I-arm_description
108	had	I-arm_description
108	received	I-arm_description
108	prior	I-arm_description
108	treatment	I-arm_description
108	with	I-arm_description
108	bortezomib	I-arm_description
108	had	O
108	significantly	O
108	lower	O
108	ORR	O
108	(	O
108	55.4	O
108	%	O
108	vs	O
108	74.3	O
108	%	O
108	;	O
108	P	O
108	¼	O
108	0.04	O
108	)	O
108	,	O
108	shorter	O
108	median	B-arm_efficacy_metric
108	PFS	B-arm_efficacy_metric
108	(	O
108	8.3	B-arm_efficacy_results
108	months	B-arm_efficacy_results
108	vs	O
108	not	O
108	reached	O
108	;	O
108	P	B-arm_efficacy_results
108	¼	I-arm_efficacy_results
108	0.0003	I-arm_efficacy_results
108	)	O
108	and	O
108	significantly	O
108	shorter	O
108	median	O
108	OS	O
108	(	O
108	12.2	O
108	months	O
108	vs	O
108	not	O
108	reached	O
108	;	O
108	Po0.002	O
108	)	O
108	compared	O
108	with	O
108	patients	O
108	who	O
108	did	O
108	not	O
108	receive	O
108	prior	O
108	bortezomib	O
108	.	O
108	In	O
108	contrast	O
108	,	O
108	patients	O
108	who	O
108	received	O
108	prior	O
108	thalidomide	O
108	therapy	O
108	had	O
108	comparable	O
108	ORR	O
108	(	O
108	57.0	O
108	%	O
108	vs	O
108	69.2	O
108	%	O
108	;	O
108	P	O
108	¼	O
108	0.24	O
108	)	O
108	,	O
108	as	O
108	well	O
108	as	O
108	comparable	O
108	median	O
108	PFS	O
108	(	O
108	8.5	O
108	months	O
108	vs	O
108	10.6	O
108	months	O
108	;	O
108	P	O
108	¼	O
108	0.10	O
108	)	O
108	and	O
108	median	O
108	OS	O
108	,	O
108	and	O
108	del(17p	O
108	)	O
108	,	O
108	32	O
108	had	O
108	del(13	O
108	)	O
108	without	O
108	t	O
108	(	O
108	4;14	O
108	)	O
108	or	O
108	del(17p	O
108	)	O
108	.	O
--------------------------------------------------------------
109	Impact	O
109	of	O
109	prior	O
109	treatment	O
109	.	O
109	Patients	O
109	who	O
109	had	O
109	received	O
109	prior	O
109	treatment	O
109	with	O
109	bortezomib	O
109	had	O
109	significantly	O
109	lower	O
109	ORR	O
109	(	O
109	55.4	O
109	%	O
109	vs	O
109	74.3	O
109	%	O
109	;	O
109	P	O
109	¼	O
109	0.04	O
109	)	O
109	,	O
109	shorter	O
109	median	B-arm_efficacy_metric
109	PFS	I-arm_efficacy_metric
109	(	O
109	8.3	O
109	months	O
109	vs	O
109	not	B-arm_efficacy_results
109	reached	I-arm_efficacy_results
109	;	I-arm_efficacy_results
109	P	I-arm_efficacy_results
109	¼	I-arm_efficacy_results
109	0.0003	I-arm_efficacy_results
109	)	O
109	and	O
109	significantly	O
109	shorter	O
109	median	O
109	OS	O
109	(	O
109	12.2	O
109	months	O
109	vs	O
109	not	O
109	reached	O
109	;	O
109	Po0.002	O
109	)	O
109	compared	O
109	with	O
109	patients	B-arm_description
109	who	I-arm_description
109	did	I-arm_description
109	not	I-arm_description
109	receive	I-arm_description
109	prior	I-arm_description
109	bortezomib	I-arm_description
109	.	O
109	In	O
109	contrast	O
109	,	O
109	patients	O
109	who	O
109	received	O
109	prior	O
109	thalidomide	O
109	therapy	O
109	had	O
109	comparable	O
109	ORR	O
109	(	O
109	57.0	O
109	%	O
109	vs	O
109	69.2	O
109	%	O
109	;	O
109	P	O
109	¼	O
109	0.24	O
109	)	O
109	,	O
109	as	O
109	well	O
109	as	O
109	comparable	O
109	median	O
109	PFS	O
109	(	O
109	8.5	O
109	months	O
109	vs	O
109	10.6	O
109	months	O
109	;	O
109	P	O
109	¼	O
109	0.10	O
109	)	O
109	and	O
109	median	O
109	OS	O
109	,	O
109	and	O
109	del(17p	O
109	)	O
109	,	O
109	32	O
109	had	O
109	del(13	O
109	)	O
109	without	O
109	t	O
109	(	O
109	4;14	O
109	)	O
109	or	O
109	del(17p	O
109	)	O
109	.	O
--------------------------------------------------------------
110	Impact	O
110	of	O
110	prior	O
110	treatment	O
110	.	O
110	Patients	O
110	who	O
110	had	O
110	received	O
110	prior	O
110	treatment	O
110	with	O
110	bortezomib	O
110	had	O
110	significantly	O
110	lower	O
110	ORR	O
110	(	O
110	55.4	O
110	%	O
110	vs	O
110	74.3	O
110	%	O
110	;	O
110	P	O
110	¼	O
110	0.04	O
110	)	O
110	,	O
110	shorter	O
110	median	O
110	PFS	O
110	(	O
110	8.3	O
110	months	O
110	vs	O
110	not	O
110	reached	O
110	;	O
110	P	O
110	¼	O
110	0.0003	O
110	)	O
110	and	O
110	significantly	O
110	shorter	O
110	median	O
110	OS	O
110	(	O
110	12.2	O
110	months	O
110	vs	O
110	not	O
110	reached	O
110	;	O
110	Po0.002	O
110	)	O
110	compared	O
110	with	O
110	patients	O
110	who	O
110	did	O
110	not	O
110	receive	O
110	prior	O
110	bortezomib	O
110	.	O
110	In	O
110	contrast	O
110	,	O
110	patients	B-arm_description
110	who	I-arm_description
110	received	I-arm_description
110	prior	I-arm_description
110	thalidomide	I-arm_description
110	therapy	O
110	had	O
110	comparable	O
110	ORR	O
110	(	O
110	57.0	O
110	%	O
110	vs	O
110	69.2	O
110	%	O
110	;	O
110	P	O
110	¼	O
110	0.24	O
110	)	O
110	,	O
110	as	O
110	well	O
110	as	O
110	comparable	O
110	median	B-arm_efficacy_metric
110	PFS	I-arm_efficacy_metric
110	(	O
110	8.5	B-arm_efficacy_results
110	months	B-arm_efficacy_results
110	vs	O
110	10.6	O
110	months	O
110	;	B-arm_efficacy_results
110	P	B-arm_efficacy_results
110	¼	B-arm_efficacy_results
110	0.10	I-arm_efficacy_results
110	)	O
110	and	O
110	median	O
110	OS	O
110	,	O
110	and	O
110	del(17p	O
110	)	O
110	,	O
110	32	O
110	had	O
110	del(13	O
110	)	O
110	without	O
110	t	O
110	(	O
110	4;14	O
110	)	O
110	or	O
110	del(17p	O
110	)	O
110	.	O
--------------------------------------------------------------
111	Impact	O
111	of	O
111	prior	O
111	treatment	O
111	.	O
111	Patients	O
111	who	O
111	had	O
111	received	O
111	prior	O
111	treatment	O
111	with	O
111	bortezomib	O
111	had	O
111	significantly	O
111	lower	O
111	ORR	O
111	(	O
111	55.4	O
111	%	O
111	vs	O
111	74.3	O
111	%	O
111	;	O
111	P	O
111	¼	O
111	0.04	O
111	)	O
111	,	O
111	shorter	O
111	median	O
111	PFS	O
111	(	O
111	8.3	O
111	months	O
111	vs	O
111	not	O
111	reached	O
111	;	O
111	P	O
111	¼	O
111	0.0003	O
111	)	O
111	and	O
111	significantly	O
111	shorter	O
111	median	O
111	OS	O
111	(	O
111	12.2	O
111	months	O
111	vs	O
111	not	O
111	reached	O
111	;	O
111	Po0.002	O
111	)	O
111	compared	O
111	with	O
111	patients	O
111	who	O
111	did	O
111	not	O
111	receive	O
111	prior	O
111	bortezomib	O
111	.	O
111	In	O
111	contrast	O
111	,	O
111	patients	O
111	who	O
111	received	O
111	prior	O
111	thalidomide	O
111	therapy	O
111	had	O
111	comparable	O
111	ORR	O
111	(	O
111	57.0	O
111	%	O
111	vs	O
111	69.2	O
111	%	O
111	;	O
111	P	O
111	¼	O
111	0.24	O
111	)	O
111	,	O
111	as	O
111	well	O
111	as	O
111	comparable	O
111	median	B-arm_efficacy_metric
111	PFS	B-arm_efficacy_metric
111	(	O
111	8.5	O
111	months	O
111	vs	O
111	10.6	B-arm_efficacy_results
111	months	B-arm_efficacy_results
111	;	B-arm_efficacy_results
111	P	B-arm_efficacy_results
111	¼	B-arm_efficacy_results
111	0.10	B-arm_efficacy_results
111	)	B-arm_efficacy_results
111	and	O
111	median	O
111	OS	O
111	,	O
111	and	O
111	del(17p	O
111	)	O
111	,	O
111	32	O
111	had	O
111	del(13	O
111	)	O
111	without	O
111	t	O
111	(	O
111	4;14	O
111	)	O
111	or	O
111	del(17p	O
111	)	O
111	.	O
--------------------------------------------------------------
112	(	O
112	9.4	O
112	months	O
112	vs	O
112	not	O
112	yet	O
112	reached	O
112	,	O
112	P	O
112	¼	O
112	0.43	O
112	)	O
112	compared	O
112	with	O
112	those	O
112	who	O
112	were	O
112	not	O
112	earlier	O
112	treated	O
112	with	O
112	thalidomide	O
112	.	O
112	Patients	B-arm_description
112	who	I-arm_description
112	progressed	I-arm_description
112	during	I-arm_description
112	thalidomide	I-arm_description
112	therapy	I-arm_description
112	had	O
112	a	O
112	significantly	O
112	shorter	O
112	PFS	B-arm_efficacy_metric
112	(	O
112	5.7	B-arm_efficacy_results
112	months	B-arm_efficacy_results
112	vs	O
112	15.7	O
112	months	O
112	;	B-arm_efficacy_results
112	Po0.0001	B-arm_efficacy_results
112	)	O
112	and	O
112	OS	O
112	(	O
112	9.7	O
112	months	O
112	vs	O
112	16.1	O
112	months	O
112	;	O
112	P	O
112	¼	O
112	0.0007	O
112	)	O
112	compared	O
112	with	O
112	those	O
112	who	O
112	did	O
112	not	O
112	progress	O
112	during	O
112	thalidomide	O
112	therapy	O
112	(	O
112	Figures	O
112	2a	O
112	and	O
112	b	O
112	)	O
112	.	O
112	Patients	O
112	who	O
112	were	O
112	thalidomide	O
112	resistant	O
112	had	O
112	received	O
112	an	O
112	additional	O
112	line	O
112	of	O
112	therapy	O
112	(	O
112	median	O
112	,	O
112	4	O
112	vs	O
112	3	O
112	)	O
112	and	O
112	a	O
112	higher	O
112	proportion	O
112	had	O
112	t(4;14	O
112	)	O
112	(	O
112	16	O
112	%	O
112	vs	O
112	9	O
112	%	O
112	)	O
112	compared	O
112	with	O
112	patients	O
112	who	O
112	were	O
112	not	O
112	thalidomide	O
112	resistant	O
112	.	O
--------------------------------------------------------------
113	(	O
113	9.4	O
113	months	O
113	vs	O
113	not	O
113	yet	O
113	reached	O
113	,	O
113	P	O
113	¼	O
113	0.43	O
113	)	O
113	compared	O
113	with	O
113	those	O
113	who	O
113	were	O
113	not	O
113	earlier	O
113	treated	O
113	with	O
113	thalidomide	O
113	.	O
113	Patients	O
113	who	O
113	progressed	O
113	during	O
113	thalidomide	O
113	therapy	O
113	had	O
113	a	O
113	significantly	O
113	shorter	O
113	PFS	B-arm_efficacy_metric
113	(	O
113	5.7	O
113	months	O
113	vs	O
113	15.7	B-arm_efficacy_results
113	months	B-arm_efficacy_results
113	;	B-arm_efficacy_results
113	Po0.0001	B-arm_efficacy_results
113	)	O
113	and	O
113	OS	O
113	(	O
113	9.7	O
113	months	O
113	vs	O
113	16.1	O
113	months	O
113	;	O
113	P	O
113	¼	O
113	0.0007	O
113	)	O
113	compared	O
113	with	O
113	those	B-arm_description
113	who	I-arm_description
113	did	I-arm_description
113	not	I-arm_description
113	progress	I-arm_description
113	during	I-arm_description
113	thalidomide	I-arm_description
113	therapy	I-arm_description
113	(	O
113	Figures	O
113	2a	O
113	and	O
113	b	O
113	)	O
113	.	O
113	Patients	O
113	who	O
113	were	O
113	thalidomide	O
113	resistant	O
113	had	O
113	received	O
113	an	O
113	additional	O
113	line	O
113	of	O
113	therapy	O
113	(	O
113	median	O
113	,	O
113	4	O
113	vs	O
113	3	O
113	)	O
113	and	O
113	a	O
113	higher	O
113	proportion	O
113	had	O
113	t(4;14	O
113	)	O
113	(	O
113	16	O
113	%	O
113	vs	O
113	9	O
113	%	O
113	)	O
113	compared	O
113	with	O
113	patients	O
113	who	O
113	were	O
113	not	O
113	thalidomide	O
113	resistant	O
113	.	O
--------------------------------------------------------------
114	Additional	O
114	analyses	O
114	were	O
114	conducted	O
114	to	O
114	determine	O
114	the	O
114	combined	O
114	impact	O
114	of	O
114	progression	O
114	on	O
114	thalidomide	O
114	and	O
114	either	O
114	del	O
114	(	O
114	13	O
114	)	O
114	or	O
114	prior	O
114	bortezomib	O
114	use	O
114	on	O
114	OS	O
114	.	O
114	For	O
114	patients	O
114	who	O
114	did	O
114	not	O
114	progress	O
114	on	O
114	thalidomide	O
114	,	O
114	the	O
114	median	O
114	OS	O
114	was	O
114	10.4	O
114	months	O
114	for	O
114	patients	O
114	with	O
114	del	O
114	(	O
114	13	O
114	)	O
114	and	O
114	not	O
114	reached	O
114	for	O
114	patients	O
114	without	O
114	del(13	O
114	)	O
114	.	O
114	However	O
114	,	O
114	for	O
114	patients	O
114	who	O
114	progressed	O
114	on	O
114	thalidomide	O
114	,	O
114	there	O
114	was	O
114	no	O
114	difference	O
114	in	O
114	OS	O
114	between	O
114	patients	O
114	with	O
114	or	O
114	without	O
114	del(13	O
114	)	O
114	(	O
114	median	O
114	9.5	O
114	months	O
114	vs	O
114	9.7	O
114	months	O
114	,	O
114	respectively	O
114	)	O
114	.	O
114	For	O
114	patients	O
114	who	O
114	progressed	O
114	on	O
114	thalidomide	O
114	,	O
114	the	O
114	median	O
114	OS	O
114	was	O
114	11.6	O
114	months	O
114	if	O
114	they	O
114	had	O
114	prior	O
114	bortezomib	O
114	and	O
114	not	O
114	reached	O
114	if	O
114	they	O
114	had	O
114	no	O
114	prior	O
114	bortezomib	O
114	.	O
114	However	O
114	,	O
114	for	O
114	patients	O
114	with	O
114	no	O
114	prior	O
114	bortezomib	O
114	use	O
114	,	O
114	there	O
114	was	O
114	no	O
114	difference	O
114	in	O
114	OS	O
114	between	O
114	patients	O
114	with	O
114	or	O
114	without	O
114	progression	O
114	on	O
114	thalidomide	O
114	(	O
114	median	O
114	not	O
114	reached	O
114	for	O
114	both	O
114	)	O
114	.	O
--------------------------------------------------------------
115	Multivariate	O
115	analysis	O
115	on	O
115	ORR	O
115	identified	O
115	lower	O
115	hemoglobin	O
115	level	O
115	o10	O
115	g	O
115	100	O
115	ml	O
115	(	O
115	hazard	O
115	ratio	O
115	(	O
115	HR	O
115	)	O
115	:	O
115	1.230	O
115	;	O
115	95	O
115	%	O
115	confidence	O
115	interval	O
115	(	O
115	CI	O
115	)	O
115	:	O
115	1.000	O
115	-	O
115	1.511	O
115	;	O
115	P	O
115	¼	O
115	0.05	O
115	)	O
115	,	O
115	increased	O
115	number	O
115	of	O
115	prior	O
115	therapies	O
115	(	O
115	HR	O
115	:	O
115	0.745	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	0.573	O
115	-	O
115	0.967	O
115	;	O
115	P	O
115	¼	O
115	0.03	O
115	)	O
115	,	O
115	and	O
115	del(13	O
115	)	O
115	(	O
115	HR	O
115	:	O
115	3.431	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	1.531	O
115	-	O
115	7.689	O
115	;	O
115	P	O
115	¼	O
115	0.003	O
115	)	O
115	as	O
115	independent	O
115	predictors	O
115	of	O
115	lower	O
115	ORR	O
115	(	O
115	Table	O
115	3	O
115	)	O
115	.	O
115	Sex	O
115	and	O
115	t(4;14	O
115	)	O
115	met	O
115	the	O
115	criteria	O
115	to	O
115	stay	O
115	in	O
115	the	O
115	model	O
115	though	O
115	they	O
115	were	O
115	not	O
115	statistically	O
115	significant	O
115	.	O
115	Age	O
115	,	O
115	sex	O
115	,	O
115	prior	O
115	transplant	O
115	,	O
115	prior	O
115	bortezomib	O
115	use	O
115	,	O
115	prior	O
115	thalidomide	O
115	use	O
115	,	O
115	and	O
115	progression	O
115	during	O
115	thalidomide	O
115	did	O
115	not	O
115	affect	O
115	ORR	O
115	(	O
115	Table	O
115	3	O
115	)	O
115	.	O
115	Multivariate	O
115	analysis	O
115	on	O
115	PFS	O
115	identified	O
115	progression	O
115	during	O
115	thalidomide	O
115	(	O
115	HR	O
115	:	O
115	2.72	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	1.66	O
115	-	O
115	4.46	O
115	;	O
115	Po0.0001	O
115	)	O
115	,	O
115	del(13	O
115	)	O
115	(	O
115	HR	O
115	:	O
115	2.35	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	1.44	O
115	-	O
115	3.83	O
115	;	O
115	Po0.001	O
115	)	O
115	,	O
115	and	O
115	lower	O
115	hemoglobin	O
115	level	O
115	o10	O
115	g	O
115	per	O
115	100	O
115	ml	O
115	(	O
115	HR	O
115	:	O
115	0.81	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	0.71	O
115	-	O
115	0.93	O
115	;	O
115	P	O
115	¼	O
115	0.002	O
115	)	O
115	as	O
115	independent	O
115	predictors	O
115	of	O
115	reduced	O
115	PFS	O
115	(	O
115	Table	O
115	4	O
115	)	O
115	.	O
115	There	O
115	was	O
115	a	O
115	trend	O
115	toward	O
115	reduced	O
115	PFS	O
115	with	O
115	prior	O
115	bortezomib	O
115	use	O
115	(	O
115	HR	O
115	:	O
115	2.37	O
115	;	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	0.91	O
115	-	O
115	6.16	O
115	;	O
115	P	O
115	¼	O
115	0.076	O
115	)	O
115	and	O
115	increased	O
115	number	O
115	of	O
115	prior	O
115	therapies	O
115	(	O
115	HR	O
115	:	O
115	1.17	O
115	.	O
115	95	O
115	%	O
115	CI	O
115	:	O
115	0.99	O
115	-	O
115	1.37	O
115	;	O
115	P	O
115	¼	O
115	0.062	O
115	)	O
115	(	O
115	Table	O
115	4	O
115	)	O
115	.	O
115	Age	O
115	,	O
115	sex	O
115	,	O
115	prior	O
115	transplant	O
115	,	O
115	prior	O
115	thalidomide	O
115	use	O
115	,	O
115	and	O
115	t(4;14	O
115	)	O
115	translocation	O
115	were	O
115	not	O
115	predictive	O
115	of	O
115	PFS	O
115	(	O
115	Table	O
115	4	O
115	)	O
115	.	O
--------------------------------------------------------------
116	Multivariate	O
116	analysis	O
116	on	O
116	OS	O
116	identified	O
116	progression	O
116	on	O
116	thalidomide	O
116	(	O
116	HR	O
116	:	O
116	1.810	O
116	;	O
116	95	O
116	%	O
116	CI	O
116	:	O
116	1.081	O
116	-	O
116	3.030	O
116	;	O
116	Po0.02	O
116	)	O
116	as	O
116	the	O
116	only	O
116	significant	O
116	independent	O
116	predictor	O
116	of	O
116	reduced	O
116	OS	O
116	(	O
116	Table	O
116	5	O
116	)	O
116	.	O
116	There	O
116	was	O
116	a	O
116	trend	O
116	toward	O
116	reduced	O
116	OS	O
116	with	O
116	prior	O
116	bortezomib	O
116	use	O
116	(	O
116	HR	O
116	:	O
116	2.611	O
116	;	O
116	95	O
116	%	O
116	CI	O
116	:	O
116	0.927	O
116	-	O
116	7.360	O
116	;	O
116	P	O
116	¼	O
116	0.07	O
116	)	O
116	(	O
116	Table	O
116	5	O
116	)	O
116	.	O
116	Del(13	O
116	)	O
116	and	O
116	t(4;14	O
116	)	O
116	met	O
116	the	O
116	criteria	O
116	to	O
116	stay	O
116	in	O
116	the	O
116	model	O
116	though	O
116	they	O
116	were	O
116	not	O
116	statistically	O
116	significant	O
116	.	O
116	Age	O
116	,	O
116	sex	O
116	,	O
116	number	O
116	of	O
116	lines	O
116	of	O
116	prior	O
116	therapy	O
116	,	O
116	prior	O
116	transplant	O
116	,	O
116	prior	O
116	thalidomide	O
116	treatment	O
116	,	O
116	and	O
116	hemoglobin	O
116	level	O
116	did	O
116	not	O
116	affect	O
116	OS	O
116	(	O
116	Table	O
116	5	O
116	)	O
116	.	O
--------------------------------------------------------------
117	Randomized	B-study_type
117	Phase	B-study_type
117	II	B-study_type
117	Trial	B-study_type
117	of	O
117	Thalidomide	B-arm_description
117	Alone	B-arm_description
117	versus	O
117	Thalidomide	O
117	Plus	O
117	Interferon	O
117	Alpha	O
117	in	O
117	Patients	O
117	with	O
117	Refractory	O
117	Multiple	O
117	Myeloma	O
117	Randomized	O
117	Phase	O
117	II	O
117	Trial	O
117	of	O
117	Thalidomide	O
117	Alone	O
117	versus	O
117	Thalidomide	O
117	Plus	O
117	Interferon	O
117	Alpha	O
117	in	O
117	Patients	O
117	with	O
117	Refractory	O
117	Multiple	O
117	Myeloma	O
117	M.D.Tzeon	O
117	-	O
117	JyeChiou	B-authors
--------------------------------------------------------------
118	Randomized	O
118	Phase	O
118	II	O
118	Trial	O
118	of	O
118	Thalidomide	O
118	Alone	O
118	versus	O
118	Thalidomide	B-arm_description
118	Plus	B-arm_description
118	Interferon	B-arm_description
118	Alpha	B-arm_description
118	in	O
118	Patients	O
118	with	O
118	Refractory	O
118	Multiple	O
118	Myeloma	O
118	Randomized	O
118	Phase	O
118	II	O
118	Trial	O
118	of	O
118	Thalidomide	O
118	Alone	O
118	versus	O
118	Thalidomide	O
118	Plus	O
118	Interferon	O
118	Alpha	O
118	in	O
118	Patients	O
118	with	O
118	Refractory	O
118	Multiple	O
118	Myeloma	O
118	M.D.Tzeon	O
118	-	O
118	JyeChiou	O
--------------------------------------------------------------
119	National	O
119	Cheng	O
119	Kung	O
119	University	O
119	Hospital	O
119	Tainan	O
119	Taiwan	O
119	M.DTsai	B-authors
119	-	O
119	YunChen	B-authors
119	Mackay	O
119	Memorial	O
119	Hospital	O
119	Taipei	O
119	Taiwan	O
119	M.DMing	B-authors
119	-	B-authors
119	ChihChang	B-authors
119	Pingtung	O
119	Christian	O
119	Hospital	O
119	Pingtung	O
119	Taiwan	O
119	M.DErh	B-authors
119	-	B-authors
119	JungHsueh	B-authors
--------------------------------------------------------------
120	Randomized	B-study_type
120	Phase	B-study_type
120	II	B-study_type
120	Trial	B-study_type
120	of	O
120	Thalidomide	B-arm_description
120	Alone	B-arm_description
120	versus	O
120	Thalidomide	O
120	Plus	O
120	Interferon	O
120	Alpha	O
120	in	O
120	Patients	O
120	with	O
120	Refractory	O
120	Multiple	O
120	Myeloma	O
120	M.D.Tzeon	B-authors
120	-	B-authors
120	JyeChiou	B-authors
120	tjchiou@vghtpe.gov.tw	O
120	National	O
120	Taiwan	O
120	University	O
120	Taipei	O
--------------------------------------------------------------
121	Randomized	O
121	Phase	O
121	II	O
121	Trial	O
121	of	O
121	Thalidomide	O
121	Alone	O
121	versus	O
121	Thalidomide	B-arm_description
121	Plus	B-arm_description
121	Interferon	B-arm_description
121	Alpha	B-arm_description
121	in	O
121	Patients	O
121	with	O
121	Refractory	O
121	Multiple	O
121	Myeloma	O
121	M.D.Tzeon	O
121	-	O
121	JyeChiou	O
121	tjchiou@vghtpe.gov.tw	O
121	National	O
121	Taiwan	O
121	University	O
121	Taipei	O
--------------------------------------------------------------
122	Taiwan	O
122	Section	O
122	of	O
122	Medical	O
122	Oncology	O
122	Department	O
122	of	O
122	Medicine	O
122	Taipei	O
122	Veterans	O
122	General	O
122	Hospital	O
122	No	O
122	.	O
122	201	O
122	Sec	O
122	.	O
122	2	O
122	,	O
122	Shih	O
122	-	O
122	Pai	O
122	Road	O
122	112	O
122	Taipei	O
--------------------------------------------------------------
123	Taiwan	O
123	Taipei	O
123	Taiwan	O
123	Randomized	B-study_type
123	Phase	B-study_type
123	II	B-study_type
123	Trial	B-study_type
123	of	O
123	Thalidomide	B-arm_description
123	Alone	B-arm_description
123	versus	O
123	Thalidomide	O
123	Plus	O
123	Interferon	O
123	Alpha	O
123	in	O
123	Patients	O
123	with	O
123	Refractory	O
123	Multiple	O
123	Myeloma	O
123	0735	O
123	-	O
123	7907	O
123	print	O
123	/	O
123	1532	O
123	-	O
123	4192	O
123	0735	O
123	-	O
123	7907	O
123	print	O
123	/	O
123	1532	O
123	-	O
123	4192	O
123	10.1080/07357900701208808	O
--------------------------------------------------------------
124	Taiwan	O
124	Taipei	O
124	Taiwan	O
124	Randomized	O
124	Phase	O
124	II	O
124	Trial	O
124	of	O
124	Thalidomide	O
124	Alone	O
124	versus	O
124	Thalidomide	B-arm_description
124	Plus	B-arm_description
124	Interferon	B-arm_description
124	Alpha	B-arm_description
124	in	O
124	Patients	O
124	with	O
124	Refractory	O
124	Multiple	O
124	Myeloma	O
124	0735	O
124	-	O
124	7907	O
124	print	O
124	/	O
124	1532	O
124	-	O
124	4192	O
124	0735	O
124	-	O
124	7907	O
124	print	O
124	/	O
124	1532	O
124	-	O
124	4192	O
124	10.1080/07357900701208808	O
--------------------------------------------------------------
125	Multiple	O
125	myeloma	O
125	(	O
125	MM	O
125	)	O
125	is	O
125	a	O
125	malignant	O
125	disease	O
125	of	O
125	the	O
125	plasma	O
125	cells	O
125	.	O
125	As	O
125	the	O
125	disease	O
125	progressing	O
125	,	O
125	it	O
125	will	O
125	destroy	O
125	normal	O
125	bone	O
125	tissue	O
125	,	O
125	causing	O
125	pain	O
125	and	O
125	crowding	O
125	normal	O
125	hematopoiesis	O
125	out	O
125	(	O
125	1)(2)(3)(4)(5	O
125	)	O
125	.	O
125	The	O
125	low	O
125	incidence	O
125	of	O
125	complete	O
125	remission	O
125	,	O
125	on	O
125	the	O
125	order	O
125	of	O
125	5	O
125	percent	O
125	,	O
125	reflects	O
125	the	O
125	marked	O
125	drug	O
125	resistance	O
125	of	O
125	myeloma	O
125	cells	O
125	.	O
125	Therapeutic	O
125	intervention	O
125	with	O
125	cytokines	O
125	is	O
125	being	O
125	evaluated	O
125	in	O
125	the	O
125	management	O
125	of	O
125	a	O
125	range	O
125	of	O
125	malignancies	O
125	.	O
125	Interferons	O
125	have	O
125	a	O
125	broad	O
125	spectrum	O
125	of	O
125	action	O
125	on	O
125	cellular	O
125	proliferation	O
125	as	O
125	well	O
125	as	O
125	immunomodulation	O
125	.	O
125	In	O
125	patients	O
125	with	O
125	myeloma	O
125	,	O
125	interferon	O
125	alpha	O
125	in	O
125	combination	O
125	with	O
125	chemotherapy	O
125	has	O
125	been	O
125	demonstrated	O
125	to	O
125	have	O
125	synergistic	O
125	anti	O
125	-	O
125	tumor	O
125	effect	O
125	(	O
125	1)(2)(3)(4)(5	O
125	)	O
125	.	O
125	Response	O
125	rates	O
125	of	O
125	20	O
125	percent	O
125	were	O
125	achieved	O
125	when	O
125	interferon	O
125	alpha	O
125	(	O
125	IFN	O
125	-	O
125	α	O
125	)	O
125	was	O
125	applied	O
125	as	O
125	single	O
125	agent	O
125	for	O
125	multiple	O
125	myeloma	O
125	(	O
125	6	O
125	)	O
125	.	O
125	A	O
125	synergistic	O
125	activity	O
125	was	O
125	observed	O
125	when	O
125	IFN	O
125	-	O
125	α	O
125	was	O
125	combined	O
125	with	O
125	chemotherapeutic	O
125	agents	O
125	in	O
125	vitro	O
125	and	O
125	in	O
125	vivo	O
125	,	O
125	resulted	O
125	in	O
125	higher	O
125	median	O
125	progression	O
125	-	O
125	free	O
125	and	O
125	overall	O
125	survival	O
125	duration	O
125	in	O
125	the	O
125	VAD	O
125	(	O
125	Vincristin	O
125	,	O
125	Adriamycin	O
125	,	O
125	Dexamethasone	O
125	)	O
125	and	O
125	IFN	O
125	-	O
125	α	O
125	combination	O
125	(	O
125	7	O
125	)	O
125	.	O
--------------------------------------------------------------
126	Thalidomide	O
126	(	O
126	TD	O
126	)	O
126	was	O
126	used	O
126	during	O
126	the	O
126	late	O
126	1950s	O
126	and	O
126	withdrawn	O
126	in	O
126	the	O
126	1960s	O
126	after	O
126	the	O
126	appearance	O
126	of	O
126	teratogenicity	O
126	and	O
126	phocomelia	O
126	.	O
126	The	O
126	recent	O
126	return	O
126	of	O
126	thalidomide	O
126	stems	O
126	from	O
126	the	O
126	broad	O
126	spectrum	O
126	of	O
126	its	O
126	potential	O
126	pharmacologic	O
126	and	O
126	immunologic	O
126	effects	O
126	(	O
126	8)(9)(10	O
126	)	O
126	.	O
126	The	O
126	mechanism	O
126	of	O
126	thalidomide	O
126	in	O
126	treating	O
126	multiple	O
126	myeloma	O
126	includes	O
126	the	O
126	possibility	O
126	that	O
126	thalidomide	O
126	suppresses	O
126	tumor	O
126	necrosis	O
126	factor	O
126	-	O
126	α	O
126	production	O
126	,	O
126	increases	O
126	the	O
126	body	O
126	's	O
126	production	O
126	of	O
126	interluekin-10	O
126	(	O
126	IL-10	O
126	)	O
126	,	O
126	and	O
126	inhibits	O
126	angiogenesis	O
126	by	O
126	preventing	O
126	the	O
126	growth	O
126	of	O
126	new	O
126	blood	O
126	vessels	O
126	to	O
126	support	O
126	the	O
126	malignant	O
126	cells	O
126	(	O
126	10,11	O
126	)	O
126	.	O
126	The	O
126	combination	O
126	of	O
126	IFN	O
126	-	O
126	alpha2b	O
126	and	O
126	thalidomide	O
126	had	O
126	been	O
126	reported	O
126	to	O
126	cause	O
126	synergistic	O
126	decrease	O
126	in	O
126	mean	O
126	vessel	O
126	count	O
126	in	O
126	tumors	O
126	that	O
126	were	O
126	resistant	O
126	to	O
126	the	O
126	antiproliferative	O
126	effects	O
126	of	O
126	IFN	O
126	-	O
126	alpha2b	O
126	and	O
126	thalidomide	O
126	in	O
126	vitro	O
126	and	O
126	have	O
126	potentiated	O
126	antiangiogenic	O
126	activity	O
126	in	O
126	a	O
126	xenograft	O
126	model	O
126	(	O
126	12	O
126	)	O
126	.	O
126	Whether	O
126	the	O
126	combination	O
126	of	O
126	IFN	O
126	-	O
126	α	O
126	with	O
126	thalidomide	O
126	in	O
126	patients	O
126	who	O
126	did	O
126	not	O
126	receive	O
126	IFN	O
126	-	O
126	α	O
126	or	O
126	thalidomide	O
126	to	O
126	treat	O
126	their	O
126	disease	O
126	before	O
126	can	O
126	improve	O
126	the	O
126	response	O
126	rate	O
126	,	O
126	duration	O
126	,	O
126	and	O
126	survival	O
126	were	O
126	interesting	O
126	to	O
126	us	O
126	.	O
126	In	O
126	this	O
126	study	O
126	,	O
126	we	O
126	will	O
126	evaluate	O
126	and	O
126	compare	O
126	the	O
126	efficacy	O
126	and	O
126	toxicity	O
126	of	O
126	thalidomide	B-arm_description
126	alone	B-arm_description
126	or	O
126	combined	O
126	with	O
126	IFN	O
126	-	O
126	α	O
126	in	O
126	refractory	O
126	MM	O
126	patients	O
126	.	O
--------------------------------------------------------------
127	Thalidomide	O
127	(	O
127	TD	O
127	)	O
127	was	O
127	used	O
127	during	O
127	the	O
127	late	O
127	1950s	O
127	and	O
127	withdrawn	O
127	in	O
127	the	O
127	1960s	O
127	after	O
127	the	O
127	appearance	O
127	of	O
127	teratogenicity	O
127	and	O
127	phocomelia	O
127	.	O
127	The	O
127	recent	O
127	return	O
127	of	O
127	thalidomide	O
127	stems	O
127	from	O
127	the	O
127	broad	O
127	spectrum	O
127	of	O
127	its	O
127	potential	O
127	pharmacologic	O
127	and	O
127	immunologic	O
127	effects	O
127	(	O
127	8)(9)(10	O
127	)	O
127	.	O
127	The	O
127	mechanism	O
127	of	O
127	thalidomide	O
127	in	O
127	treating	O
127	multiple	O
127	myeloma	O
127	includes	O
127	the	O
127	possibility	O
127	that	O
127	thalidomide	O
127	suppresses	O
127	tumor	O
127	necrosis	O
127	factor	O
127	-	O
127	α	O
127	production	O
127	,	O
127	increases	O
127	the	O
127	body	O
127	's	O
127	production	O
127	of	O
127	interluekin-10	O
127	(	O
127	IL-10	O
127	)	O
127	,	O
127	and	O
127	inhibits	O
127	angiogenesis	O
127	by	O
127	preventing	O
127	the	O
127	growth	O
127	of	O
127	new	O
127	blood	O
127	vessels	O
127	to	O
127	support	O
127	the	O
127	malignant	O
127	cells	O
127	(	O
127	10,11	O
127	)	O
127	.	O
127	The	O
127	combination	O
127	of	O
127	IFN	O
127	-	O
127	alpha2b	O
127	and	O
127	thalidomide	O
127	had	O
127	been	O
127	reported	O
127	to	O
127	cause	O
127	synergistic	O
127	decrease	O
127	in	O
127	mean	O
127	vessel	O
127	count	O
127	in	O
127	tumors	O
127	that	O
127	were	O
127	resistant	O
127	to	O
127	the	O
127	antiproliferative	O
127	effects	O
127	of	O
127	IFN	O
127	-	O
127	alpha2b	O
127	and	O
127	thalidomide	O
127	in	O
127	vitro	O
127	and	O
127	have	O
127	potentiated	O
127	antiangiogenic	O
127	activity	O
127	in	O
127	a	O
127	xenograft	O
127	model	O
127	(	O
127	12	O
127	)	O
127	.	O
127	Whether	O
127	the	O
127	combination	O
127	of	O
127	IFN	O
127	-	O
127	α	O
127	with	O
127	thalidomide	O
127	in	O
127	patients	O
127	who	O
127	did	O
127	not	O
127	receive	O
127	IFN	O
127	-	O
127	α	O
127	or	O
127	thalidomide	O
127	to	O
127	treat	O
127	their	O
127	disease	O
127	before	O
127	can	O
127	improve	O
127	the	O
127	response	O
127	rate	O
127	,	O
127	duration	O
127	,	O
127	and	O
127	survival	O
127	were	O
127	interesting	O
127	to	O
127	us	O
127	.	O
127	In	O
127	this	O
127	study	O
127	,	O
127	we	O
127	will	O
127	evaluate	O
127	and	O
127	compare	O
127	the	O
127	efficacy	O
127	and	O
127	toxicity	O
127	of	O
127	thalidomide	B-arm_description
127	alone	O
127	or	O
127	combined	B-arm_description
127	with	B-arm_description
127	IFN	B-arm_description
127	-	B-arm_description
127	α	B-arm_description
127	in	O
127	refractory	O
127	MM	O
127	patients	O
127	.	O
--------------------------------------------------------------
128	Patients	O
128	who	O
128	fulfill	O
128	the	O
128	following	O
128	criteria	O
128	were	O
128	enrolled	O
128	in	O
128	the	O
128	study	O
128	:	O
128	age	O
128	less	O
128	than	O
128	75-year	O
128	-	O
128	old	O
128	with	O
128	well	O
128	-	O
128	documented	O
128	multiple	O
128	myeloma	O
128	(	O
128	Durie	O
128	-	O
128	Salmon	O
128	staging	O
128	,	O
128	1976	O
128	)	O
128	that	O
128	relapsed	O
128	or	O
128	failed	O
128	to	O
128	first	O
128	-	O
128	line	O
128	chemotherapy	O
128	and	O
128	had	O
128	measurable	O
128	M	O
128	protein	O
128	and	O
128	paraprotein	O
128	serum	O
128	levels	O
128	;	O
128	no	O
128	history	O
128	of	O
128	exposure	O
128	to	O
128	IFN	O
128	-	O
128	α	O
128	or	O
128	thalidomide	O
128	before	O
128	;	O
128	ECOG	O
128	performance	O
128	status	O
128	≤2	O
128	with	O
128	adequate	O
128	liver	O
128	,	O
128	renal	O
128	function	O
128	,	O
128	and	O
128	hemogram	O
128	level	O
128	(	O
128	ALT	O
128	/	O
128	AST	O
128	≤3	O
128	times	O
128	upper	O
128	limit	O
128	of	O
128	normal	O
128	,	O
128	total	O
128	bilirubin	O
128	≤2	O
128	mg	O
128	percent	O
128	,	O
128	serum	O
128	creatinine	O
128	≤	O
128	2	O
128	times	O
128	normal	O
128	limit	O
128	,	O
128	Hemoglobin	O
128	>	O
128	8	O
128	g	O
128	/	O
128	dL	O
128	,	O
128	WBC	O
128	>	O
128	3000	O
128	/	O
128	mm	O
128	3	O
128	,	O
128	Platelet	O
128	>	O
128	7.5	O
128	×	O
128	10	O
128	4	O
128	/mm	O
128	3	O
128	)	O
128	;	O
128	no	O
128	history	O
128	of	O
128	nerve	O
128	damage	O
128	(	O
128	WHO	O
128	≥2	O
128	)	O
128	,	O
128	orthostatic	O
128	hypotension	O
128	,	O
128	or	O
128	other	O
128	serious	O
128	complications	O
128	;	O
128	at	O
128	least	O
128	3	O
128	weeks	O
128	interval	O
128	from	O
128	prior	O
128	chemotherapy	O
128	or	O
128	radiotherapy	O
128	and	O
128	signing	O
128	the	O
128	consent	O
128	form	O
128	prior	O
128	to	O
128	this	O
128	study	O
128	.	O
--------------------------------------------------------------
129	Based	O
129	on	O
129	previous	O
129	clinic	O
129	experience	O
129	,	O
129	a	O
129	response	O
129	rate	O
129	of	O
129	approximately	O
129	20	O
129	percent	O
129	was	O
129	assumed	O
129	for	O
129	the	O
129	study	O
129	regimen	O
129	with	O
129	thalidomide	O
129	and	O
129	an	O
129	estimated	O
129	response	O
129	rate	O
129	of	O
129	40	O
129	percent	O
129	was	O
129	assumed	O
129	for	O
129	the	O
129	study	O
129	regimen	O
129	with	O
129	thalidomide	O
129	plus	O
129	IFN	O
129	-	O
129	α	O
129	.	O
--------------------------------------------------------------
130	Simon	O
130	's	O
130	2-stage	O
130	optimal	O
130	design	O
130	was	O
130	adapted	O
130	to	O
130	calculate	O
130	the	O
130	sample	O
130	size	O
130	for	O
130	type	O
130	-	O
130	I	O
130	error	O
130	of	O
130	0.05	O
130	and	O
130	power	O
130	of	O
130	80	O
130	percent	O
130	.	O
--------------------------------------------------------------
131	The	O
131	sample	O
131	size	O
131	initially	O
131	was	O
131	determined	O
131	to	O
131	complete	O
131	43	O
131	evaluable	O
131	patients	O
131	for	O
131	the	O
131	regimen	O
131	with	O
131	thalidomide	O
131	plus	O
131	IFNα	O
131	and	O
131	29	O
131	evaluable	O
131	patients	O
131	for	O
131	the	O
131	regimen	O
131	with	O
131	thalidomide	B-arm_description
131	alone	B-arm_description
131	.	O
131	The	O
131	study	O
131	was	O
131	approved	O
131	by	O
131	the	O
131	Joint	O
131	Institutional	O
131	Review	O
131	Boards	O
131	in	O
131	Taiwan	O
131	;	O
131	it	O
131	started	O
131	in	O
131	March	O
131	2001	O
131	and	O
131	early	O
131	terminated	O
131	in	O
131	January	O
131	2004	O
131	due	O
131	to	O
131	the	O
131	interim	O
131	analysis	O
131	resulting	O
131	in	O
131	more	O
131	adverse	O
131	effects	O
131	and	O
131	less	O
131	efficacy	O
131	in	O
131	the	O
131	arm	O
131	A.	O
--------------------------------------------------------------
132	The	O
132	sample	O
132	size	O
132	initially	O
132	was	O
132	determined	O
132	to	O
132	complete	O
132	43	O
132	evaluable	O
132	patients	O
132	for	O
132	the	O
132	regimen	O
132	with	O
132	thalidomide	B-arm_description
132	plus	B-arm_description
132	IFNα	B-arm_description
132	and	O
132	29	O
132	evaluable	O
132	patients	O
132	for	O
132	the	O
132	regimen	O
132	with	O
132	thalidomide	O
132	alone	O
132	.	O
132	The	O
132	study	O
132	was	O
132	approved	O
132	by	O
132	the	O
132	Joint	O
132	Institutional	O
132	Review	O
132	Boards	O
132	in	O
132	Taiwan	O
132	;	O
132	it	O
132	started	O
132	in	O
132	March	O
132	2001	O
132	and	O
132	early	O
132	terminated	O
132	in	O
132	January	O
132	2004	O
132	due	O
132	to	O
132	the	O
132	interim	O
132	analysis	O
132	resulting	O
132	in	O
132	more	O
132	adverse	O
132	effects	O
132	and	O
132	less	O
132	efficacy	O
132	in	O
132	the	O
132	arm	O
132	A.	O
--------------------------------------------------------------
133	This	O
133	was	O
133	an	O
133	open	B-study_type
133	-	B-study_type
133	label	I-study_type
133	,	I-study_type
133	randomized	I-study_type
133	,	I-study_type
133	multicenter	I-study_type
133	Phase	I-study_type
133	II	I-study_type
133	clinical	I-study_type
133	trial	I-study_type
133	.	O
133	Patients	O
133	were	O
133	randomized	O
133	to	O
133	receive	O
133	either	O
133	thalidomide	B-arm_dosage
133	alone	I-arm_dosage
133	(	I-arm_dosage
133	200	I-arm_dosage
133	mg	I-arm_dosage
133	/	I-arm_dosage
133	day	I-arm_dosage
133	up	I-arm_dosage
133	to	I-arm_dosage
133	the	I-arm_dosage
133	maximum	I-arm_dosage
133	dose	I-arm_dosage
133	800	I-arm_dosage
133	mg	I-arm_dosage
133	/	I-arm_dosage
133	day	I-arm_dosage
133	,	B-arm_description
133	arm	I-arm_description
133	B	I-arm_description
133	)	O
133	or	O
133	the	O
133	combination	O
133	of	O
133	thalidomide	O
133	and	O
133	IFN	O
133	-	O
133	α	O
133	(	O
133	3	O
133	MIU	O
133	/	O
133	m	O
133	2	O
133	subcutaneous	O
133	injection	O
133	thrice	O
133	weekly	O
133	,	O
133	arm	O
133	A	O
133	)	O
133	.	O
133	The	O
133	randomization	O
133	list	O
133	was	O
133	generated	O
133	by	O
133	computer	O
133	using	O
133	permuted	O
133	-	O
133	block	O
133	randomization	O
133	with	O
133	a	O
133	block	O
133	size	O
133	of	O
133	5	O
133	patients	O
133	including	O
133	3	O
133	for	O
133	arm	O
133	A	O
133	and	O
133	the	O
133	other	O
133	2	O
133	for	O
133	arm	O
133	B.	O
133	Eligible	O
133	patients	O
133	recruited	O
133	from	O
133	7	O
133	medical	O
133	centers	O
133	around	O
133	Taiwan	O
133	were	O
133	registered	O
133	within	O
133	48	O
133	hours	O
133	before	O
133	the	O
133	initiation	O
133	of	O
133	therapy	O
133	.	O
133	Patients	O
133	were	O
133	then	O
133	assigned	O
133	to	O
133	either	O
133	arm	O
133	A	O
133	or	O
133	arm	O
133	B	O
133	by	O
133	an	O
133	independent	O
133	allocation	O
133	center	O
133	according	O
133	to	O
133	the	O
133	randomization	O
133	scheme	O
133	once	O
133	upon	O
133	registered	O
133	.	O
133	The	O
133	flow	O
133	diagram	O
133	of	O
133	the	O
133	progress	O
133	through	O
133	the	O
133	trial	O
133	was	O
133	shown	O
133	in	O
133	Figure	O
133	1	O
133	.	O
--------------------------------------------------------------
134	This	O
134	was	O
134	an	O
134	open	O
134	-	O
134	label	O
134	,	O
134	randomized	O
134	,	O
134	multicenter	O
134	Phase	O
134	II	O
134	clinical	O
134	trial	O
134	.	O
134	Patients	O
134	were	O
134	randomized	O
134	to	O
134	receive	O
134	either	O
134	thalidomide	O
134	alone	O
134	(	O
134	200	B-arm_dosage
134	mg	I-arm_dosage
134	/	I-arm_dosage
134	day	I-arm_dosage
134	up	I-arm_dosage
134	to	I-arm_dosage
134	the	I-arm_dosage
134	maximum	I-arm_dosage
134	dose	I-arm_dosage
134	800	I-arm_dosage
134	mg	I-arm_dosage
134	/	I-arm_dosage
134	day	I-arm_dosage
134	,	O
134	arm	O
134	B	O
134	)	O
134	or	O
134	the	O
134	combination	O
134	of	O
134	thalidomide	B-arm_dosage
134	and	B-arm_dosage
134	IFN	I-arm_dosage
134	-	I-arm_dosage
134	α	I-arm_dosage
134	(	I-arm_dosage
134	3	I-arm_dosage
134	MIU	I-arm_dosage
134	/	I-arm_dosage
134	m	I-arm_dosage
134	2	I-arm_dosage
134	subcutaneous	I-arm_dosage
134	injection	I-arm_dosage
134	thrice	I-arm_dosage
134	weekly	I-arm_dosage
134	,	B-arm_description
134	arm	B-arm_description
134	A	B-arm_description
134	)	O
134	.	O
134	The	O
134	randomization	O
134	list	O
134	was	O
134	generated	O
134	by	O
134	computer	O
134	using	O
134	permuted	O
134	-	O
134	block	O
134	randomization	O
134	with	O
134	a	O
134	block	O
134	size	O
134	of	O
134	5	O
134	patients	O
134	including	O
134	3	O
134	for	O
134	arm	O
134	A	O
134	and	O
134	the	O
134	other	O
134	2	O
134	for	O
134	arm	O
134	B.	O
134	Eligible	O
134	patients	O
134	recruited	O
134	from	O
134	7	O
134	medical	O
134	centers	O
134	around	O
134	Taiwan	O
134	were	O
134	registered	O
134	within	O
134	48	O
134	hours	O
134	before	O
134	the	O
134	initiation	O
134	of	O
134	therapy	O
134	.	O
134	Patients	O
134	were	O
134	then	O
134	assigned	O
134	to	O
134	either	O
134	arm	O
134	A	O
134	or	O
134	arm	O
134	B	O
134	by	O
134	an	O
134	independent	O
134	allocation	O
134	center	O
134	according	O
134	to	O
134	the	O
134	randomization	O
134	scheme	O
134	once	O
134	upon	O
134	registered	O
134	.	O
134	The	O
134	flow	O
134	diagram	O
134	of	O
134	the	O
134	progress	O
134	through	O
134	the	O
134	trial	O
134	was	O
134	shown	O
134	in	O
134	Figure	O
134	1	O
134	.	O
--------------------------------------------------------------
135	Thalidomide	B-arm_dosage
135	(	I-arm_dosage
135	50-mg	I-arm_dosage
135	capsules	I-arm_dosage
135	)	I-arm_dosage
135	(	I-arm_dosage
135	Thado	I-arm_dosage
135	,	I-arm_dosage
135	TTY	I-arm_dosage
135	Biopharm	I-arm_dosage
135	Co.	I-arm_dosage
135	,	I-arm_dosage
135	Taiwan	I-arm_dosage
135	,	I-arm_dosage
135	R.O.C.	I-arm_dosage
135	)	I-arm_dosage
135	was	I-arm_dosage
135	administered	I-arm_dosage
135	at	I-arm_dosage
135	a	I-arm_dosage
135	dose	I-arm_dosage
135	of	I-arm_dosage
135	200	I-arm_dosage
135	mg	I-arm_dosage
135	per	I-arm_dosage
135	day	I-arm_dosage
135	orally	I-arm_dosage
135	and	I-arm_dosage
135	divided	I-arm_dosage
135	into	I-arm_dosage
135	2	I-arm_dosage
135	times	I-arm_dosage
135	a	I-arm_dosage
135	day	I-arm_dosage
135	.	I-arm_dosage
135	The	I-arm_dosage
135	dose	I-arm_dosage
135	of	I-arm_dosage
135	thalidomide	I-arm_dosage
135	was	I-arm_dosage
135	increased	I-arm_dosage
135	by	I-arm_dosage
135	200	I-arm_dosage
135	mg	I-arm_dosage
135	every	I-arm_dosage
135	2	I-arm_dosage
135	weeks	I-arm_dosage
135	in	I-arm_dosage
135	the	I-arm_dosage
135	absence	I-arm_dosage
135	of	I-arm_dosage
135	intolerable	I-arm_dosage
135	adverse	I-arm_dosage
135	effects	I-arm_dosage
135	,	I-arm_dosage
135	to	I-arm_dosage
135	the	I-arm_dosage
135	maximal	I-arm_dosage
135	daily	I-arm_dosage
135	dose	I-arm_dosage
135	of	I-arm_dosage
135	800	I-arm_dosage
135	mg	I-arm_dosage
135	.	O
135	Patients	O
135	who	O
135	were	O
135	allocated	O
135	to	O
135	arm	O
135	A	O
135	also	O
135	received	O
135	3	O
135	MIU	O
135	/	O
135	m	O
135	2	O
135	of	O
135	interferon	O
135	alpha-2b	O
135	(	O
135	Schering	O
135	-	O
135	Plough	O
135	Limited	O
135	Co.	O
135	,	O
135	Schering	O
135	-	O
135	Plough	O
135	Labo	O
135	,	O
135	N.V.	O
135	)	O
135	subcutaneous	O
135	injection	O
135	3	O
135	times	O
135	weekly	O
135	concomitantly	O
135	.	O
--------------------------------------------------------------
136	Thalidomide	B-arm_dosage
136	(	I-arm_dosage
136	50-mg	I-arm_dosage
136	capsules	I-arm_dosage
136	)	I-arm_dosage
136	(	I-arm_dosage
136	Thado	I-arm_dosage
136	,	I-arm_dosage
136	TTY	I-arm_dosage
136	Biopharm	I-arm_dosage
136	Co.	I-arm_dosage
136	,	I-arm_dosage
136	Taiwan	I-arm_dosage
136	,	I-arm_dosage
136	R.O.C.	I-arm_dosage
136	)	I-arm_dosage
136	was	I-arm_dosage
136	administered	I-arm_dosage
136	at	I-arm_dosage
136	a	I-arm_dosage
136	dose	I-arm_dosage
136	of	I-arm_dosage
136	200	I-arm_dosage
136	mg	I-arm_dosage
136	per	I-arm_dosage
136	day	I-arm_dosage
136	orally	I-arm_dosage
136	and	I-arm_dosage
136	divided	I-arm_dosage
136	into	I-arm_dosage
136	2	I-arm_dosage
136	times	I-arm_dosage
136	a	I-arm_dosage
136	day	I-arm_dosage
136	.	I-arm_dosage
136	The	I-arm_dosage
136	dose	I-arm_dosage
136	of	I-arm_dosage
136	thalidomide	I-arm_dosage
136	was	I-arm_dosage
136	increased	I-arm_dosage
136	by	I-arm_dosage
136	200	I-arm_dosage
136	mg	I-arm_dosage
136	every	I-arm_dosage
136	2	I-arm_dosage
136	weeks	I-arm_dosage
136	in	I-arm_dosage
136	the	I-arm_dosage
136	absence	I-arm_dosage
136	of	I-arm_dosage
136	intolerable	I-arm_dosage
136	adverse	I-arm_dosage
136	effects	I-arm_dosage
136	,	I-arm_dosage
136	to	I-arm_dosage
136	the	I-arm_dosage
136	maximal	I-arm_dosage
136	daily	I-arm_dosage
136	dose	I-arm_dosage
136	of	I-arm_dosage
136	800	I-arm_dosage
136	mg	I-arm_dosage
136	.	O
136	Patients	B-arm_dosage
136	who	I-arm_dosage
136	were	I-arm_dosage
136	allocated	I-arm_dosage
136	to	I-arm_dosage
136	arm	I-arm_dosage
136	A	I-arm_dosage
136	also	I-arm_dosage
136	received	I-arm_dosage
136	3	I-arm_dosage
136	MIU	I-arm_dosage
136	/	I-arm_dosage
136	m	I-arm_dosage
136	2	I-arm_dosage
136	of	I-arm_dosage
136	interferon	I-arm_dosage
136	alpha-2b	I-arm_dosage
136	(	I-arm_dosage
136	Schering	I-arm_dosage
136	-	I-arm_dosage
136	Plough	I-arm_dosage
136	Limited	I-arm_dosage
136	Co.	I-arm_dosage
136	,	I-arm_dosage
136	Schering	I-arm_dosage
136	-	I-arm_dosage
136	Plough	I-arm_dosage
136	Labo	I-arm_dosage
136	,	I-arm_dosage
136	N.V.	I-arm_dosage
136	)	I-arm_dosage
136	subcutaneous	I-arm_dosage
136	injection	I-arm_dosage
136	3	I-arm_dosage
136	times	I-arm_dosage
136	weekly	I-arm_dosage
136	concomitantly	I-arm_dosage
136	.	O
--------------------------------------------------------------
137	The	O
137	primary	O
137	end	O
137	point	O
137	of	O
137	the	O
137	study	O
137	was	O
137	to	O
137	determine	O
137	the	O
137	decline	O
137	in	O
137	the	O
137	level	O
137	of	O
137	paraprotein	O
137	in	O
137	serum	O
137	at	O
137	least	O
137	25	O
137	,	O
137	50	O
137	,	O
137	75	O
137	,	O
137	or	O
137	90	O
137	percernt	O
137	on	O
137	2	O
137	occasions	O
137	at	O
137	least	O
137	4	O
137	weeks	O
137	apart	O
137	.	O
137	The	O
137	response	O
137	was	O
137	evaluated	O
137	according	O
137	to	O
137	the	O
137	criteria	O
137	of	O
137	Cooper	O
137	et	O
137	al	O
137	.	O
137	and	O
137	Osterborg	O
137	et	O
137	al	O
137	.	O
137	(	O
137	2,3	O
137	)	O
137	.	O
137	Time	O
137	-	O
137	to	O
137	-	O
137	response	O
137	was	O
137	defined	O
137	as	O
137	the	O
137	interval	O
137	between	O
137	the	O
137	start	O
137	of	O
137	therapy	O
137	and	O
137	response	O
137	.	O
137	The	O
137	time	O
137	-	O
137	toprogression	O
137	was	O
137	calculated	O
137	only	O
137	for	O
137	patients	O
137	with	O
137	a	O
137	paraprotein	O
137	response	O
137	and	O
137	was	O
137	defined	O
137	as	O
137	the	O
137	time	O
137	from	O
137	the	O
137	start	O
137	of	O
137	therapy	O
137	to	O
137	disease	O
137	progression	O
137	.	O
137	Event	O
137	-	O
137	free	O
137	survival	O
137	was	O
137	calculated	O
137	from	O
137	the	O
137	start	O
137	of	O
137	therapy	O
137	to	O
137	disease	O
137	progression	O
137	,	O
137	removal	O
137	from	O
137	the	O
137	study	O
137	for	O
137	any	O
137	reason	O
137	,	O
137	death	O
137	from	O
137	any	O
137	cause	O
137	,	O
137	or	O
137	the	O
137	last	O
137	follow	O
137	-	O
137	up	O
137	visit	O
137	.	O
--------------------------------------------------------------
138	The	O
138	demographic	O
138	and	O
138	baseline	O
138	characteristics	O
138	,	O
138	comparison	O
138	of	O
138	continuous	O
138	variables	O
138	of	O
138	age	O
138	,	O
138	baseline	O
138	M	O
138	protein	O
138	levels	O
138	,	O
138	mean	O
138	treatment	O
138	duration	O
138	,	O
138	and	O
138	mean	O
138	total	O
138	thalidomide	O
138	used	O
138	dose	O
138	between	O
138	two	O
138	arms	O
138	were	O
138	determined	O
138	by	O
138	the	O
138	student	O
138	's	O
138	t	O
138	-	O
138	test	O
138	.	O
138	The	O
138	gender	O
138	,	O
138	immunophenotype	O
138	,	O
138	and	O
138	previous	O
138	treatments	O
138	were	O
138	summarized	O
138	as	O
138	categorical	O
138	parameters	O
138	and	O
138	were	O
138	assessed	O
138	with	O
138	the	O
138	use	O
138	of	O
138	chi	O
138	-	O
138	square	O
138	test	O
138	.	O
138	Analyses	O
138	for	O
138	the	O
138	efficacy	O
138	variables	O
138	and	O
138	safety	O
138	analysis	O
138	were	O
138	conducted	O
138	on	O
138	an	O
138	intention	O
138	-	O
138	to	O
138	-	O
138	treat	O
138	basis	O
138	.	O
138	The	O
138	primary	O
138	efficacy	O
138	analysis	O
138	was	O
138	in	O
138	descriptive	O
138	statistics	O
138	,	O
138	presented	O
138	by	O
138	point	O
138	estimate	O
138	and	O
138	95	O
138	percent	O
138	confidence	O
138	interval	O
138	for	O
138	the	O
138	primary	O
138	efficacy	O
138	variable	O
138	.	O
138	Comparison	O
138	of	O
138	the	O
138	response	O
138	according	O
138	to	O
138	the	O
138	response	O
138	criteria	O
138	was	O
138	assessed	O
138	with	O
138	the	O
138	use	O
138	of	O
138	the	O
138	chi	O
138	-	O
138	square	O
138	test	O
138	.	O
138	Ninetyfive	O
138	percent	O
138	confidence	O
138	intervals	O
138	(	O
138	95%CIs	O
138	)	O
138	for	O
138	the	O
138	confirmed	O
138	response	O
138	probability	O
138	were	O
138	calculated	O
138	using	O
138	binomial	O
138	95%CIs	O
138	.	O
138	Toxicity	O
138	incidence	O
138	was	O
138	estimated	O
138	and	O
138	summarized	O
138	using	O
138	fre	O
138	-	O
138	quency	O
138	and	O
138	descriptive	O
138	techniques	O
138	to	O
138	assess	O
138	any	O
138	patterns	O
138	.	O
138	Survival	O
138	distributions	O
138	(	O
138	Kaplan	O
138	-	O
138	Meier	O
138	)	O
138	of	O
138	event	O
138	-	O
138	free	O
138	survival	O
138	(	O
138	EFS	O
138	)	O
138	and	O
138	overall	O
138	survival	O
138	(	O
138	OS	O
138	)	O
138	were	O
138	compared	O
138	by	O
138	means	O
138	of	O
138	the	O
138	logrank	O
138	test	O
138	.	O
138	The	O
138	statistical	O
138	evaluation	O
138	was	O
138	conducted	O
138	by	O
138	the	O
138	software	O
138	program	O
138	of	O
138	SPSS	O
138	version	O
138	10.0	O
138	(	O
138	SPSS	O
138	Inc.	O
138	,	O
138	Chicago	O
138	,	O
138	IL	O
138	,	O
138	USA	O
138	)	O
138	.	O
138	All	O
138	patients	O
138	were	O
138	not	O
138	cohort	O
138	comparable	O
138	to	O
138	their	O
138	disease	O
138	duration	O
138	and	O
138	refractoriness	O
138	.	O
138	The	O
138	preparation	O
138	of	O
138	the	O
138	reports	O
138	after	O
138	early	O
138	terminating	O
138	this	O
138	trial	O
138	was	O
138	modified	O
138	from	O
138	the	O
138	CONSORT	O
138	Statement	O
138	(	O
138	13,14	O
138	)	O
138	.	O
--------------------------------------------------------------
139	From	O
139	March	O
139	2001	O
139	to	O
139	January	O
139	2004	O
139	,	O
139	28	O
139	patients	O
139	with	O
139	MM	O
139	whose	O
139	disease	O
139	relapsed	O
139	or	O
139	failed	O
139	to	O
139	first	O
139	-	O
139	line	O
139	chemotherapy	O
139	were	O
139	enrolled	O
139	in	O
139	this	O
139	study	O
139	.	O
139	Twelve	O
139	of	O
139	28	O
139	patients	O
139	were	O
139	randomized	B-study_type
139	to	O
139	receive	O
139	thalidomide	B-arm_description
139	alone	B-arm_description
139	(	B-arm_description
139	arm	B-arm_description
139	B	B-arm_description
139	)	B-arm_description
139	,	O
139	and	O
139	16	O
139	received	O
139	thalidomide	O
139	combined	O
139	with	O
139	interferon	O
139	alpha	O
139	(	O
139	3	O
139	MIU	O
139	/	O
139	m	O
139	2	O
139	subcutaneous	O
139	injection	O
139	3	O
139	times	O
139	weekly	O
139	,	O
139	arm	O
139	A	O
139	)	O
139	.	O
139	No	O
139	obvious	O
139	differences	O
139	of	O
139	patients	O
139	'	O
139	characteristics	O
139	were	O
139	found	O
139	between	O
139	arm	O
139	B	O
139	and	O
139	arm	O
139	A.	O
139	The	O
139	median	O
139	cumulative	O
139	dose	O
139	of	O
139	interferon	O
139	was	O
139	31	O
139	MIU	O
139	/	O
139	m2	O
139	(	O
139	ranged	O
139	,	O
139	5	O
139	-	O
139	163	O
139	MIU	O
139	/	O
139	m2	O
139	)	O
139	in	O
139	arm	O
139	A.	O
139	However	O
139	,	O
139	the	O
139	average	O
139	treatmentduration	O
139	was	O
139	significantly	O
139	longer	O
139	in	O
139	arm	O
139	B	O
139	than	O
139	arm	O
139	A	O
139	(	O
139	236	O
139	days	O
139	versus	O
139	101	O
139	days	O
139	,	O
139	p	O
139	=	O
139	0.029	O
139	)	O
139	.	O
139	The	O
139	total	O
139	dose	O
139	of	O
139	thalidomide	O
139	in	O
139	B	O
139	arm	O
139	was	O
139	also	O
139	higher	O
139	(	O
139	Table	O
139	1	O
139	)	O
139	.	O
--------------------------------------------------------------
140	From	O
140	March	O
140	2001	O
140	to	O
140	January	O
140	2004	O
140	,	O
140	28	O
140	patients	O
140	with	O
140	MM	O
140	whose	O
140	disease	O
140	relapsed	O
140	or	O
140	failed	O
140	to	O
140	first	O
140	-	O
140	line	O
140	chemotherapy	O
140	were	O
140	enrolled	O
140	in	O
140	this	O
140	study	O
140	.	O
140	Twelve	O
140	of	O
140	28	O
140	patients	O
140	were	O
140	randomized	O
140	to	O
140	receive	O
140	thalidomide	O
140	alone	O
140	(	O
140	arm	O
140	B	O
140	)	O
140	,	O
140	and	O
140	16	O
140	received	O
140	thalidomide	B-arm_description
140	combined	B-arm_description
140	with	B-arm_description
140	interferon	B-arm_dosage
140	alpha	I-arm_dosage
140	(	I-arm_dosage
140	3	I-arm_dosage
140	MIU	I-arm_dosage
140	/	I-arm_dosage
140	m	I-arm_dosage
140	2	I-arm_dosage
140	subcutaneous	I-arm_dosage
140	injection	I-arm_dosage
140	3	I-arm_dosage
140	times	I-arm_dosage
140	weekly	I-arm_dosage
140	,	B-arm_description
140	arm	B-arm_description
140	A	B-arm_description
140	)	O
140	.	O
140	No	O
140	obvious	O
140	differences	O
140	of	O
140	patients	O
140	'	O
140	characteristics	O
140	were	O
140	found	O
140	between	O
140	arm	O
140	B	O
140	and	O
140	arm	O
140	A.	O
140	The	O
140	median	O
140	cumulative	O
140	dose	O
140	of	O
140	interferon	O
140	was	O
140	31	O
140	MIU	O
140	/	O
140	m2	O
140	(	O
140	ranged	O
140	,	O
140	5	O
140	-	O
140	163	O
140	MIU	O
140	/	O
140	m2	O
140	)	O
140	in	O
140	arm	O
140	A.	O
140	However	O
140	,	O
140	the	O
140	average	O
140	treatmentduration	O
140	was	O
140	significantly	O
140	longer	O
140	in	O
140	arm	O
140	B	O
140	than	O
140	arm	O
140	A	O
140	(	O
140	236	O
140	days	O
140	versus	O
140	101	O
140	days	O
140	,	O
140	p	O
140	=	O
140	0.029	O
140	)	O
140	.	O
140	The	O
140	total	O
140	dose	O
140	of	O
140	thalidomide	O
140	in	O
140	B	O
140	arm	O
140	was	O
140	also	O
140	higher	O
140	(	O
140	Table	O
140	1	O
140	)	O
140	.	O
--------------------------------------------------------------
141	Seven	O
141	of	O
141	16	O
141	patients	O
141	(	O
141	43.8	O
141	percent	O
141	)	O
141	in	O
141	arm	B-arm_description
141	A	B-arm_description
141	were	O
141	intolerable	O
141	or	O
141	have	O
141	disease	O
141	-	O
141	progression	O
141	during	O
141	the	O
141	first	O
141	8-week	O
141	treatment	O
141	whereas	O
141	only	O
141	2	O
141	of	O
141	12	O
141	patients	O
141	(	O
141	16.7	O
141	percent	O
141	)	O
141	in	O
141	arm	O
141	B	O
141	were	O
141	withdrawn	O
141	from	O
141	the	O
141	study	O
141	earlier	O
141	.	O
141	Patients	O
141	had	O
141	higher	O
141	dropout	O
141	rate	O
141	(	O
141	43.8	O
141	percent	O
141	)	O
141	in	O
141	the	O
141	arm	O
141	A	O
141	because	O
141	of	O
141	higher	O
141	incidence	O
141	of	O
141	leucopenia	O
141	,	O
141	neutropenia	O
141	,	O
141	thrombocytopenia	O
141	,	O
141	and	O
141	patients	O
141	'	O
141	refusal	O
141	rate	O
141	in	O
141	regards	O
141	to	O
141	the	O
141	adverse	O
141	effects	O
141	of	O
141	interferon	O
141	alpha	O
141	.	O
--------------------------------------------------------------
142	Seven	O
142	of	O
142	16	O
142	patients	O
142	(	O
142	43.8	O
142	percent	O
142	)	O
142	in	O
142	arm	O
142	A	O
142	were	O
142	intolerable	O
142	or	O
142	have	O
142	disease	O
142	-	O
142	progression	O
142	during	O
142	the	O
142	first	O
142	8-week	O
142	treatment	O
142	whereas	O
142	only	O
142	2	O
142	of	O
142	12	O
142	patients	O
142	(	O
142	16.7	O
142	percent	O
142	)	O
142	in	O
142	arm	B-arm_description
142	B	B-arm_description
142	were	O
142	withdrawn	O
142	from	O
142	the	O
142	study	O
142	earlier	O
142	.	O
142	Patients	O
142	had	O
142	higher	O
142	dropout	O
142	rate	O
142	(	O
142	43.8	O
142	percent	O
142	)	O
142	in	O
142	the	O
142	arm	O
142	A	O
142	because	O
142	of	O
142	higher	O
142	incidence	O
142	of	O
142	leucopenia	O
142	,	O
142	neutropenia	O
142	,	O
142	thrombocytopenia	O
142	,	O
142	and	O
142	patients	O
142	'	O
142	refusal	O
142	rate	O
142	in	O
142	regards	O
142	to	O
142	the	O
142	adverse	O
142	effects	O
142	of	O
142	interferon	O
142	alpha	O
142	.	O
--------------------------------------------------------------
143	Paraprotein	O
143	response	O
143	,	O
143	indicating	O
143	of	O
143	at	O
143	least	O
143	a	O
143	25	O
143	percent	O
143	decline	O
143	in	O
143	serum	O
143	or	O
143	urine	O
143	level	O
143	,	O
143	was	O
143	obtained	O
143	in	O
143	6	O
143	of	O
143	12	O
143	patients	O
143	(	O
143	50.0	O
143	percent	O
143	)	O
143	whom	O
143	were	O
143	treated	O
143	with	O
143	arm	B-arm_description
143	B	I-arm_description
143	,	O
143	and	O
143	3	O
143	of	O
143	the	O
143	16	O
143	patients	O
143	(	O
143	18.8	O
143	percent	O
143	)	O
143	whom	O
143	were	O
143	treated	O
143	with	O
143	arm	O
143	A.	O
143	Patients	O
143	in	O
143	arm	O
143	B	O
143	seems	O
143	to	O
143	have	O
143	higher	O
143	paraprotein	O
143	response	O
143	rate	O
143	(	O
143	PPR	O
143	)	O
143	in	O
143	our	O
143	study	O
143	.	O
143	There	O
143	were	O
143	2	O
143	paraprotein	O
143	responders	O
143	in	O
143	level	O
143	of	O
143	25	O
143	,	O
143	50	O
143	,	O
143	and	O
143	75	O
143	percent	O
143	reduction	O
143	of	O
143	serum	O
143	M	O
143	protein	O
143	in	O
143	arm	O
143	B	O
143	,	O
143	while	O
143	only	O
143	3	O
143	patients	O
143	in	O
143	arm	O
143	A	O
143	achieved	O
143	PPR	O
143	of	O
143	25	O
143	percent	O
143	.	O
143	Neither	O
143	a	O
143	PPR	O
143	≥90	O
143	percent	O
143	nor	O
143	complete	O
143	remissions	O
143	were	O
143	observed	O
143	in	O
143	this	O
143	study	O
143	.	O
143	Of	O
143	those	O
143	6	O
143	patients	O
143	who	O
143	had	O
143	response	O
143	to	O
143	thalidomide	O
143	alone	O
143	regimen	O
143	,	O
143	4	O
143	had	O
143	200	O
143	-	O
143	400	O
143	mg	O
143	of	O
143	thalidomide	O
143	per	O
143	day	O
143	and	O
143	the	O
143	other	O
143	2	O
143	patients	O
143	had	O
143	600	O
143	and	O
143	800	O
143	mg	O
143	per	O
143	day	O
143	,	O
143	respectively	O
143	.	O
143	In	O
143	patients	O
143	who	O
143	had	O
143	response	O
143	to	O
143	arm	O
143	A	O
143	regimen	O
143	,	O
143	2	O
143	patients	O
143	had	O
143	600	O
143	mg	O
143	and	O
143	one	O
143	had	O
143	400	O
143	mg	O
143	of	O
143	thalidomide	O
143	per	O
143	day	O
143	combined	O
143	with	O
143	IFN	O
143	-	O
143	α	O
143	during	O
143	their	O
143	treatment	O
143	periods	O
143	(	O
143	Table	O
143	2	O
143	)	O
143	.	O
--------------------------------------------------------------
144	Paraprotein	O
144	response	O
144	,	O
144	indicating	O
144	of	O
144	at	O
144	least	O
144	a	O
144	25	O
144	percent	O
144	decline	O
144	in	O
144	serum	O
144	or	O
144	urine	O
144	level	O
144	,	O
144	was	O
144	obtained	O
144	in	O
144	6	O
144	of	O
144	12	O
144	patients	O
144	(	O
144	50.0	O
144	percent	O
144	)	O
144	whom	O
144	were	O
144	treated	O
144	with	O
144	arm	O
144	B	O
144	,	O
144	and	O
144	3	O
144	of	O
144	the	O
144	16	O
144	patients	O
144	(	O
144	18.8	O
144	percent	O
144	)	O
144	whom	O
144	were	O
144	treated	O
144	with	O
144	arm	B-arm_description
144	A.	B-arm_description
144	Patients	O
144	in	O
144	arm	O
144	B	O
144	seems	O
144	to	O
144	have	O
144	higher	O
144	paraprotein	O
144	response	O
144	rate	O
144	(	O
144	PPR	O
144	)	O
144	in	O
144	our	O
144	study	O
144	.	O
144	There	O
144	were	O
144	2	O
144	paraprotein	O
144	responders	O
144	in	O
144	level	O
144	of	O
144	25	O
144	,	O
144	50	O
144	,	O
144	and	O
144	75	O
144	percent	O
144	reduction	O
144	of	O
144	serum	O
144	M	O
144	protein	O
144	in	O
144	arm	O
144	B	O
144	,	O
144	while	O
144	only	O
144	3	O
144	patients	O
144	in	O
144	arm	O
144	A	O
144	achieved	O
144	PPR	O
144	of	O
144	25	O
144	percent	O
144	.	O
144	Neither	O
144	a	O
144	PPR	O
144	≥90	O
144	percent	O
144	nor	O
144	complete	O
144	remissions	O
144	were	O
144	observed	O
144	in	O
144	this	O
144	study	O
144	.	O
144	Of	O
144	those	O
144	6	O
144	patients	O
144	who	O
144	had	O
144	response	O
144	to	O
144	thalidomide	O
144	alone	O
144	regimen	O
144	,	O
144	4	O
144	had	O
144	200	O
144	-	O
144	400	O
144	mg	O
144	of	O
144	thalidomide	O
144	per	O
144	day	O
144	and	O
144	the	O
144	other	O
144	2	O
144	patients	O
144	had	O
144	600	O
144	and	O
144	800	O
144	mg	O
144	per	O
144	day	O
144	,	O
144	respectively	O
144	.	O
144	In	O
144	patients	O
144	who	O
144	had	O
144	response	O
144	to	O
144	arm	O
144	A	O
144	regimen	O
144	,	O
144	2	O
144	patients	O
144	had	O
144	600	O
144	mg	O
144	and	O
144	one	O
144	had	O
144	400	O
144	mg	O
144	of	O
144	thalidomide	O
144	per	O
144	day	O
144	combined	O
144	with	O
144	IFN	O
144	-	O
144	α	O
144	during	O
144	their	O
144	treatment	O
144	periods	O
144	(	O
144	Table	O
144	2	O
144	)	O
144	.	O
--------------------------------------------------------------
145	The	O
145	median	O
145	time	O
145	to	O
145	response	O
145	were	O
145	42.0	O
145	days	O
145	(	O
145	95%CI	O
145	,	O
145	38.8∼45.2	O
145	)	O
145	and	O
145	69.0	O
145	days	O
145	(	O
145	95%CI	O
145	,	O
145	19.8∼118.2	O
145	)	O
145	in	O
145	arm	B-arm_description
145	A	B-arm_description
145	and	O
145	B	O
145	,	B-arm_description
145	respectively	O
145	.	O
145	Median	O
145	duration	O
145	of	O
145	response	O
145	are	O
145	105.0	O
145	days	O
145	(	O
145	95%CI	O
145	,	O
145	64.9∼145.01	O
145	)	O
145	in	O
145	arm	O
145	A	O
145	and	O
145	357.0	O
145	days	O
145	(	O
145	95%CI	O
145	,	O
145	312.7∼401.3	O
145	)	O
145	in	O
145	arm	O
145	B.	O
145	Patients	O
145	who	O
145	received	O
145	thalidomide	O
145	alone	O
145	seems	O
145	to	O
145	have	O
145	longer	O
145	response	O
145	duration	O
145	than	O
145	thalidomide	B-arm_description
145	combined	I-arm_description
145	with	I-arm_description
145	IFN	I-arm_description
145	-	I-arm_description
145	α	I-arm_description
145	.	O
145	The	O
145	estimated	O
145	EFS	O
145	was	O
145	7.9	O
145	months	O
145	(	O
145	95%CI	O
145	,	O
145	0.5	O
145	-	O
145	15.4	O
145	)	O
145	and	O
145	1.5	O
145	months	O
145	(	O
145	95%CI	O
145	,	O
145	0.0	O
145	-	O
145	3.4	O
145	)	O
145	for	O
145	patients	O
145	receiving	O
145	arm	O
145	B	O
145	and	O
145	arm	O
145	A	O
145	,	O
145	respectively	O
145	(	O
145	log	O
145	-	O
145	rank	O
145	test	O
145	,	O
145	p	O
145	=	O
145	0.0193	O
145	)	O
145	.	O
145	There	O
145	was	O
145	no	O
145	statistically	O
145	significant	O
145	difference	O
145	of	O
145	overall	O
145	survival	O
145	between	O
145	arm	O
145	A	O
145	and	O
145	B	O
145	(	O
145	Figure	O
145	2	O
145	)	O
145	.	O
--------------------------------------------------------------
146	The	O
146	median	O
146	time	O
146	to	O
146	response	O
146	were	O
146	42.0	O
146	days	O
146	(	O
146	95%CI	O
146	,	O
146	38.8∼45.2	O
146	)	O
146	and	O
146	69.0	O
146	days	O
146	(	O
146	95%CI	O
146	,	O
146	19.8∼118.2	O
146	)	O
146	in	O
146	arm	B-arm_description
146	A	O
146	and	O
146	B	B-arm_description
146	,	O
146	respectively	O
146	.	O
146	Median	O
146	duration	O
146	of	O
146	response	O
146	are	O
146	105.0	O
146	days	O
146	(	O
146	95%CI	O
146	,	O
146	64.9∼145.01	O
146	)	O
146	in	O
146	arm	O
146	A	O
146	and	O
146	357.0	O
146	days	O
146	(	O
146	95%CI	O
146	,	O
146	312.7∼401.3	O
146	)	O
146	in	O
146	arm	O
146	B.	O
146	Patients	O
146	who	O
146	received	O
146	thalidomide	B-arm_description
146	alone	I-arm_description
146	seems	O
146	to	O
146	have	O
146	longer	O
146	response	O
146	duration	O
146	than	O
146	thalidomide	O
146	combined	O
146	with	O
146	IFN	O
146	-	O
146	α	O
146	.	O
146	The	O
146	estimated	O
146	EFS	O
146	was	O
146	7.9	O
146	months	O
146	(	O
146	95%CI	O
146	,	O
146	0.5	O
146	-	O
146	15.4	O
146	)	O
146	and	O
146	1.5	O
146	months	O
146	(	O
146	95%CI	O
146	,	O
146	0.0	O
146	-	O
146	3.4	O
146	)	O
146	for	O
146	patients	O
146	receiving	O
146	arm	O
146	B	O
146	and	O
146	arm	O
146	A	O
146	,	O
146	respectively	O
146	(	O
146	log	O
146	-	O
146	rank	O
146	test	O
146	,	O
146	p	O
146	=	O
146	0.0193	O
146	)	O
146	.	O
146	There	O
146	was	O
146	no	O
146	statistically	O
146	significant	O
146	difference	O
146	of	O
146	overall	O
146	survival	O
146	between	O
146	arm	O
146	A	O
146	and	O
146	B	O
146	(	O
146	Figure	O
146	2	O
146	)	O
146	.	O
--------------------------------------------------------------
147	As	O
147	for	O
147	the	O
147	patients	O
147	in	O
147	arm	B-arm_description
147	B	B-arm_description
147	,	O
147	the	O
147	major	O
147	adverse	O
147	effects	O
147	were	O
147	neutropenia	O
147	(	O
147	50.0	O
147	percent	O
147	)	O
147	,	O
147	constipation	O
147	(	O
147	75.0	O
147	percent	O
147	)	O
147	,	O
147	and	O
147	edema	O
147	(	O
147	50.0	O
147	percent	O
147	,	O
147	face	O
147	or	O
147	extremities	O
147	)	O
147	.	O
147	Most	O
147	were	O
147	tolerable	O
147	after	O
147	dose	O
147	reductions	O
147	or	O
147	symptomatic	O
147	treatment	O
147	,	O
147	except	O
147	one	O
147	patient	O
147	with	O
147	severe	O
147	fluid	O
147	retention	O
147	on	O
147	his	O
147	face	O
147	and	O
147	extremities	O
147	and	O
147	skin	O
147	rashes	O
147	all	O
147	over	O
147	the	O
147	trunk	O
147	after	O
147	his	O
147	initial	O
147	12	O
147	days	O
147	of	O
147	treatment	O
147	and	O
147	was	O
147	withdrawn	O
147	from	O
147	the	O
147	study	O
147	.	O
147	In	O
147	5	O
147	patients	O
147	who	O
147	had	O
147	experienced	O
147	mild	O
147	to	O
147	moderate	O
147	edema	O
147	in	O
147	arm	O
147	B	O
147	,	O
147	the	O
147	average	O
147	treatment	O
147	-	O
147	duration	O
147	was	O
147	61.8	O
147	weeks	O
147	(	O
147	95%CI	O
147	,	O
147	39.7	O
147	-	O
147	83.9	O
147	)	O
147	.	O
147	Comparing	O
147	to	O
147	an	O
147	average	O
147	of	O
147	30.3	O
147	weeks	O
147	(	O
147	95%CI	O
147	,	O
147	10.8	O
147	-	O
147	49.8	O
147	)	O
147	for	O
147	the	O
147	other	O
147	6	O
147	patients	O
147	who	O
147	did	O
147	not	O
147	have	O
147	edema	O
147	during	O
147	the	O
147	study	O
147	,	O
147	it	O
147	suggested	O
147	that	O
147	the	O
147	longer	O
147	duration	O
147	of	O
147	thalidomide	O
147	used	O
147	,	O
147	the	O
147	higher	O
147	incidence	O
147	of	O
147	edema	O
147	developed	O
147	.	O
--------------------------------------------------------------
